

Manuscript Number: STOTEN-D-15-00149R1

Title: What have we learned from worldwide experiences on the management and treatment of hospital effluent?- An overview and a discussion on perspectives

Article Type: Review Article

Keywords: advanced oxidation processes; environmental risk assessment; hospital effluent; pharmaceutical removal; toxicity; treatment costs

Corresponding Author: Dr. Paola Verlicchi, Engineering

Corresponding Author's Institution: University of Ferrara

First Author: Paola Verlicchi, Engineering

Order of Authors: Paola Verlicchi, Engineering; Mustafa Al Aukidy, PhD; Elena Zambello, Degree in Engineering

Abstract: This study overviews lessons learned from experimental investigations on dedicated treatment systems of hospital effluent carried out worldwide in the last twenty years. It includes 48 peer reviewed papers from 1995 to 2015 assessing the efficacy of different treatment levels (preliminary, primary, secondary and polishing) of hospital wastewater in removing a wide spectrum of pharmaceutical compounds as well as conventional contaminants. Moreover, it highlights the rationale and the reasons for each study: reducing the discharge of micropollutants in surface water, improving existing wastewater treatment technologies, reducing the risk of spread of pathogens causing endemic diseases and finally, it offers a critical analysis of the conclusions and suggestions of each study. The most investigated technologies are membrane bioreactors equipped with ultrafiltration membranes in the secondary step, ozonation followed by activated carbon filtration (in powder and in granules) in the polishing step. Interesting research projects deal with photo-Fenton processes acting as primary treatments to enhance biodegradation before biological treatment, and as a polishing step, thus further reducing micro-contaminant occurrence. Investment and operational costs are also presented and discussed for the different treatment technologies tested worldwide, in particular membrane bioreactors and various advanced oxidation processes. This study also discusses the need for further research to evaluate toxicity resulting from advanced oxidation processes as well as the need to develop an accurate feasibility study that encompasses technical, ecotoxicological and economic aspects to identify the best available treatment in the different situations from a global view point.

Response to Reviewers: We greatly appreciated comments and suggestions made by the reviewers and we replied to all of them as reported in the following.

Reviewer #1:

Without any doubt, this is a very interesting review paper that tackles a timely issue, not presented comprehensively in the literature before.

It is also well written and presented. It should be accepted for publication in STOTEN (I expect that such a paper has a good potential to attract many citations), after a major refinement.  
My comments are provided below:

1. Not all keywords are suitable and specific. Most of them are quite vague, generic and not specific to the point. These should be carefully revised (critical overview? of what? dedicated treatment? experimental investigations? perspectives? research needs?). Keywords are used by libraries and searches to identify topics. Those given in the parenthesis will definitely not help.  
Changes were done: "environmental risk assessment; toxicity; treatment costs" were added and "critical overview; dedicated treatment; experimental investigations; perspectives; research needs" were erased.

2. Line81-103: Here two review papers on WWTPs and pharmaceuticals demonstrating/discussing the removal capacities of such plants to remove such compounds and ARB-ARG should be cited and discussed. These are:

Michael et al., Water Research: I. Michael, L. Rizzo, C.S. McArdell, C.M. Manaia, C. Merlin, T. Schwartz, C. Dagot, D. Fatta-Kassinos, "Urban wastewater treatment plants as hotspots for the release of antibiotics in the environment: A review", Water Research, 2013, 47, 957-995.

Rizzo et al., STOTEN: L. Rizzo, C.M. Manaia, C. Merlin, T. Schwartz, C. Dagot, M.C. Ploy, I. Michael, D. Fatta-Kassinos, "Urban wastewater treatment plants as hotspots for antibiotic resistance spreading into the environment", Science of the Total Environment, 2013, 447, 345-360.

The two reviews are extremely interesting: they refer to treatment of urban wastewater not to hospital effluent. The second one was cited as more pertinent to the context (Introduction).

3. line93 and 114: it is not correct to refer to BOD / COD as common contaminants. These are global parameters.

We agree with this consideration, we modified the text by replacing "contaminants" with parameters".

4. line 106: examined publications and not reviewed papers  
Done

5. 114: all selected compounds and not all of the selected  
Done

6. line 165: Asian and not Asiatic  
Done

7. In the case that the authors would like to refer to chemicals and microbiological load pollution as is in line 178, they must use the term contaminants and not pollutants  
Done

8. Also, better to use the term "contaminants of emerging concern" instead of emergent or emerging contaminants.  
We disagree with this suggestion as in the literature both are used.

9. 221: ... fragrances are removed by more than 60%  
Done

10. 229: I do not understand why the sentence here refers to "absorbance removal"  
The reason is because the investigation by Arslan et al., 2014 took into consideration two aspects: COD removal and absorbance removal in raw hospital effluent by AOP processes.

11. 261: capacity instead of adequateness  
Done

12. 272: studies instead of investigations, available in the literature  
Done

13. 279: ... included herein  
Done

14. 310: determined instead of determined  
we did not change the term "observed"

15. 334: an SRT and not a SRT  
Done

16. Delete "More in general" in line 365  
Done

17. 389: Comparison between CAS and MBR (not an MBR) as is the process that is being compared and not a specific MBR plant, correct? This should be the idea.  
Done

18. - 392: lower and not worse  
We prefer to maintain "worse" as the removal was lower and thus worse

19. 392: as was the removal  
Done

20. 394: CAS and MBR  
Done

21. - 406: I do not agree with this absolute statement here. UF might be efficient but it cannot guarantee disinfection as not every microorganism is examined in studies like this. So the possibility for some contaminants to escape is always there.

We know that UF retain some microorganisms and not all of them. But the term "disinfection" does not imply a complete removal of each kind of microorganisms (corresponding to a sterilization). For this reason we wrote: "reducing the spread of pathogenic bacteria". Reducing does not mean eliminating the risk. For this reason, we preferred to maintain the text. An in-depth discussion is available in the following.

22. 428: It consists of  
Done

23. 472: The removal percentages need to be given here  
Data are available in graphs  $c/c_0$  vs. times (removal rates, and not removal efficiencies) and the profile was compound dependant. The comparison MBBR-CAs was made by the Authors. We changed the text.

24. - 474: "Very good results" .. this is a judgement made by the authors and is not justified with scientific criteria. The authors need to refer to the various results subjectively with scientific justifications.

We changed the text

25. 493: merging contaminants should be corrected and this is obviously a typo

Done

26. 516: Swiss and German research study

Done

27. 539: It is not clear that the authors would like to say by "as regards neutral compounds at pH 8.8" This means that compounds at pH= 8.8 are not positively nor negatively charged, as reported in the Additional information in Kovalova et al., 2013, Table S10.

28. GAC and PAC may be efficient in removing microcontaminants but they also have the disadvantage of transferring them in the solid phase and not destroying. Comments towards this directions should be given in the relevant discussion. Its cost also is quite relevant in the pros and cons. Considerations are added in the section of COSTS

29. Hydroxyl radicals should be written according to the IUPAC rules of electronegativity : HO\* and not OH\*. The latter is not a hydroxyl radical  
Right, we agree, we changed accordingly!

30. 678: delete "very" before negligible as this is redundant.

Done

31. 709: The main reactions of AOPs are given in numerous other publications (e.g. Klavarioti et al, 2009, Environment International summarizes all AOPs against pharmaceuticals). Therefore the authors can cite another review paper and avoid extending their paper which is already long.

Equations are reported in Supplementary data and not in the text. We preferred to maintain them in an additional file that the reader may easily found. In that file we cited books dealing with removal of compounds of emerging interest.

32. 797: The best disinfection efficiency

Done

33. 801: damage of the

Done

34.- E. coli etc should be written in italics

Done

35. 908: MBR and PAC. It is not clear here if the authors refer to a combined process.  
We refer to a treatment train including MBR as a secondary step and PAC as tertiary step

36. - The section on policy relevant to the management of hospital effluents is quite interesting although very short. I would advice the authors to make an extra effort to compile a table presenting national policies to this respect.

We tried to collect data and info to create such a table, but despite our efforts (in these years) in asking Authors and the different organizations for legal constraints in managing, treating and discharging hospital effluent, we do not have (yet) formal information about them in different countries!

37. - 953: Proper... has to consider... (not has to bear in mind)  
Done

38. - 954: as well as towards the environment  
Done

39. -1030: are reported herein  
Done

40. - 1033: In European countries efforts are made to improve...  
Done

41. 1051: authors and not Authors  
Done

42. - 1066: according to studies examined in this review study  
Done

43. - Table 1: the range of concentrations should be compiled by more than one study. In most parameters only one reference is given. Sometimes cited references are review and thus they report variability ranges of monitored parameters.

44. - Table 2: Rationale and Investigated parameters should be separated both in the title and in the column below. This table needs some reworking as is long and not comprehensive. The data and information should be encoded and the authors need to avoid big narrative texts as these are already discussed out of the table. In my opinion some of these information and some of the information presented in figures should be combined so that the table offers more readily, important quantified information on the various studies. For examples, design parameters and removals. Also no duplication should exist between the text and the tables. The text must present critical thoughts and new insight and not repeat or summarize information already given in the table. The (original) third column has been divided as requested. According to the suggestion, the table has been revised and in particular design and operational parameters are provided when available. As to removal efficiencies, we did not add anything in this table: data are reported in figures and also in Table SD-3.

45. Table 7: by different technologies (not with)  
Done

46.- A discussion and a deeper elaboration on the very varying values of MBR - MBR +Ozone (4.7 / 2.4) should be given. How can this be explained?  
We checked the values from the source documents and we confirm them. It is quite strange but the two research groups within PILLS projects did not investigate this difference.

47 Finally and I believe most importantly, the authors should discuss technologies against the physicochemical characteristics of the various contaminants of emerging concern and what new can be

extracted out if this review. Is there a conclusion on this? Or is there anything that can be said with reference to their removal and the removal of global parameters like COD in the same studies?

A new paragraph addressing this aspect was added (par 4.6)

48. Toxicity testing should be elaborated more. The absence of such studies against hospital effluents is a gap of research and this deserves much attention, especially in cases where HWW is reused or discharged in surface water for subsequent reuse etc.

We underlined the necessity of further research in the text.

Reviewer #2: STOTEN-D-15-00149

The MS fits in with the worldwide concern on pharmaceuticals in the aquatic environment. For this purpose, the MS gives a literature overview on the management and treatment of hospital effluents in the last 20 years. The introduction is clear and the objectives seemed to be ambitious as the study considers 48 peer reviewed papers on hospital effluents treatments, but, actually, the results have been reached. The discussion is well-organized and well-oriented. The paper could have an interesting impact on the scientific community as it represents a good collection about the history and the development of plants technologies. In my opinion, the MS should be published in STOTEN.

I don't have specific comments except as regards the section Costs. It is rather vague and it needs to be improved.

49. Lines 1009-1011 page 29: do the authors mean the costs reported in euro for each m<sup>2</sup> of treated water?

Unfortunately we do not have any further information.

Reviewer #3: General comments:

The manuscript presents a review of data about the treatment and management of hospital effluents, giving a worldwide perspective. Different kinds of treatments are discussed and the removal of pharmaceuticals and conventional parameters are evaluated and compared. The topic approached in the present manuscript is relevant, pertinent and actual. The work presents a good literature review and the collected data is summarized in tables and figures, which allows having a good perspective of what was done and the results obtained. In general, the manuscript is well written and the collected data is properly and critical discussed, giving an important overview of the treatment and management of hospital effluents. I recommend that the paper should be accepted for publication in the journal after minor corrections.

Specific comments:

50. Keywords: The number of keywords was exceeded. Please reduce it to 6 (maximum).

Done

51. Abbreviations: Please include here all the abbreviations used in the manuscript.

Done

52. Page 6, lines 186-187: This phrase repeats information that is in the next section. Delete the phrase.  
done

53. Page 7, line 212: Replace "...than 70% if 200 mg/L..." by "...than 70% when 200 mg/L..."

done

54. Page 11, line 343: Which pharmaceutical is D617? Please clarify.

Done: added the meaning in the list of abbreviations and in the text the first time it appears.

55. Page 15, line 487: The percentage symbol is missing. Add it.

Done

56. Page 15, line 493: Replace "...merging contaminants." by "...emerging contaminants."

Done

57. Page 25, line 857: What do you want to mean with "...bioacid activity..."?

We changed the text. The meaning was that chlorine disinfection is an efficient treatment against bacteria, some viruses, fungi...

58. Page 26, line 888: Replace "...UV and ozonation is more..." by "...UV and ozonation are more..."

done

59. Tables: Data present in table 3 can be placed in table 2, given that the information present in both tables is overlapping. Please put all the data together in an only table.

In a first phase we put all the data of Table 2 and table 3 in the same table. But then we preferred to split it in two different tables in order to grouped references referring to the same kind of tested technology and to give the possibility to the reader to easily find studies regarding the same treatment.

60. Figures: Usually the authors present two figures to the same kind of treatment, giving different number to the figures. This is a little bit confusing. I suggest that the figures 4 and 5 and should be included in an only figure numerating as 4a and 4b. The same should be done for figures 6 and 7, and 8 and 9.

We preferred to maintain figures with the original numbering.

Ferrara, February, 5<sup>th</sup> 2015

Dear Prof. Damia Barcelo,  
Editor-in-Chief  
Science of the Total Environment

The following manuscript:

**What have we learned from worldwide experiences on the management and treatment of hospital effluent?– An overview and a discussion on perspectives.**

**Verlicchi P.\*<sup>°</sup>, Al Aukidy M.\* Zambello E.\***

\*Department of Engineering, University of Ferrara, Via Saragat 1, I-44122 Ferrara, Italy

<sup>°</sup> Terra&Acqua Tech Technopole of the University of Ferrara, Via Borsari 46, 44123 Ferrara, Italy  
[paola.verlicchi@unife.it](mailto:paola.verlicchi@unife.it), [mustafakether.alaukidi@unife.it](mailto:mustafakether.alaukidi@unife.it) , [elena.zambello@unife.it](mailto:elena.zambello@unife.it)

is submitted to your Journal STOTEN to be considered for publication.

I would like to make the following remarks:

- The current manuscript was revised according to all the suggestions made by the reviewers, as reported in the “Replies to reviewers”
- the work described in this paper has not been previously published, in whole or in part, and it is not under consideration for publication elsewhere,
- the *Corresponding Author* is PAOLA VERLICCHI, PhD
- Her address is:

Department of Engineering  
University of Ferrara  
Via Saragat 1  
I-44122 Ferrara  
Italy  
Tel +39.(0)532.974938  
Fax +39.(0)532.974870  
mail [paola.verlicchi@unife.it](mailto:paola.verlicchi@unife.it)

- I confirm that all the Authors are aware of and accept responsibility for the manuscript.

**RATIONALE AND UNIQUE FEATURES OF THE STUDY**

The paper is a critical review referring to investigations carried out from 1995 to 2015 about management and dedicated treatment of hospital effluent in the different countries facing various issues.

Based on collected removal data, it mainly presents and discusses the efficacy of the different investigated technologies and treatment trains, in case of dedicated treatment of hospital effluent, in removing conventional macropollutants as well as pharmaceutical compounds. The study includes 48 peer reviewed papers published on international journals and it refers to 108 selected pharmaceuticals belonging to 17 therapeutic classes. It also presents and



discusses investment and operational costs of the different treatment trains. It highlights lessons learned from past investigations and discusses future perspectives.

We think that our manuscript fulfils aims and scope of Your international journal: in particular it refers to “Hydrosphere” (hospital effluent) and “Anthroposphere” (discharge data) and to the following *Subject areas*: Waste and water treatments, Human Health risk assessment and management, Persistent organic pollutants.

For these reasons we submit it to be considered for publication on Your Journal.

Sincerely Yours

Paola Verlicchi

## Highlights

Different technologies investigated for a dedicated treatment of hospital effluent are presented and discussed.

Photo-Fenton process seems to be a promising preliminary treatment

Membrane bioreactor is a proper secondary treatment for hospital effluent

AOPs showed a good removal efficiency for most classes of pharmaceuticals

UV irradiation is a promising technology in the removal of X-ray contrast media

# What have we learned from worldwide experiences on the management and treatment of hospital effluent?– An overview and a discussion on perspectives.


Verlicchi P.\*°, Al Aukidy M.\* Zambello E.\*

\*Department of Engineering, University of Ferrara, Via Saragat 1, I-44122 Ferrara, Italy

° Terra&Acqua Tech Technopole of the University of Ferrara, Via Borsari 46, 44123 Ferrara, Italy

[paola.verlicchi@unife.it](mailto:paola.verlicchi@unife.it), [mustafakether.alaukidi@unife.it](mailto:mustafakether.alaukidi@unife.it), [elena.zambello@unife.it](mailto:elena.zambello@unife.it)

## Graphical abstract



## Abstract

This study overviews lessons learned from experimental investigations on dedicated treatment systems of hospital effluent carried out worldwide in the last twenty years. It includes 48 peer reviewed papers from 1995 to 2015 assessing the efficacy of different treatment levels (preliminary, primary, secondary and polishing) of hospital wastewater in removing a wide spectrum of pharmaceutical compounds as well as conventional contaminants. Moreover, it highlights the rationale and the reasons for each study: reducing the discharge of micropollutants in surface water, improving existing wastewater treatment technologies, reducing the risk of spread of pathogens causing endemic diseases and finally, it offers a critical analysis of the conclusions and suggestions of each study. The most investigated technologies are membrane bioreactors equipped with ultrafiltration membranes in the secondary step, ozonation followed by

24 activated carbon filtration (in powder and in granules) in the polishing step. Interesting research projects  
1  
25 deal with photo-Fenton processes acting as primary treatments to enhance biodegradation before  
2  
3  
26 biological treatment, and as a polishing step, thus further reducing micro-contaminant occurrence.  
4  
5  
27 Investment and operational costs are also presented and discussed for the different treatment  
6  
7  
28 technologies tested worldwide, in particular membrane bioreactors and various advanced oxidation  
8  
9  
29 processes.

10  
30 This study also discusses the need for further research to evaluate toxicity resulting from advanced  
11  
12  
31 oxidation processes as well as the need to develop an accurate feasibility study that encompasses  
13  
14  
32 technical, ecotoxicological and economic aspects to identify the best available treatment in the different  
15  
16  
33 situations from a global view point.

17  
34  
18  
35 **Keywords:** advanced oxidation processes; environmental risk assessment; critical overview; dedicated  
19  
20  
36 treatment; experimental investigations; hospital effluent; pharmaceutical removal; toxicity; treatment  
21  
22  
37 costs. perspectives; research needs.  
23  
24  
25

## 26 38 **Abbreviations**

27  
39 AOP = advanced oxidation process; AOX = adsorbable organic compounds; ARB = antibiotic resistant  
28  
29  
40 bacteria; ARG = antibiotic resistant genes; AS = activated sludge; BAT = best available technology; CAS =  
30  
31  
41 conventional activated sludge; Chlorin = chlorination; Coag = coagulation; CPCs = cancerogenic platinum  
32  
33  
42 compounds; CWs= constructed wetlands; D617 = N-dealkylverapamil;  $D_{ow}$  = octanol water distribution  
34  
35  
43 coefficient; DNA = deoxyribonucleic acid; DO = Dissolved oxygen; DOC = dissolved organic carbon; EE2 =  
36  
37  
44 ethinyl estradiol or 17- $\alpha$  ethinyl estradiol; EQS = environmental quality standard; FL = flocculation; FLO =  
38  
39  
45 flotation; GAC = granular activated carbon; HDPE = high density polyethylene; HRT = hydraulic retention  
40  
41  
46 time; H-SSF = horizontal subsurface flow; HWW = hospital wastewater; ICM = iodinated contrast media;  $K_a$   
41  
42  
47 = dissociation constant;  $k_{biol}$  = biological degradation rate;  $K_{ow}$  = octanol water partition coefficient; LP = low  
43  
44  
48 pressure; MBBR = moving bed biofilm reactor; MBR = membrane biological reactor; MCWO = molecular  
45  
46  
49 weight cut off; MP = medium pressure; NF = nanofiltration; O&M = maintenance and operation; PAC =  
47  
48  
50 powdered activated carbon; PhC = pharmaceutical compound; RO = reverse osmosis; SARS = severe acute  
49  
50  
51 respiratory syndrome; SRT = sludge retention time; T = temperature; TDS = total dissolved solids; TOC=  
50  
51  
52 total organic carbon; TSS = total suspended solids; UASB = upflow anaerobic sludge blanket; UF =  
52  
53  
53 ultrafiltration; UV = ultraviolet; UWW = urban wastewater;  $v_f$  = filtration velocity; V-SSF = vertical  
54  
55  
54 subsurface flow; WWTP = wastewater treatment plant  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1. Introduction

In recent years, hospital effluent has been the object of study and research in various countries throughout the world facing different issues. The specific driving and inspiring force has been to improve the knowledge of the chemical and physical characterization of such wastewater for conventional parameters, namely BOD<sub>5</sub>, COD, TSS, N and P compounds, pH and T (Sarafraz et al., 2007; Verlicchi et al., 2012a); the microbiological load of hospital effluent and also the risk of the spread of antibiotic resistant bacteria (Boillot et al., 2008; Chitnis et al., 2004); differences in composition between hospital effluent and urban wastewater (UWW) (Verlicchi et al., 2010); seasonal variation of hospital effluent compositions (Verlicchi et al., 2012a, 2012c); strategies in their management (co-treatment or dedicated treatment with UWW) (Pauwels and Verstraete, 2006, Verlicchi et al., 2010), evaluation of the adequacy of adopted treatment strategies with respect to the removal of specific contaminants (Mesdaghinia et al., 2009, Beier et al., 2010); technical and economic feasibility of dedicated treatment trains for hospital wastewater (HWW) (PILLS report, 2012); contribution of hospital effluent to the influent of a municipal wastewater treatment plant (WWTP) (Verlicchi et al., 2012a; Santos et al., 2013).

On occasion, the occurrence of disease outbreaks due to pathogens occurring in sewage, such as SARS (severe acute respiratory syndrome) in China in 2003, has led scientists to develop specific research projects to identify safety measures to rapidly adopt in existing WWTPs, in particular in plants receiving hospital effluent, not only to deal with the current emergency, but also to prevent further ones (Wang et al., 2005).

Quite rarely, national (or regional) legal regulations have been established to define how to manage and treat hospital effluent before its disposal (discharge in public sewage for treatment at a municipal WWTP or discharge into a surface water body) (Boillot et al., 2008; Verlicchi et al., 2010). Indeed, hospital effluent was and (still) is generally considered of the same pollutant nature as UWW and thus it is commonly discharged in public sewage systems, conveyed to an urban WWTP where it is subjected to conventional treatment, often consisting in primary clarification, activated sludge process and sometimes disinfection. This practice is very common although recent studies (Verlicchi et al., 2010; Santos et al., 2013, McArdell et al., 2011) highlighted that higher concentrations of pharmaceuticals (PhCs), disinfectants, X-ray contrast media occur in hospital effluent as well as a microbiological load exhibiting a higher resistance to treatment (Chitnis et al., 2004).

Municipal WWTPs were conceived and, in some cases, recently upgraded to guarantee a high removal efficiency of carbon, nitrogen and phosphorus compounds, as well as microorganisms (mainly bacteria): pollutants regularly arriving with and occurring in the WWTP influent at concentrations in the order of units (P compounds), tens (NH<sub>4</sub>, TKN) and hundreds (COD, BOD<sub>5</sub>) of mg/L and thousands of MPN/100 mL (*Escherichia coli*).

Commonly adopted treatments at municipal WWTPs include: preliminary treatments, (sometimes) primary clarification, secondary biological (usually consisting in a conventional activated sludge –CAS - process), and

92 polishing treatments (chemical disinfection or sometimes rapid filtration followed by UV disinfection).  
1  
2 93 Unfortunately, these WWTPs are not adequate enough to reach high removal efficiencies for the wide  
3  
4 94 spectrum of micropollutants (PhCs, adsorbable organic compounds commonly known with the acronym  
5  
6 95 AOX) commonly present in hospital effluent. They are also among the main sources of antibiotic release  
7  
8 96 into the environment and thus they may promote the selection of antibiotic resistant genes (ARG) and  
9  
10 97 antibiotic resistant bacteria (ARB), as deeply investigated in Rizzo et al. (2013). Moreover, in some  
11  
12 98 circumstances, conventional treatments have been adopted for HWW, but they are not well managed and  
13  
14 99 very low efficiencies are achieved even for common contaminants parameters, namely BOD<sub>5</sub>, COD, TSS and  
15  
16 100 Total coliform (Mesdaghinia et al., 2009). Sometimes, a simple primary treatment is adopted for hospital  
17  
18 101 effluent (primary clarification, prechlorination) but it is not efficient (Martins et al., 2008).  
19  
20 102 In other cases, no treatment is adopted at all and direct discharge of raw HWW into surface rivers is  
21  
22 103 common practice (Liu et al., 2010).

23  
24 104 The main focus of this study is to present and discuss lessons learned from previous investigations and  
25  
26 105 studies carried out on dedicated treatment of HWW in the different countries worldwide. It offers a critical  
27  
28 106 analysis of data collected from lab, pilot and full scale treatment plants acting as primary, secondary and  
29  
30 107 tertiary steps. Attention is paid to the removal efficiencies observed for contaminants, including  
31  
32 108 conventional parameters but in particular emerging ones: mainly PhCs, detergents and disinfectants. The  
33  
34 109 analysis also compares the assessment of investment and operational costs for each applied technology.

## 35 110 2. Object and framework of the survey

36 111 This study is based on 48 peer reviewed papers publications regarding investigations into the *dedicated*  
37  
38 112 treatment of hospital effluent in lab, pilot and full scale plants acting as primary, secondary or tertiary  
39  
40 113 steps. They were carried out in 24 different countries all over the world between 1995 and 2015.  
41  
42 114 Collected data that are presented and discussed herein mainly refer to observed removal efficiencies for  
43  
44 115 108 PhCs belonging to 17 different classes: analgesics and anti-inflammatories (20), anaesthetics (1),  
45  
46 116 anthelmintics (5), antibiotics (23), antifungals (1), antihypertensives (6), antineoplastics (6), antiseptics (1),  
47  
48 117 antivirals (5), beta-blockers (6), contrast media (9), fragrances (3), hormones (4), lipid regulators (4),  
49  
50 118 psychiatric drugs (12), receptor antagonists (1), stimulants (1). Table SD-2 in Supplementary Data compiles  
51  
52 119 all of the selected compounds grouped according to their class. Moreover, conventional pollutants (BOD<sub>5</sub>,  
53  
54 120 COD, SS, N and P compounds, microorganisms...) are also reported and discussed.  
55  
56 121 In discussing removal efficiencies of selected PhCs observed for the different treatment technologies and  
57  
58 122 steps, particular attention is paid to the potential capacity of each technology in retaining/degrading  
59  
60 123 specific compounds and, when possible, to the operational conditions which could maximize them. Data  
61  
62 124 are presented in graphs in the manuscript and further details are provided in Tables in Supplementary  
63  
64 125 Data.  
65

127 All removal values reported and discussed (in the following graphs and tables) must be considered with the  
128 necessary caution, bearing in mind their origin and that they may be affected by many factors, namely:

- 129 • influent characteristics (macro- and micropollutant concentrations),  
130 • operational conditions (sludge concentration, sludge retention time SRT, hydraulic retention time  
131 HRT, pH, temperature T, feeding mode, dosage of ozone, H<sub>2</sub>O<sub>2</sub>, UV irradiation, catalyst type and  
132 contact time),  
133 • reactor types (conventional activated sludge system or membrane bioreactor MBR;  
134 compartmentalization),  
135 • environmental conditions (temperature, irradiation)  
136 • water sampling mode and frequency.

137 Before discussing the main results derived from these studies, a snapshot of the main chemical, physical  
138 and microbiological characteristics of HWW is provided in Table 1. References are also provided for each  
139 compiled parameter or class of compounds of PhCs.

140 To ease the reading of the manuscript, a brief presentation of each investigation is reported in Table 2 and  
141 the list of all the investigated treatment trains is provided in Table 3 with the corresponding references.

142  
143 **Table 1.**

### 145 **3. Technologies and treatment trains for HWW under review**

146 Table 2 reports the main characteristics of the studies included in this review referring to the dedicated  
147 treatment of hospital effluent and the *rationale* behind each one.

148 A rapid glance at Table 2 points out that hospital effluent was subjected to different treatment levels: just a  
149 preliminary/primary (potential or actual) dedicated treatment before its co-treatment with UWW at a  
150 municipal WWTP, sometimes conventional secondary biological treatments (CAS) or modified CAS  
151 processes that are systems combining attached and suspended biomass, but also MBRs, and advanced  
152 oxidation processes (AOPs). In some countries AOPs were investigated as preliminary-primary treatments  
153 in order to enhance biodegradation in the stream.

154 In order to help in the reading of this review, Table 3 lists **all the types** of investigated technologies and  
155 treatment trains with the corresponding references. Their distribution in the different countries in the  
156 world can be found in the graphical abstract, as well as on a larger scale in Fig SD-1 in the Supplementary  
157 Data.

158 Most of the investigations referred to pilot/lab scale plants (69%) and the remaining 31% to full scale  
159 dedicated facilities (see Table SD-1 in the Supplementary data). The latter include the following treatment  
160 trains: septic tank followed by an anaerobic filter (Brazil, de Almeida et al., 2013, Martins et al., 2008),  
161 UASB + anaerobic filters (Brazil, Prado et al., 2011); series of maturation and facultative ponds (Ethiopia,

162 Beyene and Redaie, 2011); septic tank + constructed wetlands (H-SSF + V-SSF beds) (Nepal, Shrestha et al.,  
163 2001); MBR (in Germany, Beier et al., 2011, 2012; in China: Liu et al., 2010, Wen et al., 2004); CAS+  
164 chlorination (in Greece, Kosma et al., 2010; in Brazil, Prado et al., 2011; in Iran, Mahvi et al., 2009); MBR+  
165 chlorination (in China, Liu et al., 2010); flocculation+activated carbon or flocculation+CAS (Republic of  
166 Korea, Sim et al., 2013), MBR+O<sub>3</sub>+UV (Italy, Verlicchi et al., 2010), MBR+O<sub>3</sub> or PAC and then sand filtration  
167 (in Germany, PILLS Project Report 2012), MBR+O<sub>3</sub>+GAC (a full scale demo plant called Pharmaphilter  
168 operating in the Netherlands, Pharmafilter report, 2013), MBR+GAC+O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub> and MBR+GAC+UV (Denmark,  
169 Grundfoss biobooster, 2012).

170 Moreover, 53% of the studies were carried out in European countries (Austria, Belgium, Denmark, France,  
171 Germany, Greece, Italy, Luxembourg, Netherlands, Switzerland and Turkey), 27% in Asiatic countries  
172 (China, India, Indonesia, Iran, Iraq, Nepal, Republic of Korea, Thailandia and Taiwan), 16% in South America  
173 (Brazil) and 4% in Africa (Egypt and Ethiopia). PhCs were detected and removal efficiencies evaluated in  
174 60% of the studies included, whereas the remaining ones only refer to conventional parameters. All the  
175 studies developed in Europe investigated PhCs with the only exception of Nardi et al., 1995 (referring to  
176 prechlorination of raw hospital effluent), and Arslan et al., 2014 regarding AOPs applied on a raw HWW.

177  
178 It is worth noting that often in Asian countries, the main reason for investigating hospital effluent  
179 treatment is the need to guarantee “safe” treatment for this kind of wastewater and to evaluate the  
180 possibility of directly reusing the treated effluent due to water scarcity for various requirements, in  
181 particular for irrigation (Al Hashimia et al., 2013). As discussed below, although it is highly appreciable that  
182 this problem has been tackled, their common conclusion, based on an analysis of conventional pollutants  
183 contaminants whereby a secondary biological treatment followed by chlorination may be considered  
184 adequate treatment even in case of direct reuse, is not backed up by comprehensive research into  
185 micropollutants or ecotoxicology.

186 In European countries, the main reason for research is generally an awareness of the potential risk posed  
187 by the occurrence of PhC residues in secondary effluent and the need to reduce the PhC load discharged  
188 into the environment via WWTP effluent. There is a lively debate on the need to adopt dedicated and  
189 proper treatments for hospital effluents (Ort et al., 2010, Verlicchi et al., 2012a, Santos et al., 2013) based  
190 on the evaluation of the contribution of the health care structure and the corresponding catchment area in  
191 the discharge of PhCs.

192 All the following figures refer to removal efficiencies observed for PhCs by the different analyzed  
193 technologies.

194  
195 **Table 2**

196  
197  
198 **Table 3**



199  
1  
2  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235

#### 4. Results and Discussion

The following sections present and discuss collected data on the removal efficiencies of selected PhCs as well as conventional parameters from HWW by different systems acting as primary, secondary and tertiary steps. A specific section is devoted to the removal ability of microorganisms observed in the different technologies and on measures suggested to reduce the spread of pathogens and also of antibiotic resistant bacteria. Supplementary Data provides a brief overview on the main reactions taking place during AOPs and might help in reading the following discussion.

##### 4.1. Preliminary and primary treatments –Pharmaceutical removal

Preliminary treatments are generally adopted and tested with the aim of removing rough and coarse material from raw wastewater, thus protecting mechanical and electrical parts in the downstream treatment steps. Specific treatments have also been tested in lab and pilot plants to reduce the toxicity of chemical mixtures occurring in hospital effluent and to enhance biodegradability (namely to increase the BOD<sub>5</sub>/COD ratio) and to improve downstream biological processes.

Coagulation-flocculation and flotation are processes that satisfy the first objective as they promote the removal of suspended solids and colloids from wastewater which do not settle spontaneously (Gautam et al., 2007; Suarez et al., 2009), whereas ozonation (Chiang et al., 2003) and AOPs (Kajitvichyanukul and Suntronvipart, 2006) satisfy the second objective.

COD removal was found greater than 70% when 200 mg/L of ferric chloride was added to raw hospital effluent and removal increased to over 98% if the coagulant was added to settled HWW. A following step of disinfection by calcium hydrochloride not only reduces microorganisms, but also COD. It was found that with a contact time of 30 minutes, the Ca(ClO)<sub>2</sub> break point dose is 20 mg/L (Gautam et al., 2007).

A few studies have been carried out on the effectiveness of coagulation, flocculation and flotation in removing PhCs from hospital effluent (Suarez et al., 2009; Martins et al., 2008). Figure 1 shows the main results when common coagulants Al<sub>2</sub>(SO<sub>4</sub>)<sub>3</sub> and FeCl<sub>3</sub> at a dosage of 25 mg/L are added to the raw wastewater, with and without flotation. These processes are not particularly efficient in removing PhCs, confirming the considerations reported in Verlicchi et al. (2012b). In fact, only diclofenac and some fragrances achieve a removal efficiency greater are removed by more than 60%. Figure 1 also reports the somewhat modest removal efficiency (17%) observed for ciprofloxacin using a septic tank followed by an anaerobic filter fed with raw effluent from a hospital in Brazil (Martins et al., 2008).

Attempts to improve COD removal and increase biodegradability in raw hospital effluent were made by applying ozonation, O<sub>3</sub>/UV and O<sub>3</sub>/UV/H<sub>2</sub>O<sub>2</sub> as a pretreatment (Arslan et al., 2014). Based on lab scale tests on effluent from a diagnostic centre, nuclear medicine, oncology, radiology and medical genetics departments, it was found that the highest COD removal (47.5%) was obtained in a system O<sub>3</sub>/UV/H<sub>2</sub>O<sub>2</sub>

234 operating at pH 6.0, O<sub>3</sub> concentration 10 mg/L, monochromatic UV lamp (254 nm) and dosage of H<sub>2</sub>O<sub>2</sub> 1.8  
235 mL within 60 min. As for absorbance removal, the best AOP is O<sub>3</sub>/UV: in fact the addition of H<sub>2</sub>O<sub>2</sub> led to a  
236 scavenger effect on hydroxyl radicals resulting in a lower removal efficiency (see Supplementary Data for  
237 more details).  
238 The results achieved from the ozonation of effluent from a kidney dialysis unit are quite interesting: at a  
239 dose of 25 mg/L of ozone and a contact time of 20 min, COD was reduced from 132 mg/L to 97 mg/L and  
240 the ratio BOD<sub>5</sub>/COD increased from 0.15 to 0.26 confirming a consistent increment in the biodegradability  
241 of the stream (Chiang et al., 2003).  
242 Another option to improve biodegradability is achieved using photo-Fenton processes (see Supplementary  
243 Data for the main reactions involved). It was found that in hospital effluent of average pollutant strength  
244 (COD 1350-2250 mg/L, BOD<sub>5</sub>/COD 0.30) with a dosage ratio COD:H<sub>2</sub>O<sub>2</sub>:Fe<sup>+2</sup> equal to 1:4:0.1, a reaction pH  
245 of 3 and a reaction time of 2 h, the removal efficiencies for BOD<sub>5</sub>, COD and TOC were: 61%, 77% and 52%  
246 and the BOD<sub>5</sub>/COD ratio increased from 0.30 to 0.52. It was also found that for higher COD values,  
247 optimum reaction conditions have to be tested to guarantee good mineralization of organic compounds  
248 and to enhance biodegradability (Kajitvichyanukul and Suntronvipart, 2006). The increased biodegradability  
249 of the wastewater was also confirmed by batch experiments on raw and pretreated effluent subjected to a  
250 biological process using activated sludge. It was found that in the case of pretreated wastewater, the  
251 removal of COD amounted to 90% after a 72 h treatment time, whereas it was only 30% in the case of raw  
252 hospital effluent (Kajitvichyanukul and Suntronvipart, 2006).  
253 A Fenton process may also act as a disinfectant step: in fact it greatly removes total coliforms and  
254 thermotolerant coliforms as documented by Berto et al. (2009). The cases of complete removal observed in  
255 their investigation were ascribed to acidic conditions and the occurrence of hydroxyl radicals. Low pH  
256 values would cause bacteria death and HO• would assure DNA denaturation.  
257 These studies led to suggest ozonation, Fenton as well as photo-Fenton processes as suitable solutions for  
258 the preliminary treatment of hospital wastewater from a technical viewpoint. An economic analysis would  
259 be necessary to assess investment, operational and maintenance costs. Moreover, the adequateness of  
260 adopting these advanced technologies as “pretreatment” also needs to be confirmed from a toxicological  
261 view point, but unfortunately, there is no available research to investigate.

## 264 **Figure 1**

### 266 **4.2. Secondary treatments – Pharmaceutical removal**

267 Most of the studies investigated the **adequateness capacity** of MBRs as a biological stage for the treatment  
268 of HWW. Other systems analyzed include: CAS systems in Iran (Mahvi et al., 2009), Greece (Kosma et al.,  
269 2010), Egypt (Abd El-Gawad and Aly, 2011) and Belgium (Pauwels et al., 2006), an anaerobic-aerobic fixed  
270 film bioreactor in Iran (Rezaee et al., 2005), an aerated fixed film biofilter in Indonesia (Prayitno et al.,

271 2014), a moving bed biofilm reactor in Denmark (Andersen et al., 2014), ultrafiltration membranes coupled  
272 with a modified CAS reactor by addition of biofilm supports in France (Moussaab et al., 2015), maturation  
273 and polishing ponds in Ethiopia (Beyene and Redaie, 2011), horizontal and vertical subsurface flow systems  
274 in Nepal (Shrestha et al., 2001), and a fungal bioreactor in Spain (Cruz-Morato et al., 2014). In the first part  
275 of this section MBRs and CAS are critically analyzed and compared, the remaining systems are analyzed and  
276 compared in the second part.

277  
278 *MBR* – Lessons learned from the reviewed studies, carried out all over the world, regarding the efficacy of  
279 MBRs applied to UWW in the removal of macro- and micropollutants (Verlicchi et al., 2012b) are certainly  
280 useful in an analysis of the performance of an MBR fed with hospital effluent. As regards this type of  
281 wastewater, special attention must be paid to evaluate the potential inhibition effect on the biological  
282 activities of PhCs, heavy metals, disinfectants, detergents that occur at higher concentrations in HWW  
283 rather than UWW thus, the risk that they could negatively affect the degradation processes of micro  
284 contaminants has to be assessed.

285 In the studies included herein, hospital effluent is generally subjected to a coarse screening (2 mm),  
286 sometimes through a fine screen or a sieve (0.5-1 mm), whereas a primary clarifier is only rarely adopted  
287 (HRT 2-10 h). Adequate pretreatments are extremely useful in guaranteeing continuous operation of MBRs.  
288 As reported in the investigation by Verlicchi et al. (2008), the raw HWW may contain rags, filaments, pieces  
289 of cardboard that can adversely interfere with moving parts within the WWTPs or clog membranes and  
290 thus they have to be efficiently removed at the start of the treatment train. This is in agreement with  
291 suggestions by Gabarron et al. (2013) which investigated different pretreatment processes to find the most  
292 adequate technology that would consistently contribute in minimizing the ragging impact over MBR  
293 performance.

294 A storage/equalization tank before an MBR guarantees homogeneous feeding, avoids damage to the  
295 membrane units and may also promote sorption removal mechanisms due to the contact between solid  
296 particles and micropollutants. This is the case of cancerogenic platinum compounds (CPCs), such as  
297 cisplatin, that show a high affinity for suspended solids (Lenz et al. 2007a). In this study, the feed from the  
298 oncological ward, was first collected in a tank (24 h residence time), then processed through a sieve (1 μm,  
299 to separate suspended solids from the liquid phase) and finally sent to an MBR treatment. The CPC  
300 concentration was significantly reduced after passing through the sieve and the membranes due to particle  
301 and biomass sorption onto the surface.

302  
303 A biological reactor usually consists in an anoxic/oxic compartments to promote complete nitrification and  
304 denitrification. P removal, when necessary, is achieved by a co-precipitation with FeCl<sub>2</sub>. Biomass  
305 concentration in the aerated compartment varied between 2 and 20 g/L, the sludge retention time ranged

306 between 20 and 100 d with the only exception of an MBR operating in parallel with a CAS system whose  
307 SRTs were 12-15 d in each (Pauwels et al., 2006).

308 Ultrafiltration membranes (tubular or flat sheet, 0.03-0.06  $\mu\text{m}$ ) were more frequently investigated (Nielsen  
309 et al., 2013; Lenz et al., 2007a, PILLS report 2012 – at the Swiss, German and Dutch units within the project)  
310 than microfiltration membranes (sheet, 0.4  $\mu\text{m}$ ; Pauwels et al., 2006; Beier et al., 2011; Luxembourg unit  
311 within the PILLS project – PILLS report 2012). Submerged membrane modules integrated in the bioreactor  
312 was the most commonly adopted configuration; side stream modules were equipped only in the Dutch unit  
313 within the PILLS project and in the Austrian investigation where the MBR was fed by the oncological ward  
314 effluent (Lenz et al., 2007a).

315

316 A rapid glance at the macro pollutant removal observed in the different MBRs shows that notably high  
317 values were found (94% for DOC, 99% for COD, 93-99% for  $\text{NH}_4^+$ , around 85% for nitrates) resulting in a  
318 high quality permeate, with reduced variability intervals for the different pollutants: DOC 6-11 mg/L, COD  
319 20-30 mg/L, total N 3-17 mg/L with a few exceptions (McArdell et al., 2011; Wen et al., 2004).

320 Good biological activity was in general guaranteed and maintained throughout each observation period in  
321 the different investigations. Chemical or physical parameter shocks could occasionally occur resulting in  
322 disturbances at the biological reactors and, from a macroscopic point of view, reduced removal of macro  
323 pollutants, namely COD, SS, N compounds, from a microscopic point of view changes, modification or  
324 disintegration of the activated sludge flocks (Pauwels et al., 2006; McArdell et al., 2011).

325 In this context, quaternary ammonia disinfectants are potential critical parameters, as their consumption  
326 may greatly vary from one hospital to another as remarked by Kovalova et al. (2012). As for the common  
327 quaternary ammonia disinfectant BAC C12, tolerable concentrations may reach up to 150  $\mu\text{g/L}$  without  
328 inducing negative effects on the biomass (Kovalova et al., 2012, McArdell et al., 2011).

329 Moreover, hospital laundrette effluent represents a hotspot for certain pollutants (Kist et al., 2008). A  
330 sudden increase in formic acid concentrations may occur as reported by Pauwels et al. (2006), leading to a  
331 pH shock (2.5) in the bioreactor. This results in a process performance decrease due to the disintegration of  
332 the sludge and consequently in a dramatic decrease in COD removal.

333 Figures 2 and 3 report all collected data on removal of PhCs in hospital effluent by an MBR operating at  
334 different SRT values.

335 As underlined by different studies (Clara et al., 2005; Verlicchi et al., 2012a, 2012b, Monteiro and Boxall  
336 2010), SRT greatly affects the removal performance of many PhCs. Long SRT values promote adaptation of  
337 different kinds of microorganisms and the presence of slower growing species which could have a greater  
338 capacity for removing more recalcitrant compounds while simultaneously improving suspended solid  
339 separation (Kreuzinger et al., 2004). Based on data shown in Figures 2 and 3 involving removal efficiencies  
340 of compounds observed at different sludge ages, it emerges that an SRT equal to 20-25 d promotes the  
341 removal of atenolol and clarithromycin, slightly higher values (around 30 d) enhance diclofenac and

342 erythromycin removal and around 50 d a larger number of compounds are better removed: naproxen,  
343 lidocaine, ciprofloxacin, sulfamethoxazole and cyclophosphamide.  
344 Very good removal efficiencies of over 90% were in general observed at a SRT greater than 30 d for many of  
345 the selected compounds.  
346 Modest removal efficiencies (< 50%) were observed for metoprolol, iopamidol, carbamazepine, gabapentin,  
347 ritanilic acid.  
348 Unfortunately, removal efficiency was always scarce (< 25%) for various PhCs, namely: indomethacin,  
349 phenazone, roxithromycin, D617 (N-dealkylverapamil, a metabolite of Verapamil), cyclophosphamide,  
350 oseltamivir carboxylate, propranolol, sotalol, iodixinal, iohexol, iomeprol, ioversol, oxazepam.  
351 The antineoplastic agents included in the CPC group show a higher removal efficiency with respect to  
352 cyclophosphamide, due to their higher affinity to sorbing onto particles and activated sludge flocks within  
353 the MBR (Lenz et al., 2007a,b).

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

**Fig. 2**

**Fig. 3**

Releases sometimes occur for diclofenac, phenazone, ciprofloxacin, clarithromycin, sulfadiazine, sulfamethoxazole, propranolol, iopamidol, carbamazepine, probably due to deconjugation during biological treatment (Kovalova et al., 2012, Nielsen et al., 2013). These are not reported in the graph in Figures 2 and 3. An in-depth discussion of the potential release of many PhCs is reported in Verlicchi et al. (2012b) as well as in Monteiro and Boxall (2010).

Based on the Swiss research carried out within the PILLS project involving 56 compounds of different therapeutic classes, it emerged that an MBR (SRT equal to 30-50 days) is able to remove up to 90% of pharmaceuticals and metabolite load (X-ray contrast media excluded), although removal of some of the selected compounds was very poor (in particular, clindamycin, diclofenac and furosemide). Only 2% of the influent contrast media load was removed in the investigated MBR.

An MBR is not a satisfactory treatment process for the removal of AOX compounds: in the permeate, AOXs occur in the range of 0.56-0.85 mg/L (Beier et al., 2011; McArdell et al., 2011) and further advanced treatment is necessary to reduce their content in the final effluent (Machado et al., 2007).

The absence of suspended solids in the MBR effluent represents a strength as it is the most important condition required by many advanced technologies in the removal of trace contaminants, as suspended solids may negatively interfere with the removal performance of said technologies.

An MBR appears to be an adequate secondary treatment for hospital effluent as it produces very good quality and stable effluent throughout the running time, and is thus suitable for advanced technologies (Venditti et al., 2011; Beier et al., 2011), including NF/RO and AOPs. Full scale MBRs have been adopted for

380 the treatment of HWW in Italy (Verlicchi et al., 2010), Germany (PILLS report 2012) and China (Liu et al.,  
381 2010).

382  
383 CAS – Only two research projects were found dealing with the removal of PhCs from hospital effluent  
384 involving “dedicated” CAS systems: one lab scale (Pauwels et al., 2006) and one full scale (Kosma et al.,  
385 2010). Pretreatment was only reported in the second case, consisting in a grit removal and mixing tank.  
386 Biological reactors had anoxic/aerobic compartments in the first case and only aerobic in the second. In the  
387 research by Kosma et al., 2010 removal efficiencies were provided for PhCs after CAS (HRT 6 h)+  
388 chlorination.

389 Only 10 PhCs were monitored in these dedicated CAS systems. High removal efficiencies were observed for  
390 ibuprofen (92%), salicylic acid (79%) and caffeine (75%), naproxen, gemfibrozil, paracetamol and ethynyl  
391 estradiol (EE2) were moderately removed (67%, 63%, 61% and 43% respectively), whereas scant removal  
392 was found for carbamazepine and phenazone (30% and 13% respectively). A modest release (-17%) was  
393 observed for diclofenac.

394  
395 **Comparison between CAS and MBR** - In the research by Pauwels et al. (2006), CAS and an MBR were  
396 operating in parallel, fed with the same hospital effluent (spiked with EE2 up to 1 mg/L). With respect to  
397 the MBR, the CAS system exhibited a slower start up and was more prone to bulking. Moreover, COD  
398 removal was worse in the CAS system (88% in CAS vs. 93% in an MBR) as was the removal of various  
399 bacterial groups: total coliforms, fecal coliforms and total anaerobic bacteria (about 2 log units less) and  
400 total aerobic bacteria (1.4 log units less). No differences were found in the removal of EE2 between CAS  
401 and MBR.

402 The higher removal efficiencies observed for some bacterial groups in the MBR permeate is due to  
403 membrane retention. Their occurrence in the MBR effluent may instead be explained by unavoidable  
404 bacteria regrowth from the effluent vessel into the permeate collecting tube and also by the absence of  
405 proper membrane cleaning while the system was running, as disinfection was not applied (Pauwels et al.,  
406 2006).

407 Lessons learned from previous studies on removal of PhCs by means of CAS and an MBR fed with UWW  
408 (Verlicchi et al., 2012a,b) highlighted that in the MBR, the combination of higher biomass concentration in  
409 the aerated basin, development of different bacterial species within the biomass, smaller sludge flocks that  
410 may enhance sorption on the surface of different contaminants, higher SRTs and higher removal of  
411 suspended solids, greatly contribute to the removal of PhCs from the stream. Moreover, as discussed  
412 below, passage through ultrafiltration membranes guarantees disinfection of the wastewater, thus  
413 reducing the risk of spread of pathogenic bacteria and of multi drug resistant bacteria.

414  
60  
61  
62  
63  
64  
65

415 *MBR upgrade* - Recently, an upgrade of the MBR system was researched by Mousaab et al. (2015) with the  
416 aim of improving PhC removal efficiencies and membrane function. The system consisted in an activated  
417 sludge basin coupled with an external ultrafiltration membrane module (0.2  $\mu\text{m}$ ), operating at a SRT 20 d,  
418 HRT 22 h, T 18-20 °C and pH 6.8-7.9. In the first 75 d, it worked under “usual” conditions. Then, HDPE  
419 support media were added to the biological reactor (specific area: 600  $\text{m}^2/\text{m}^3$ ; diameter: 12.2 mm; length:  
420 12 mm, density: 0.95-0.98  $\text{kg}/\text{m}^3$ ) promoting the development of a hybrid (attached and suspended)  
421 biomass and a longer SRT of fixed organisms. In the modified bioreactor, higher removal efficiencies were  
422 observed for soluble COD (91.8% vs. 86.9%), TSS (100% vs. 99.6%) and VSS (93.2% vs. 87.9%) and removal  
423 efficiencies greater than 95% for codeine, pravastatin, ketoprofen, diclofenac, roxithromycin, gemfibrozil  
424 and iohexol, whereas in the unmodified MBR their removal was either absent or very low. The presence of  
425 biofilm supports also enhanced particle sorption and improved effluent quality, thus offering better  
426 protection of the membranes against fouling and reducing cleaning operations.  
427 Enhanced removal of P compounds from hospital effluent could be obtained by sequencing  
428 anoxic/anaerobic MBRs. Al-Hashimia et al. (2013) found that the optimal phase for this type of system is  
429 operating with an internal recycling mode of 2 h anoxic followed by 2 h anaerobic. These conditions  
430 provide an optimal simultaneous removal efficiency of 93% for N compounds and 83% for P compounds  
431 (expressed as  $\text{P-PO}_4^-$ ).

432  
433 *Other investigated biological systems* -In Nepal, in 1997 a dedicated treatment plant was built for hospital  
434 effluent. It consists of a three chambered septic tank (16.7  $\text{m}^3$ ) providing pretreatment, followed by CW  
435 systems: a horizontal subsurface flow bed (140  $\text{m}^2$ , 0.65 m deep and 0.75 m high, filled with 5 mm crushed  
436 gravel) and a vertical flow bed (120  $\text{m}^2$ , 1 m deep, filled with clean sand) as a secondary step. Very good  
437 removal efficiencies were observed for TSS and  $\text{BOD}_5$  (97-99%), COD (94-97%),  $\text{N-NH}_4$  (80-99%), total  
438 coliform 99.87-99.999%), *E. coli* (99.98-99.999%) and *Streptococcus* (99.3-99.99%) (Shrestha et al., 2001)  
439 In Ethiopia, a series of waste stabilisation ponds (2 facultative ponds, 2 maturation ponds and 1 fish pond  
440 covering an area of about 3000  $\text{m}^2$  with a total retention time of 43 d) was found to be reasonably efficient  
441 in the removal of  $\text{BOD}_5$ , COD, sulphide, suspended solids and N compounds from hospital effluent (Beyene  
442 and Redaie, 2011). Despite the satisfactory removal of total and fecal coliform (99.7 and 99.4%  
443 respectively), their final concentrations do not fulfil WHO recommendations for restricted and unrestricted  
444 irrigation. Options to improve the quality of the final effluent were considered: for instance adoption of (i)  
445 constructed wetlands; (ii) two successive lagoons followed by infiltration into the land, (iii) MBR advanced  
446 oxidation treatment to better remove all the parameters as well as pharmaceuticals, (iv) photo-Fenton  
447 process to reduce toxicity. Only the first option was considered feasible, whereas the second could lead to  
448 groundwater contamination and the applicability of the remaining options was found difficult in terms of  
449 cost, installation, operation and maintenance.

450 In Iran, hospital effluents are generally discharged into a public sewage system and then co-treated with  
451 urban effluents. Usually they are subjected to a secondary treatment; disinfection is mandatory in case of  
452 disease outbreaks and in critical periods (in the summer and autumn due to reduced river water flow)  
453 (Mahvi et al., 2009). The most common malfunctions are due to operator inexperience at the WWTP and  
454 negligent WWTP management by the authorities. Investigations were carried out on pilot plants with the  
455 aim of evaluating (i) proper pretreatment of hospital effluent before discharge into a public sewage system  
456 followed by co-treatment (Rezaee et al., 2005) and (ii) a (co)-treatment train able to respect Iranian legal  
457 requirements for physical, chemical and microbiological parameters for direct discharge into the surface  
458 body, disposal to wells and reuse in agriculture (Azar et al., 2010). These investigations found that an  
459 integrated anaerobic/aerobic fixed film bioreactor can greatly remove organic and nitrogen compounds  
460 from raw hospital wastewater and when followed by co-treatment consisting in primary treatment, an  
461 aerobic/anaerobic activated sludge reactor fulfils the legal requirements for conventional parameters.  
462 These conclusions however do not consider any kind of more recalcitrant compounds (pharmaceuticals,  
463 contrast agents, disinfectants) whose removal is poor in the investigated biological systems.  
464 Another treatment train was investigated in Indonesia consisting in an aerated fixed film biofilter followed  
465 by an ozone reactor. Satisfactory removal efficiencies were observed for BOD<sub>5</sub> (97.5%), fecal coliform  
466 (99.23%), Pb and phenol (100%), but there was no chemical analysis involving pharmaceuticals,  
467 disinfectants or detergents (Prayitno et al. 2014).  
468 As for preliminary treatments, in addition to what has already been reported in section 4.1, chemical  
469 flocculation followed by a CAS process represents an efficient barrier for anthelmintic drugs (albendazole  
470 and flubendazole) considering that overall removal is in the range of 67-75% (Sim et al., 2013).  
471  
472 Modifications to biological reactors to enhance micropollutant removal have undergone in-depth analysis  
473 during the last years. This is the case of Andersen et al. (2014) where on a pilot scale, the combination of a  
474 moving bed biofilm reactor followed by an ozonation stage was investigated. A biological system was  
475 developed (called a staged MBBR) to attempt to improve the creation of fixed biofilms where slow-growing  
476 bacteria would stand a better chance of development (these bacteria are very efficient in removing  
477 pharmaceuticals) compared to biomass developed in CAS systems. Higher removal efficiencies were  
478 observed for ketoprofen and gemfibrozil and occasionally for diclofenac and clofibrac acid.  
479  
480 Very good interesting and promising results were observed for many PhCs in a batch fluidized bed  
481 bioreactor under sterile and non sterile conditions with *Trametes versicolor* pellets (Cruz-Morato et al.,  
482 2014) fed with hospital effluent, operating at pH 4.5, T 25 °C, 1.4 g dry weight biomass per litre and with a  
483 continuous addition of glucose and ammonium tartrate as a nutrient source for the biomass. Sterile  
484 conditions showed that *T. versicolor* is responsible of the removal of the detected compounds. Very good  
485 removal efficiencies were observed for analgesics and anti-inflammatory drugs after 1 day and complete



486 removal of most was observed after 8 d, with the only exception of salicylic acid and dexamethasone.  
487 Although antibiotics were partially removed and required longer times (5 d against 1 d for analgesics), the  
488 fungal treatment achieved better results than conventional activated sludge (CAS) processes (Verlicchi et  
489 al., 2012a,b) for the most part. This is the case of ciprofloxacin (69% and 99% in sterile and non sterile  
490 conditions respectively, vs. 58-78% in CAS) and clarithromycin (80% in non-sterile conditions vs. 46-62% in  
491 CAS). Higher removal efficiencies were also observed for the anti-hypertensives: valsartan (90 and 95%  
492 after 8 d in sterile and non-sterile conditions), irbesartan (73 and 98% in sterile and non-sterile conditions),  
493 diuretic furosemide (100% and 80% in sterile and non-sterile conditions vs. 33-54 % in CAS). As for  
494 diclofenac, complete removal was observed. This is an important result as it is one of the most persistent  
495 compounds in CAS and also a potential candidate for regulation by European legislation. On the other hand,  
496 a disadvantage of this process is that after treatment, pH neutralization is necessary as secretion of organic  
497 acids by the fungus lowers the overall pH.  
498 As concerns the investigations carried out in Iran, Iraq and Indonesia, it is important to underline that final  
499 effluent from treatment trains including CAS or ponds generally should not be directly reused for irrigation  
500 purposes due to the occurrence of residues of PhCs and other emerging contaminants. AOPs should be  
501 included in the treatment trains and in any case, further research into the ecotoxicological characteristics  
502 of the final effluent should be carried out.

### 504 **4.3. Tertiary treatments – Pharmaceutical removal**

#### 505 **4.3.1. Filtration through powdered or granular activated carbon (PAC and GAC)**

506 Filtration through PAC and GAC has undergone in-depth investigation by different European research  
507 groups. Figures 4 and 5 report all the collected data. In all cases included in this study, PAC/GAC treatment  
508 followed an MBR fed only with hospital effluent. In the permeate DOC was in the range of 6-8 mg/L, TOC  
509 around 20 mg/L (McArdell et al., 2011; Nielsen et al., 2013).

510 The adsorbent used in the Swiss research was PAC (McArdell et al., 2011) with a surface area of 1300 m<sup>2</sup>/g,  
511 a particle size d<sub>50</sub> 15µm, a zero surface charge point pH<sub>PZC</sub> equal to 8.8 (this last value represents the pH at  
512 which on the carbon surface there are as many positively as negatively charged functional groups; below  
513 this value the carbon surface is positively charged). In the PAC reactor, good mixing guaranteed a constant  
514 concentration of the adsorbent, its retention time was 2 days as a few differences were found with longer  
515 times. Good separation between loaded PAC and treated effluent was achieved by *filtration* through UF  
516 membrane flat sheets (pore size 0.04 µm) in the PILLS project plants (McArdell et al., 2011, PILLS report  
517 2012) and through a 1 µm glass fibre filter in the Dutch research (Nielsen et al., 2013). Nanofiltration  
518 opposed to ultrafiltration would certainly be convenient from a technical view point (improved PhC  
519 removal), but not from an economic one, as nanofiltration concentrate would require dedicated treatment  
520 due to the high concentrations of micropollutants. Another option could be pumping the loaded activated

521 carbon from the PAC reactor to the MBR for recycling: a consistent improvement in the removal of  
522 contaminants could result. But neither of these processes were researched.

523 The investigated doses of PAC ranged between 8-23 mg/L in the Swiss and German research study (PILLS  
524 2012) and between 150 and 450 mg/L in Dutch studies (Nielsen et al., 2013). The former range, which is  
525 absolutely more sustainable from an economic view point, was defined on the basis of costs and  
526 reasonable removal rates for a wide spectrum of micropollutants (56 compounds), the latter was based on  
527 a Swedish study on the removal of micropollutants in aquatic environments (Wahlberg et al., 2010).

528 In the PAC filter effluent, DOC occurred at about 4-4.5 mg/L (PAC dose 8 mg/L), 2.7-3.7 (PAC dose 23 mg/L)  
529 and about 2 mg/L (PAC dose 43 mg/L)

530 Within the Swiss campaigns, at the applied PAC dose of 8 mg/L, 25 out of the 56 investigated  
531 pharmaceuticals were subjected to high removal efficiencies (> 80%) whereas 10 compounds exhibited  
532 removal efficiencies below 20%; at the intermediate value of 23 mg/L a removal efficiency greater than  
533 80% was observed for 36 compounds and less than 20% for only two contrast media (diatrizoate and  
534 ioxitalamic acid). When 43 mg/L of PAC were dosed, 38 compounds had high removal efficiencies (> 80%)  
535 and the same two contrast agents still had scant removal efficiencies (< 20%).

536 A rapid glance at the results achieved within the Dutch research (Nielsen et al., 2013) shows that no  
537 significant differences were observed in the removal of the 30 selected pharmaceuticals by applying 150  
538 mg/L or 450 mg/L of PAC.

539 A comparison between the Dutch campaign and the PILLS project, referring only to the 24 compounds  
540 monitored in all the cited studies, highlights that only for 5 PhCs a higher removal efficiency was achieved  
541 with the (extremely high) Dutch dosages. This occurred for the antibiotics sulfadiazine (40% vs. 78% at both  
542 high doses), sulfamethoxazole (62% vs. 71% and 99% at the two doses), trimethoprim (83% vs. 99.9% at  
543 both doses), the contrast agent ifosfamide (60 vs. 96%), and the beta blocker atenolol (88 vs. 99%).

544 Attempts to correlate the observed removal efficiency of PhCs by using PAC and their sorption potential  
545 expressed in terms of  $K_{ow}$  or  $D_{ow}$  (also accounting for acid-base speciation) were done by the Swiss research  
546 group (Kovalova et al., 2013; McArdell et al., 2011). As regards neutral (not charged) compounds at pH 8.8  
547 (namely carbamazepine, oxazepam, 4-acetamidoantipyrine, cyclophosphamide, iomeprol, iopamidol,  
548 iopromide, metronidazole, phenazone and primidone), it was found that the higher the  $D_{ow}$  value, the  
549 higher the observed removal by sorption. On the contrary there is no agreement between experimental  
550 data and prediction from Log  $D_{ow}$  of sorption removal for *charged* compounds.

551 These results confirm that removal mechanisms consist in nonspecific dispersive interactions and  
552 electrostatic interactions as well between the charged adsorbent surface and ionic adsorbate. Moreover,  
553 not only Log  $D_{ow}$  influences the behaviour of a pharmaceutical, but also its  $pK_a$ , molecular size and  
554 aromaticity/aliphaticity potential as well the presence of functional groups. As regards PAC, effective

555 removal mechanisms depend on surface area, pore size and texture, surface chemistry (in particular  
556 functional groups and point of zero charge) and mineral matter content.

557 As a rule of thumb, adsorption is most effective for compounds which are uncharged and apolar.

558 An interesting analysis and discussion of the behaviour of many compounds is reported in Kovalova et al.  
559 (2013) and McArdell et al. (2011).

560

561

562 **Fig. 4.**

563

564 A consistent improvement in the removal of contrast media may be achieved by recycling PAC to biological  
565 treatment as documented in the MicroPoll projects (Zwickenpflug et al., 2010)

566

567 *GAC filter*

568

569 GAC filtration was investigated at the Netherlands research unit within the PILLS project (PILLS report,  
570 2012) and also in Austria where the oncological ward effluent in a hospital was subjected first to an MBR

571

572 then to GAC treatment (Lenz et al., 2007b). In the first case, the filter bed had a height of 3.0 m and an  
573 empty bed contact time of 51 min. It was fed by MBR permeate (TOC equal to 8.7 mg/L). After GAC

574

575 filtration, all investigated pharmaceuticals were found below their detection limits. Also sulfamethoxazole,  
576 reluctant to PAC sorption, was removed by more than 96%. Unfortunately data referring to contrast agents  
577 were not collected.

578

579 In the second case, the GAC filter had a height of 36.7 cm, a cross surface of 19.6 cm<sup>2</sup> and a flow rate of 7.6  
580 L/h. Antineoplastic compounds (the cancerostatic platinum compounds CPC cisplatin, carboplatin,  
581 oxaliplatin and 5-fluorouracil) were monitored in the GAC influent (corresponding to an MBR permeate)  
582 and effluent. Referring to total Pt content, it was observed that GAC contributed to a removal rate of about  
583 50%. As discussed below, a combination of UV with GAC leads to a lesser removal rate of total Pt. This may  
584 be due to the fact that the photodegradation products of CPCs exhibit lower affinity to activated carbon  
585 than the parent compounds.

586

587 It is interesting to observe that with PAC and GAC no byproducts occur, with respect to all oxidation  
588 processes (ozonation and AOPs in general) where oxidation and photodegradation compounds are  
589 unavoidable and often they have ecotoxicological effects.

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

**Figure 5.**

#### 4.3.2. Ozonation

In ozonation investigations, the influent to each ozone reactor was always an MBR permeate (McArdell et al., 2011, Nielsen et al., 2013), with a COD ranging from 12 and 30 mg/L, a DOC ranging from 6 to 11 mg/L, pH 8-8.5, T 20-22 °C (Kovalova et al., 2012). Contact time within the ozone reactor was between 12 and 23

594 min and the applied dose of ozone was between 0.45 and 2 g O<sub>3</sub>/g DOC (PILLS Project) and between 4.1  
595 and 7.8 g O<sub>3</sub>/g TOC in the study by Nielsen et al. (2013). Higher concentrations of ozone were not tested as  
596 they would lead to the formation of potentially toxic bromates, according to literature (von Gunten 2003).  
597 As is clearly shown in Figures 6 and 7, the higher the applied ozone dose, the greater the number of  
598 compounds with a removal efficiency > 90%. At the lowest tested value of 0.45 g O<sub>3</sub>/g DOC (German unit  
599 within the PILLS project, PILLS report, 2012), 3 out of the 11 investigated compounds were efficiently  
600 removed (namely diclofenac, sulfamethoxazole and erythromycin), the number increases to 26 out of the 48  
601 selected compounds at 0.64 g O<sub>3</sub>/g DOC (Kovalova et al., 2013), to 28 out of 49 at 0.89 and 29 out of 49 at  
602 1.08 g O<sub>3</sub>/g DOC (Kovalova et al., 2013).

603  
604 **Figure 6.**

605  
606 **Figure 7.**

607  
608  
609 The classes of cytostatics and contrast agents were quite reluctant to removal by ozonation: the average  
610 removal efficiencies observed were always lower than those observed for other classes. At medium-high  
611 ozone doses, only some compounds of these two classes were removed by about 50-60%. This occurred to  
612 cyclophosphamide, ifosfamide, iopamidol and iopromide at doses of about 1.1 g O<sub>3</sub>/g DOC and 4.1-7.8 g  
613 O<sub>3</sub>/g TOC (Nielsen et al., 2013). The most reluctant compounds to be removed by ozone were the contrast  
614 agents diatrizoate and ioxitalamic acid, the antibiotic metronidazole and the anthelmintic flubendazole  
615 whose average observed removal efficiencies were between 13 and 27%.

616 This treatment did not consistently decrease COD and DOC as ozonation does not *eliminate* (that is,  
617 *mineralize*) organic matter and micropollutants but rather transforms them into other more degradable  
618 compounds also measured as COD and DOC.

619 It is quite interesting to point out that ozonation seems to be a quite promising treatment for the  
620 abatement of most of the micropollutant load in hospital effluent. It is important to bear in mind one of the  
621 lessons learned by the PILLS Project: based on a Swiss research referring to the top 100 administered  
622 pharmaceuticals in the investigated large hospital (McArdell et al., 2011), a removal efficiency of 90% was  
623 observed for all the PhC and metabolite *load* (ICM excluded) by ozone (1.08 g O<sub>3</sub>/g DOC, pH 8.5, T = 22 °C).  
624 This removal reduces to 50% if contrast agents are included. This could lead to the consideration that  
625 sewage conveying radiological ward effluent could be separated and treated by a dedicated WWTP, so it  
626 could also be possible to recover iodine.

627  
628 The main disadvantages in adopting ozonation, and more in general AOPs, is the formation of oxidation  
629 byproducts (like bromates) due to the matrix compounds (for instance bromides). As these products could  
630 have ecotoxicological effects, it is advisable to adopt a biological step (namely a sand filter or an MBBR)  
631 that will act as a barrier. In the Swiss research, the concentration of bromide in the permeate was 30-40

632  $\mu\text{g/L}$  and after the addition of the highest dose of ozone ( $1.08 \text{ g O}_3/\text{g DOC}$ , corresponding to  $7 \text{ mg O}_3/\text{L}$ ),  
633 bromate was found at a concentration of  $1 \mu\text{g/L}$ , well below the Swiss drinking water standard set at  $10$   
634  $\mu\text{g/L}$ .

635  
636 Ozonation reactions were due to the very selective attack of ozone to specific functional moieties of  
637 organic substances and to the less selective attacks of hydroxyl radicals ( $\text{HO}^\cdot$ ), formed during ozone  
638 decomposition, to a wider spectrum of functional groups within the molecules. Ozone decomposition is  
639 favoured by the presence of hydroxyl ions ( $\text{OH}^-$ ) at alkaline pH ( $\text{pH} > 9$ )

640 The following rules of thumb could lead to a rough prediction of the efficacy of ozonation in removing  
641 different types of micropollutants resulting from studies on the kinetics of ozonation reactions and on the  
642 potential correlation between molecular structure (presence of moieties within the molecule) of a  
643 compound and its reactivity with ozone (Lee and Gunten 2010):

- 644 (i) olefin, phenol, aniline, thiophenol, thiol and tertiary amine exhibit a high reactivity with ozone,
- 645 (ii) secondary amines, thioester and anisole an intermediate reactivity,
- 646 (iii) primary amines and nitro group a slow reactivity and (iv) amides do not react with ozone.

647 Compounds with a high reactivity to ozone are already removed to a high extent at the lowest dose of  $0.64$   
648  $\text{g O}_3/\text{g DOC}$ . For compounds with intermediate reactivity, such as benzotriazole and ritalinic acid, higher  
649 removal efficiencies were observed with higher ozone doses. Lowest removal efficiency was found in  
650 contrast agents without moieties.

### 651 652 **4.3.3. UV radiation**

653 Only a few investigations (within the PILLS Project (PILLS report 2012) and at the oncologic ward in a  
654 hospital in Vienna (Lenz et al., 2007b), dealt with the ability and the contribution of an UV irradiation  
655 process in the removal of PhCs from (pretreated) hospital effluent: in each one, the UV reactor was always  
656 fed by an MBR permeate ( $\text{DOC} = 6\text{-}8 \text{ mg/L}$ ). The main characteristics of the tested equipment are reported  
657 in table 4 (PILLS, 2012, McArdell et al., 2011, Lenz et al., 2007b): in particular different fluence values were  
658 tested and, in the Luxembourg unit, low and medium pressure (LP, MP) UV lamps were used and for some  
659 runs, a polychromatic light was applied to the water stream. The collected data are reported in Figures 8  
660 and 9 referring to the lamp type and the applied fluence.

661 Observed removal efficiencies for the investigated compounds were always less than 50% when the UV  
662 fluence of  $800 \text{ J/m}^2$  was applied. At  $2400 \text{ J/m}^2$ , 12 out of 31 PhCs were removed at more than 50% and with  
663  $7200 \text{ J/m}^2$ , 18 out of 31 compounds exceeded the 50% removal threshold. If the UV is irradiated at higher  
664 fluence values, removal increases (for instance at  $29700 \text{ J/m}^2$  or  $47250 \text{ J/m}^2$ ). When MP lamps were used, a  
665 polychromatic light was produced and all the seven investigated compounds were successfully removed.  
666 Figures 8 and 9 clearly show, with the exception of cyclophosphamide ( $\eta = 58\%$ ), that the removal  
667 efficiency of the other compounds ranged between 81 and 98%, on average 83%.

668 Compounds with the highest removal efficiencies were: 4-acetamidoantipyrene (99% with LP and 7200  
669 J/m<sup>2</sup>), diclofenac (99% with LP lamp and 29700 and 47250 J/m<sup>2</sup>), diclofenac and 4-formylaminoantipyrene  
670 (98%, with LP and 7200 J/m<sup>2</sup>), sulfamethoxazole (98% with LP lamp and 47250 J/m<sup>2</sup>), diatrizoate (97% with  
671 LP and 7200 J/m<sup>2</sup>), sotalol (95% with LP and 7200 J/m<sup>2</sup>) and the remaining X ray contrast media (iomeprol  
672 90%, iopamidol, iopromide and ioxitalamic acid 92% with LP and 7200 J/m<sup>2</sup>). This last result is quite  
673 interesting, as the UV process seems to be the most effective treatment to remove these from the  
674 wastewater.

675  
676 **Table 4.**

677  
678 **Fig. 8**

679  
680 **Fig. 9**

681  
682 The contribution of an UV process in the removal of antineoplastic compounds was found to be negligible.  
683 This was concluded by Lenz et al. (2007b) who monitored the cancerostatic platinum compounds (CPCs)  
684 cisplatin, carboplatin, oxaliplatin and 5-fluoracil in the effluent of a hospital oncological ward. They found  
685 that oxidation of CPC by UV leads to a marginal reduction of total Pt as, even if the substances are  
686 transformed by oxidation, the total amount of Pt remains the same. As for cyclophosphamide, removal  
687 efficiency was found higher in the case of medium pressure UV lamps than in the case of LP lamps (58% vs.  
688 3%)

689  
690  
691 It was observed that UV irradiation is a promising technology in the removal of X-ray contrast media. Very  
692 appreciable results were observed when a fluence of 7200 J/cm<sup>2</sup> was applied. At higher values the removal  
693 of different analgesics, antibiotics, beta-blockers increased (Kovalova et al., 2013).

694 Transmission of UV in water is strictly correlated to water turbidity. Very low turbidity is recommended in  
695 order to greatly reduce potential interferences with the water matrix. Excessive dosages of chemical  
696 oxidisers may act as a scavenger thus inhibiting contaminant destruction efficiency.

697 UV transmission is subject to decrease due to lamp fouling. To reduce lamp fouling, adequate  
698 pretreatments are necessary, insoluble oil and grease concentrations should be minimized and heavy metal  
699 ion concentration should be maintained at a concentration less than 10 mg/L

#### 700 701 **4.3.4. Advanced oxidation processes (AOPs)**

##### 702 **4.3.4.1. Removal of pharmaceuticals**

703 Advanced oxidation processes include different technologies aiming to completely oxidize and/or destroy  
704 different kinds of organic pollutants in water and wastewater streams into H<sub>2</sub>O, CO<sub>2</sub> and mineral salts.

705 Each one is characterized by a variety of *radical reactions* due to highly reactive species (mainly hydroxyl  
1  
706 radicals HO•, but also superoxide radical anions O<sub>2</sub><sup>-•</sup>, hydroperoxyl radicals HO<sub>2</sub>•, ROO<sup>-</sup>), generated on site  
3  
707 in different ways, involving combinations of chemical agents (namely ozone, hydrogen peroxide, transition  
5  
708 metals, metal oxides) and auxiliary energy sources (namely UV irradiation, electronic current, γ-radiation  
7  
709 and ultrasound). This study includes combinations between O<sub>3</sub> and H<sub>2</sub>O<sub>2</sub> as chemical agents and UV  
8  
710 irradiation as an energy source.

10  
711 HO• is the primary oxidant in AOPs and unlike many other radicals it is non-selective, it readily reacts with  
12  
712 many organic pollutants occurring in the water, converting them into more hydrophilic compounds than  
14  
713 the original ones.

16  
714 A brief presentation of each, including the main reactions occurring during AOPs is reported in the  
18  
715 Supplementary Data, whereas below, the results obtained in the different investigations into AOPs applied  
19  
716 to hospital effluents as polishing treatments are presented (Figure 10) and discussed.

21  
717 In the experimental setup tested in Switzerland within the PILLS project (McArdell et al., 2011), the  
23  
718 photocatalysis process UV/TiO<sub>2</sub> was compared to the UV process alone. This setup includes a reaction  
25  
719 column containing four conical cartridges, consisting in a photocatalytic fibre (titanium-dispersed silica-  
26  
720 based fibre with a sintered anatase-TiO<sub>2</sub> layer on the surface), around a low pressure UV lamp (254 nm, 220  
27  
721 V, 100-400 W overall energy consumption, 10 mW/cm<sup>2</sup> nominal fluence rate). To protect the fibre from  
28  
722 particle contamination, two pre-filters with a mesh width of 25 and 5 μm were installed. The elimination  
30  
723 rate was evaluated after 1, 3 and 9 cycles with the photocatalytic chamber (UV/TiO<sub>2</sub>) and with UV only.  
32  
724 Removal obtained with one cycle was marginal.

34  
725 Another interesting investigation was carried out by Vasconcelos et al. (2009), aiming to compare the  
36  
726 degradation of just ciprofloxacin in hospital effluent by ozonation, UV irradiation, UV/TiO<sub>2</sub> and O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub>. As  
38  
727 to TiO<sub>2</sub>/UV lab scale equipment was used and TiO<sub>2</sub> was added as a suspension (400 mgTiO<sub>2</sub>/700 mL) to the  
40  
728 hospital effluent set at pH = 3 to enhance photocatalyst activity (see Supplementary Data for process  
42  
729 details). After the treatment, the samples were filtered through a 0.22 μm membrane to separate TiO<sub>2</sub>  
44  
730 particles from the solution. Complete removal of ciprofloxacin was observed after 60 min within the  
46  
731 photocatalytic reactor. The same result was obtained after 300 min in an UV reactor (equipped with a 125  
48  
732 W medium pressure mercury lamp).

50  
733 UV/TiO<sub>2</sub> exhibited a better removal than UV only for a few compounds, in particular for 4- aminoantipyrine,  
52  
734 4-methylaminoantipyrine and sulfapyridine. In general the removal efficiencies increased by a factor of two  
54  
735 for most of the compounds without a photocatalyst.

56  
736 An increment in the cycles slightly improved the removal of contaminants. Only X-ray contrast agents  
58  
737 achieved higher removal efficiencies than in the other post-treatments (20-70%). These results led to the  
60  
738

739 consideration that direct phototransformation with UV dominated the micropollutant removal and indirect  
740 phototransformation due to the presence of the embedded TiO<sub>2</sub> did not occur.

741 Generally the removal efficiencies observed with TiO<sub>2</sub>/UV in 9 cycles were observed in only 3 cycles when  
742 using UV alone.

743 The lower removal efficiency observed by UV/TiO<sub>2</sub> might also be due to the fact that photocatalytic fibre  
744 could have adsorbed UV light and shaded part of the reaction chamber, thus the water could have been  
745 exposed to less UV irradiation.

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

**Figure 10.**

An improvement in the removal of PhCs was observed when H<sub>2</sub>O<sub>2</sub> was added to the UV reactor. No  
consistent differences were found between a dosage of 0.56 g /L and 1.11 g/L (Kohler et al., 2012). It was  
also found that the optimum light wavelength for the UV/H<sub>2</sub>O<sub>2</sub> system is 254 nm as it guarantees the  
lowest background absorbance of the investigated water and high H<sub>2</sub>O<sub>2</sub> absorbance resulting in an efficient  
generation of hydroxyl radicals. As a consequence, LP lamps are recommended as about 90% of their  
irradiated light is emitted at 254 nm, whereas MP lamps emit 254 nm light for 5-10% of the total emission.  
The good results obtained with LP UV irradiation in AOPs lead to the consideration that for many PhCs,  
degradation processes are mainly due to chemical oxidation (between the molecule and the generated  
radicals) rather than to direct photolysis (Kohler et al., 2012).

Wilde et al. (2014) achieved promising results thanks to the degradation of a mixture of beta-blockers  
(atenolol, propranolol and metoprolol) in hospital effluent (pretreated in a septic tank followed by an  
anaerobic filter) by O<sub>3</sub> and Fe<sup>+2</sup>/O<sub>3</sub>: they showed that, in 120 min, complete degradation of the parent  
compounds was observed but not their complete elimination. The degradation process was found strictly  
correlated to pH. Alkaline pH values promote the removal of metoprolol and propranolol, whereas acidic  
values enhance the removal of organic load (expressed as COD). The investigation also highlighted the risk  
of undesired byproducts due to ozonolysis with a more intense degree of recalcitrance with respect to their  
parent compounds. This lead to better investigated ecotoxicological characteristics of the polished effluent.

A slight increment in the removal of micropollutants was observed by adding H<sub>2</sub>O<sub>2</sub> into the system. H<sub>2</sub>O<sub>2</sub>  
accelerates the decomposition of ozone and partially increases the amount of hydroxyl radicals. Two  
different application modes were tested within the PILLS Project (McArdell et al., 2011):

- addition of H<sub>2</sub>O<sub>2</sub> into the ozone reactor influent;
- pre-ozonation of the MBR permeate with 1.2 g O<sub>3</sub>/g DOC, addition of 2.5 mg/L H<sub>2</sub>O<sub>2</sub> to half of the  
treated wastewater and both parts again treated with 0.7 g O<sub>3</sub>/g DOC.



775 Differences were observed of about  $\pm 20\%$  which were not considered significant because within  
776 experimental error, in agreement with data already published confirming that little improvement was  
777 found especially in water with relatively high DOC (Acero and von Gunten, 2001) and that hydroxyl radicals  
778 attack is less effective than  $O_3$  attack.

779 A significant removal efficiency is observed if very high doses of ozone and  $H_2O_2$  are applied to the  
780 permeate as tested by Nielsen et al. (2013) (130  $mgO_3/L$  and 60  $mgH_2O_2/L$  5 min; 450  $mgO_3/L$  and 200  $mg$   
781  $H_2O_2/L$  15 min): in these operational conditions with few exceptions (sulfamethoxazole) all the selected  
782 micropollutants were removed below their PNEC/EQS (environmental quality standard) value.

783  
784 In order to guarantee a clear, polished effluent, sometimes a “trap” step follows the AOP reactor. In this  
785 context, the effluent of a PAC reactor was filtered through UF membrane flat sheets (pore size 0.04  $\mu m$ )  
786 (Switzerland, McArdeil et al., 2011). Moreover within the PILLS Project units, a moving bed bioreactor (HRT  
787 = 0.3-1 d) was used following PAC,  $O_3$  or  $TiO_2/UV$  and a sand filter (filtration velocity  $v_f < 12$  m/h) was  
788 equipped after ozone or the PAC unit.

#### 789 790 **4.3.4.2. Removal of microorganisms**

791 Disinfection efficiency is strictly correlated to the applied technologies. Table 5 reports the efficacy of 7  
792 different treatments applied to a secondary hospital effluent (Machado et al., 2007) or a secondary hospital  
793 laundry effluent (Kist et al., 2008) carried out in Brazil:

794 The main influent characteristics to the disinfection step were: 25 °C, pH = 9.5, upstream treatments: septic  
795 tank + anaerobic/aerobic treatment fed with hospital/laundry effluent. A dose of 12  $mgO_3/L$  was applied  
796 and equipped with a UV lamp with an emission at 254 and 365 nm, radiating an energy of 31.9  $J/cm^2$ .

797 Catalyst fixation was obtained by preparing a suspension of  $TiO_2$  in  $CHCl_3$  (10% m/v) and by spreading it on  
798 a plate (2.96  $mg TiO_2/cm^2$ ). The contact time was 60 min for each.

#### 799 800 **Table 5**

801  
802 The best disinfection efficiency was observed for the combination  $UV/TiO_2/O_3$ , that also provides very good  
803 turbidity removal (from 234 to 36.5 NTU), surfactants (8.0  $10^6$   $mg/L$  to < detection limit) and toxicity ( $EC_{50}$   
804 *Daphnia Magna* from 65 to 100). A contact time of 10 min will result in a concentration of 330 MPN/100  
805 mL and of 30 min of about 70 MPN/100 mL.

806 The disinfection performance is due to damage of the microorganism’s cell wall and cytoplasmatic  
807 membrane. Thus cell permeability increases allowing intracellular content to flow through the membrane  
808 leading to cell death.

809  
59  
60  
61  
62  
63  
64  
65

810  
811  
2  
812  
4  
813  
5  
814  
7  
815  
9  
816  
11  
817  
12  
818  
13  
14  
819  
16  
820  
18  
821  
20  
822  
21  
823  
23  
824  
25  
825  
27  
826  
28  
827  
30  
828  
31  
829  
32  
830  
34  
35  
831  
36  
37  
832  
39  
833  
41  
834  
42  
835  
43  
44  
836  
46  
837  
48  
838  
49  
839  
51  
840  
52  
841  
53  
842  
54  
843  
55  
56  
844  
57  
845  
58  
59  
846  
61  
62  
63  
64  
65

#### 4.3.5. Nanofiltration and reverse osmosis

Nanofiltration (NF) and reverse osmosis (RO) processes are considered potential polishing treatments for hospital effluent, pretreated in an MBR from a technical view point. Residues of PhCs, still present in the permeate, may be retained due to molecular weight and size, sorption onto the membrane and also charge. Each membrane is characterized by a molecular weight cut off (MWCO) that represents the weight of those substances retained between 60 and 90%. Sorption is a potential removal mechanism for poorly soluble non-polar compounds, negatively charged compounds are rejected by NF/RO membranes due to electrostatic repulsion between the compounds and the negatively charged membrane surface (Kimura et al., 2004). Moreover, water characteristics such as pH, ionic strength, hardness, organic matter and membrane biofouling also have an influence on solute rejection.

In the study by Beier et al. (2010) the permeate of an MBR (COD < 30 mg/L, 5-10 mgN/L) equipped with microfiltration membranes was then subjected to NF and RO processes, characterized by a MWCO of 300-400 da and 100-150 da, respectively. It was found that RO exhibited a higher removal for all selected PhCs with respect to NF. However, RO presents major disadvantages due to the limited yield and the retentates that have to be properly disposed of. However, no suitable prediction model has been developed up to now as the rejection of the different micropollutants in NF/RO processes is specific for each membrane (Siegest and Joss, 2012).

#### 4.3.6. Chlorination

Only a few data are available regarding the removal efficiency of PhCs observed after a final chlorination. These are reported in Fig. 11 and refer to the investigation carried out by Nielsen et al. (2013). The added amount of ClO<sub>2</sub> was 60 mg/L in each run, and two different contact times were adopted: 15 min and 60 min. Ciprofloxacin showed higher concentrations in the effluent rather than in the influent to the treatment. In addition, chlorination seems to be able to remove diclofenac: in the study by Nielsen et al. (2013), its concentration in the influent (MBR permeate) was quite low (< 5 ng/L) and in the effluent it was 1 ng/L (15 min as contact time). But it was found that under lab scale controlled chlorination with surface water, diclofenac exhibited a large degree of reactivity and its final concentration was below detection limit (Westerhoff et al., 2005)

Fig. 11.

#### 4.4. Disinfection performance

In some countries disinfection is mandatory for the effluent generated in infectious disease wards or in health care specialized in infectious diseases (Nardi et al., 1995; Emmanuel et al., 2004). Fecal and total coliforms were found in the ranges 10<sup>2</sup>- 10<sup>4</sup> MPN/100 mL and 10<sup>4</sup>-10<sup>6</sup> MPN/100 mL respectively (Table 1).

847 These values are lower than those usually found in raw urban wastewater (Verlicchi et al., 2012a), probably  
848 due to the antimicrobial activity of antibiotic and disinfectant residues present in the infectious disease  
849 ward effluent.

850 At a dosage of 10 mg/L of ClO<sub>2</sub> and a contact time of 30 mins fecal and total coliforms drop to less than  
851 12000 and 20000 MPN/100 mL and a complete removal of viruses was always observed (Nardi et al., 1995).  
852 Predisinfection of raw hospital effluent is still an issue of great concern: based on a theoretical hypothesis,  
853 Korzeniewska et al. (2013) recommend a preliminary disinfection of the hospital effluent before its  
854 immission into public sewage in order to minimize the spread of antibiotic resistant bacteria, on the other  
855 hand, research by Emmanuel et al. (2004) found that disinfection by means of NaOCl of the effluent from  
856 infectious and tropical disease departments can reduce the content of microorganisms, but at the same  
857 time it has toxic effects on aquatic organisms.

858 In many countries, including China, direct chlorination or primary treatment followed by chlorination  
859 represent the most widely used methods to treat and, in particular, disinfect hospital effluent in order to  
860 prevent the spread of pathogenic microorganisms (Liu et al., 2010). Despite the fact that chlorine  
861 disinfection has a broad spectrum of bioacid activities against bacteria, virus and fungi and it is simple to  
862 use, it may produce toxic byproducts, its performance depends on the water quality and only a low removal  
863 efficiency is achieved for viruses as they have a greater tolerability against chlorine compounds than  
864 bacteria. As a consequence, a high excess of disinfectant is generally applied to guarantee a (rough)  
865 disinfection of the hospital effluent, but inevitably extremely high concentrations of residual chloride (as  
866 high as 100-130 mg/L) will occur, resulting in serious pollution problems to the receiving aquatic  
867 environment, as remarked by Emmanuel et al. (2004) who investigated the effect of the addition of NaClO  
868 to hospital effluent: it can greatly reduce bacteria population, but it has toxic effects on aquatic organisms.  
869 In China, to avoid an excessive use of chlorine, the removal of different types of microorganisms from  
870 hospital effluent is dealt with by means of an MBR, mostly employing submerged membranes (pore size  
871 about 0.2-0.4 µm), followed by a chlorination step with a dosage of NaClO of 1-2 mg/L as free chlorine with  
872 a contact time of 1.5 min. Since 2000, many plants based on membrane technologies have been built for  
873 the treatment of hospital effluent, with a capacity ranging between 20 and 2000 m<sup>3</sup>/d, in compliance with  
874 the severe limits of 50 PFU/100 ml such as *E. coli* (Liu et al., 2010).

875 While a (UF) MBR followed by a specific disinfection step may be considered a viable option for the removal  
876 of a wide group of bacteria occurring in hospital effluent, studies into their performance in reducing  
877 pathogenic viruses are still scarce. The removal of viruses in an MBR is substantially due to three  
878 mechanisms: virus rejection depending on the cake generating on the membrane surface, viral inactivation  
879 of the biomass, and adsorption onto the surface of suspended solids which makes these microorganisms  
880 more stable.

883 In a Brazilian investigation (Prado et al., 2011) the removal of some enteric viruses (Rotavirus A, human  
884 adenovirus, norovirus genogroup I and II and hepatitis A viruses) was compared in two different treatment  
885 trains: an anaerobic one including a UASB followed by three anaerobic filters and an aerobic one consisting  
886 of a conventional activated sludge process followed by chlorination. It was found that both systems are not  
887 suited to their removal. Their frequencies of detection and quantification results varied according to the  
888 virus type and effluents coming from different health care structures.

889 An MBR, equipped with ultrafiltration membranes is able to remove groups of bacteria as reported above  
890 mainly due to membrane retention, reducing the spread of multiple antibiotic resistant strains, usually  
891 occurring in hospital effluent. But specific disinfection is advisable, in order to avoid regrowth of (survival)  
892 bacteria as discussed in Pauwels et al. (2006). For inactivation of pathogens and possible removal of  
893 antibiotic resistant bacteria, UV and ozonation are more efficient with respect to PAC and GAC.

894 In wastewater disinfection, the fluence to apply depends on the required microorganism limits (Verlicchi et  
895 al., 2010). For instance 100 J/m<sup>2</sup> are applied if the aim is to guarantee 1000 MPN/100 mL of total coliforms,  
896 750-850 J/m<sup>2</sup> if a concentration of 23 MPN/100 mL of total coliform has to be guaranteed and finally a  
897 fluence greater than 1000 J/m<sup>2</sup> if the residual concentration of total coliform is < 2.2 MPN/100 mL, thus  
898 allowing an unrestricted irrigation of the disinfected effluent (Crites and Tchobanoglous, 1998).

899 To inactivate specific microorganisms, oocysts or viruses, the requested fluence could be higher. To  
900 inactivate 3 log of Adenovirus type 40, a fluence of 1670 J/m<sup>2</sup> is required, whereas to inactivate up to 3 log  
901 of Cryptosporidium and Giardiasis, a fluence of 120 J/m is required (Hijen et al., 2006).

902 These considerations lead to the consideration that when ozonation, UV, AOPs in general are applied to  
903 hospital effluent to remove recalcitrant compounds, at the same time it is disinfected to a very high degree.  
904 But in order to guarantee safe reuse of the disinfected effluent for unrestricted irrigation, a higher fluence  
905 is required (as well as further studies into the ecotoxicologic characteristics of the water)

#### 906 907 908 **4.5. Comparison between the different treatments**

909 A comparison of the performance of the different analyzed secondary and tertiary dedicated treatments  
910 for HWW is depicted in Figure 12 in terms of number of investigated compounds and the number of  
911 compounds exhibiting a removal efficiency greater than 80%. It is based on all the data collected about  
912 PhCs in the peer reviewed papers included in this manuscript. What clearly emerges is that the most  
913 investigated technologies are MBR, PAC, ozonation and UV. The best results were performed by MBR  
914 (secondary step) and PAC (tertiary step).

915 Moreover Table SD-3 in Supplementary Data compiles compounds that exhibited a removal efficiency  
916 greater than 80% during secondary and tertiary treatment, with the corresponding references.

917 An in-depth analysis of the comparison of pairs of treatment is performed in Kovalova et al. (2013) with  
918 respect to the different classes of PhCs. They found that iodinated contrast media were better removed by

919 MBR+UV (66% of the total influent load), all the selected PhCs except iodinated contrast media by  
920 MBR+PAC or MBR +UV (99%).  
921 Lessons learned from these campaigns led to consider 1.08 g O<sub>3</sub>/g DOC, 23 mg/L PAC and 2400 J/m<sup>2</sup> UV the  
922 values that best satisfy the two following choice criteria: relatively good abatement for most  
923 micropollutants and reasonable running costs (Kovalova et al., 2013).  
924 Table 6 reports a rough estimation of the global removal of the different kind of classes with respect to  
925 different technologies, based on all the collected data.

926  
927 **Table 6.**

928 It is important to observe that the choice of the best technologies for treatment of hospital effluent should  
929 not necessarily lead to the complete removal of specific parent compounds, but to the removal of the  
930 estrogenic activity of the effluent itself, or more generally, a reduction in its ecotoxicological effects.  
931 Bearing this concept in mind, processes including TiO<sub>2</sub> photocatalysis seem to be promising technologies as  
932 they are able to remove estrogenic activity of 17-β-estradiol (Byrne et al., 1998), 17-α-ethinylestradiol  
933 (Coleman et al., 2000).  
934 AOPs seem to be the most promising technologies as they can be effective in removing compounds not  
935 affected by other technologies as discussed above, reactions are generally fast, resulting in more compact  
936 reactors, finally (no or) low chemical doses are required leading to (no or) lower residuals, but they may  
937 have undesirable drawbacks, namely: unselective hydroxyl radicals, production of more hydrophiles and  
938 more difficult to treat byproducts than the original ones; as have been clearly listed by Sutý et al. (2004).

939  
940 **Figure 12.**

941  
942  
943  
944 The spread of disease due to pathogens and of specific strains of antibiotic resistant bacteria can be  
945 countered by a disinfection step (Korzeniewska et al., 2013). Some laws and regulations (including the  
946 Italian Deliberation by the Inter-ministerial Committee dated 4 February 1977) require treatment of the  
947 effluent from health care structures, blood analysis laboratories, and in particular, for the effluent from  
948 infectious disease wards. As an example, the effluent produced by the very large laboratory for blood  
949 analysis in Pievesestina (Cesena, North Italy, effluent flow-rate about 10<sup>3</sup> m<sup>3</sup>/year) is subjected to  
950 ozonation and filtration through activated carbon prior to being immitted into the public sewage system  
951 and is then co-treated at the municipal WWTP. Alternatively, the addition of 10 mg/L of ClO<sub>2</sub> and a contact  
952 time of 30 min, guarantee an efficient removal of fecal and total coliform, with a negligible increment of  
953 AOX (Nardi et al., 1995). This increment is consistent if the applied disinfectant is NaClO (Emmanuel et al.,  
954 2004).

955 Due to the different nature of pollutants that may be present in hospital effluent (residues of PhCs, their  
956 metabolites, disinfectants and antiseptics, heavy metals, radio-elements, pathogens), the risk posed by this  
957 effluent may be toxic, radioactive and infectious.  
958 Proper management of hospital effluent has to be considered and must include measures to mitigate the  
959 consequences at a WWTP level as well as towards the environment.

#### 4.6. Removal efficiencies vs. physical-chemical properties of investigated compounds

960 Many studies were developed in order to investigate potential correlations between observed  
961 pharmaceutical removal efficiencies achieved by the different wastewater treatments and pharmaceutical  
962 molecular properties (among them Cunningham, 2008; Joss et al., 2006, Rogers, 1996; Tadkaew et al.,  
963 2011). They underlined that it is always very difficult to find reliable correlations, because many factors (i.e.  
964 operational and environmental conditions) affect removal mechanisms of such complex molecules thus a  
965 wide range of variability is generally observed for the removal of a specific compound during a treatment.  
966 Studies referring to UWW led to rules of thumb that try to correlate the behavior of a specific molecule on  
967 the basis of its properties:  $k_{biol}$ ,  $K_d$ ,  $K_{ow}$ ,  $pK_a$ , as discussed and reported in Tadkaew et al. (2011) and Verlicchi  
968 et al. (2013). Lessons learned from UWW may be also useful in making a rough prediction of efficacy of  
969 specific treatments in HWW managing.

970 Moreover attempts to correlate the behavior of common parameters, such as COD or SS, and specific  
971 pharmaceuticals during hospital wastewater treatment were carried out, but unfortunately they did not  
972 suggest any reliable relationship (Emmanuel et al., 2004, Pauwels et al., 2006, Vasconcelos et al., 2009,  
973 Wilde et al., 2014).

### 5. Hospital effluent toxicity and Environmental risk assessment

974 Interesting and useful research has been accomplished dealing with hospital effluent toxicity and  
975 assessment of the environmental risk posed by pharmaceutical residues in treated hospital effluent (Boillot  
976 et al., 2008; Perrodin et al., 2013; Emmanuel et al., 2004). This is quite a complex problem and is beyond  
977 the aim of this manuscript, but some lessons learned from published studies are discussed herein to point  
978 out concerns that merit further research.

979 It is well known that hospital effluent is 5-15 more toxic than urban wastewater due to the high  
980 concentrations of detergent and disinfectants, often containing chlorine or aldehydes (such as sodium  
981 hypochlorite and glutaraldehyde), iodinated contrast media that lead to the generation of AOX in the  
982 drainage network, heavy metals (namely silver used in radiology departments), radio-elements injected or  
983 administered in nuclear medicine studies and completely excreted in urine, PhC residues. That being said,  
984 hospital effluent can inhibit the activity of the biomass in the aeration tank of a sewage facility by 7-8% as  
985 documented in Boillot et al. (2008) and Panouillères et al. (2007).

990 Investigations are often based on Microtox and acute *Daphnia magna* tests (Emmanuel et al., 2004; Boillot  
991 et al., 2008), but also to batteries including different kinds of test (Perrodin et al., 2013).

992 Lessons learned from these studies suggest that different pollutants may induce or contribute to toxicity:  
993 namely free chlorine, AOX (Emmanuel et al., 2004), ethanol, propanol, metals including Zn, Cu, As, Pb  
994 (Boillot et al., 2008).

995 Environmental risk assessment of hospital wastewater is generally based on the risk quotient  $RQ$ , defined  
996 as the ratio between PhC concentration in the effluent and its predicted non- effect concentration (PNEC).

997 According to the classification that was adopted in many studies (Straub, 2002; Verlicchi et al., 2012a;  
998 Santos et al., 2013) the risk is classified high if  $RQ \geq 1$ , medium if  $1 < RQ < 0.1$  and low if  $RQ \leq 0.1$ .

999 Based on *measured* effluent concentrations Verlicchi et al. (2012a) and Santos et al. (2013) found that in  
1000 raw hospital effluent a high risk is posed by azithromycin, clarithromycin, erythromycin, ofloxacin,  
1001 sulfamethoxazole, metronidazole fluoxetine, ibuprofen, acetaminophen and iopromide. This fact pinpoints  
1002 that adequate treatment is necessary for hospital wastewater to reduce its negative effect on the  
1003 environment. Bearing this in mind, the frameworks provided by Al Aukidy et al. (2014), Emmanuel et al.  
1004 (2005), Escher et al., (2011), Lienert et al., 2011, Mullot et al., 2010 might help in evaluating and comparing  
1005 the efficacy of different treatment trains.

1006 *Antibiotic resistance bacteria* - Another source of risk in hospital effluent is correlated to the occurrence of  
1007 antibiotics and consists in the potential development and release of antibiotic-resistant bacteria (ARB) and  
1008 genes (ARG). The PILLS project pinpoints that the risk of the spread of resistance to specific antibiotic  
1009 molecules is higher in hospital effluent than in urban WW. The efficiency of advanced biological and  
1010 chemical processes varies in the range of 1-5 log units. Ultrafiltration MBRs guarantee a consistent  
1011 reduction of this risk, whereas a following step including ozonation, sand or PAC filtration does not  
1012 contribute to further reduction.

1013  
1014

43  
44

## 1015 **6. Costs**

1016 A summary of the investment and operational and maintenance (O&M) costs for the different scenarios are  
1017 reported in Table 7 referring to economic evaluations carried out in the cited studies in a design step.

1018 Unfortunately they are not homogeneous and not always investment and operational and maintenance  
1019 data are available. The investments are amortized over 10 or 15 years depending on the investigations.

1020 Table 7 just offers a rapid comparison of the different technologies and of the order of magnitude of the  
1021 different treatment trains.

1022 Many considerations may arise from these reported values. For example, it emerged from previous  
1023 discussion of collected removal data of PhCs that activated carbon seems a promising technology in  
1024 reducing their occurrence in the final effluent. But activated carbon requires expensive maintenance

62  
63  
64  
65

1025 operations in order to guarantee proper performance. In this context, investment cost for an activated  
1026 carbon filter is lower than that of another AOP treatment, but if DOC levels in the stream fed to the carbon  
1027 filter are above 10 mg/L, carbon treatment could become uncompetitive against AOPs, due to frequent  
1028 change out, regeneration and disposal of the exhausted carbon. Moreover, GAC and PAC do not destroy  
1029 microcontaminants, but they allow their transfer from a liquid phase to a solid one. Operational costs  
1030 should also include costs of final disposal of GAC and PAC.

1031  
1032 To have an idea of the potential cost of dedicated treatment of hospital effluent, total costs range between  
1033 4.1 €/m<sup>3</sup> and 5.5 €/m<sup>3</sup> in case of secondary treatment by means of an MBR and polishing AOPs with the  
1034 exception of Kovalova et al. (2013) that reported lower total costs ranging around 2.4-2.7 €/m<sup>3</sup>. These  
1035 differences were not commented by the two research groups within the PILLS projects.

1036  
1037

1038 **Table 7.**

1039  
1040

1041  
1042

## 1041 **7. Current strategies and future perspectives in the treatment of hospital effluent -** 1042 **Conclusions**

1043 Management and treatment of hospital effluent greatly vary in different countries. In developed ones they  
1044 may be completely absent, meaning that HWW is directly discharged into a surface water body or they  
1045 consist in simple chlorination, or primary clarification followed by a chlorination or primary and secondary  
1046 treatments followed by chemical disinfection (Prayitno et al., 2014).

1047 Various research projects have been carried out in these countries, aiming to evaluate the suitability of  
1048 some (simple) treatment trains for hospital effluent. They generally refer to a discussion of the observed  
1049 removal efficiencies of *conventional* contaminants and microorganisms, and the possibilities to directly re-  
1050 use this reclaimed water for irrigation purposes as they have to face problems arising from water shortage  
1051 (among them Chitnis et al., 2004; Shetha et al., 2001; Beyene and Redaie, 2011, Abd-El-Gawad and Aly,  
1052 2011). Suggestions to improve the adopted treatment are also provided with a view to their applicability in  
1053 terms of land requirement, footprint, costs, installation, operation and maintenance. Some case studies are  
1054 reported herein. Direct reuse of reclaimed water should be evaluated, including the risk posed by  
1055 persistent emerging contaminants and their (acute and chronic) effects on the environment and human  
1056 health.

1057 In European countries efforts are made to improve removal of these persistent compounds by means of  
1058 end-of pipe treatments and in this context, AOP technologies are the most researched ones. Studies  
1059 generally refer to occurrence and removal of a consistent number of PhCs, as well as ecotoxicological  
1060 evaluation by means of the risk quotient ratio, i.e. the ratio between maximum measured concentrations  
1061 and predicted no-effect concentration (Verlicchi et al., 2012a,; Escher et al., 2011). Different full scale

1062  
1063  
1064  
1065



1062 WWTPs have already been constructed for the dedicated treatment of hospital effluent. Each one consists  
1063 in preliminary treatment, MBR (Beier et al., 2011), MBR followed by ozonation and UV (Verlicchi et al.,  
1064 2010), ozonation and PAC (PILLS report, 2012), ozonation and GAC (Pharmafilter, 2013;Grundfos  
1065 Biobooster, 2012).

1066 An interesting approach has been adopted in France to manage and treat the effluent of the Centre  
1067 Hospitalier Alpes Lemon in Annemasse. Thanks to dedicated piping, the HWW is conveyed to the near  
1068 municipal WWTP where it is treated in a specific line and subjected to continuous monitoring to improve  
1069 the removal of persistent compounds. This was a decision taken by the local authorities who have even  
1070 drawn up a specific law for this site (Sibipel Report, 2014).

1071 The best option in the management and treatment of hospital effluent is strictly correlated to hospital size  
1072 and catchment area dimension and must be defined on the basis of a technical and economical feasibility  
1073 study that would focus on the most appropriate measures able to reduce the (macro and micro) pollutant  
1074 load discharged into the surface water environment. Dedicated treatments for hospital effluent are  
1075 recommended by many authors worldwide, segregation and special treatment seems adequate for specific  
1076 effluent including effluent generated in radiology wards, containing ICMs, the most recalcitrant  
1077 compounds, at extremely high concentrations, but also for the effluent from laundries, oncological wards  
1078 and clinical analysis laboratories, as in the case of the large and centralized Italian lab services discussed  
1079 above. In any case, dilution with surface water should not represent the proper action to mitigate potential  
1080 adverse negative effects of PhC residues in the environment.

1081 A final remark is suggested by studies promoting the implementation of energy-intensive systems with  
1082 indirect solar energy by aggregating photovoltaic cells for the generation of electrical energy. This may  
1083 result in energy storage and in a balanced use of energy during periods in which light incidence is lower.

1084

40

41

1085

42

1086

43

1087

44

1088

45

1089

46

1090

47

1091

48

1092

49

1093

50

1094

51

1095

52

1096

53

1097

54

1098

55

1099

56

1100

57

1101

58

1102

59

1103

60

1104

61

1105

62

1106

63

1107

64

1108

65

## 8. Supplementary Data

The Supplementary Data includes figures and tables referring to: worldwide distribution of all treatment trains and technologies, investigated in lab, pilot and full scale plants, included in this study together with the corresponding reference; list of pharmaceuticals included in this study; reactions involved in AOPs processes, list of compounds exhibiting a removal higher than 80 % in secondary and tertiary treatment steps, according to studies examined in this review study.

## References

- Abd El-Gawad HA, Aly AM. Assessment of aquatic environmental for wastewater management quality in the hospitals: A case study. *Aust J Basic & Appl Sci* 2011;5:474-82.
- Acero JL, Von Gunten U. Characterization of oxidation processes: ozonation and the AOP O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub>, *J Am Water Works Ass* 2001;93:90-100.

- 1098 Al Aukidy M, Verlicchi P, Voulvoulis N. A framework for the assessment of the environmental risk posed by  
1099 pharmaceuticals originating from hospital effluents. *Sci Total Environ* 2014;493:54-64.
- 1100 Al-Hashimia M, Abbas TR, Jasema YI. Performance of sequencing anoxic/anaerobic membrane bioreactor  
1101 (SAM) system in hospital wastewater treatment and reuse. *Eur Sci J* 2013;9:169-180.
- 1102 Andersen HR, Chhetri RK, Hansen MS, Christensson M, Sundmark K, Sund C et al. Staged MBBR optimized  
1103 for pharmaceutical biodegradation and ozonation of hospital wastewater. Poster presentation at the  
1104 8th World Water Congress, Lisbon, 2014.
- 1105 Arslan A, Veli S, Bingol D. Use of response surface methodologies for pretreatment of hospital wastewater  
1106 by O<sub>3</sub>/UV and O<sub>3</sub>/UV/H<sub>2</sub>O<sub>2</sub> processes. *Separ Purif Method* 2014;132:561-7.
- 1107 Azar AM, Jelogir AG, Bidhendi GN, Mehrdadi N, Zaredar N, Poshtegal MK. Investigation of optimal method  
1108 for hospital wastewater treatment. *J Food Agric Environ* 2010;8:1199-1202.
- 1109 Beier S, Cramer C, Köster S, Mauer C, Palmowski L, Schröder HFr et al. Full scale membrane bioreactor  
1110 treatment of hospital wastewater as forerunner for hot-spot wastewater treatment solutions in high  
1111 density urban areas. *Water Sci Technol* 2011;63:66-71.
- 1112 Beier S, Cramer C, Mauer C, Köster S, Schröder HFr, Pinnekamp J. MBR technology: A promising approach  
1113 for the (pre-)treatment of hospital wastewater. *Water Sci Technol* 2012;65:1648-53.
- 1114 Beier S, Köster S, Veltmann K, Schröder HFr, Pinnekamp J. Treatment of hospital wastewater effluent by  
1115 nanofiltration and reverse osmosis. *Water Sci Technol* 2010;61:1691-8.
- 1116 Berto J, Rothenbach GC, Barreiros MAB, Corrêa AXR, Peluso-Silva S, Radetski CM. Physico-chemical,  
1117 microbiological and ecotoxicological evaluation of a septic tank/Fenton reaction combination for the  
1118 treatment of hospital wastewaters. *Ecotox Environ Safe* 2009;72:1076-81.
- 1119 Beyene H, Redaie G. Assessment of waste stabilization ponds for the treatment of hospital wastewater: The  
1120 case of hawassa university referral hospital. *World Appl Sci J* 2011;15:142-150.
- 1121 Boillot C, Bazin C, Tissot-Guerraz F, Droguet J, Perraud M, Cetre JC et al. Daily physicochemical,  
1122 microbiological and ecotoxicological fluctuations of a hospital effluent according to technical and care  
1123 activities. *Sci Total Environ* 2008;403:113-29.
- 1124 Byrne JA, Eggins BR, Brown NMD, McKinney B, Rouse M. Immobilisation of TiO<sub>2</sub> powder for the treatment  
1125 of polluted water. *Appl Catal B-Environ* 1998;17:25-36.
- 1126 Chiang CF, Tsai CT, Lin ST, Huo CP, Lo KW. Disinfection of Hospital wastewater by continuous ozonation. *J*  
1127 *Environ Sci Heal A* 2003, A38, 12, 2895-908.
- 1128 Chitnis V, Chitnis S, Vaidya K, Ravikant S, Patil S, Chitnis DS. Bacterial population changes in hospital effluent  
1129 treatment plant in central india. *Water Res* 2004;38:441-7.
- 1130 Clara M, Strenn B, Gans O, Martinez E, Kreuzinger N, Kroiss H. Removal of selected pharmaceuticals,  
1131 fragrances and endocrine disrupting compounds in a membrane bioreactor and conventional  
1132 wastewater treatment plants. *Water Res*, 2005;39:4797-807.
- 1133 Coleman HM, Eggins BR, Byrne JA, Palmer FL, King E. Photocatalytic degradation of 17-β-oestradiol on  
1134 immobilised TiO<sub>2</sub>. *Appl Catal B-Environ* 2000;24:L1-L5.
- 1135 Crites RW, Tchobanoglous G. Small and decentralized wastewater management systems, WCB/McGraw-Hill  
1136 Editor. New York 1998.
- 1137 Cruz-Morato C, Lucas D, Llorca M, Rodriguez-Mozaz S, Gorga M, Petrovic, M et al. Hospital wastewater  
1138 treatment by fungal bioreactor: Removal efficiency for pharmaceuticals and endocrine disruptor  
1139 compounds. *Sci Total Environ* 2014;493:365-76.
- 1140 **Cunningham VL. Special Characteristics of Pharmaceuticals related to Environmental fate. In: Kummerer K,**  
1141 **editor. Pharmaceutical in the environment - Sources, fate, effects and risks, III ed., Springer Berlin**  
1142 **Heidelberg; 2008 p, 23-34.**
- 1143 De Almeida CAA, Brenner CGB, Minetto L, Mallmann CA, Martins AF. Determination of anti-anxiety and  
1144 anti-epileptic drugs in hospital effluent and a preliminary risk assessment. *Chemosphere* 2013;93:2349-  
1145 55.
- 1146 Emmanuel E, Keck G, Blanchard JM, Vermande P, Perrodin Y. Toxicological effects of disinfections using  
1147 sodium hypochlorite on aquatic organisms and its contribution to AOX formation in hospital  
1148 wastewater. *Environ Int* 2004;30:891-900.

60  
61  
62  
63  
64  
65

- 1149 Emmanuel E, Perrodin Y, Keck G, Blanchard J, Vermande P. Ecotoxicological risk assessment of hospital  
1150 wastewater: A proposed framework for raw effluents discharging into urban sewer network. *J Hazard*  
1151 *Mater* 2005;117:1-11.
- 1152 Escher BI, Baumgartner R, Koller M, Treyer K, Lienert J, McArdell CS. Environmental toxicology and risk  
1153 assessment of pharmaceuticals from hospital wastewater. *Water Res* 2011;45:75–92.
- 1154 Gabarron S, Gómez M, Monclús H, Rodríguez-Roda I, Comas J. Ragging phenomenon characterisation and  
1155 impact in a full-scale MBR. *Water Sci Technol* 2013;67:810-6.
- 1156 Gautam AK, Kumar S, Sabumon PC. Preliminary study of physico-chemical treatment options for hospital  
1157 wastewater. *J Environ Manage* 2007;83:298-306.
- 1158 Grundfos biobooster, Wastewater Treatment at Herlev Hospital, Denmark, 2012, available at the web site:  
1159 [http://www.herlevhospital.dk/NR/rdonlyres/74234BCB-4E38-4B84-9742-](http://www.herlevhospital.dk/NR/rdonlyres/74234BCB-4E38-4B84-9742-80FFCDB416AF/0/10988_Biobooster_Herlev_LOW_opslag.pdf)  
1160 [80FFCDB416AF/0/10988\\_Biobooster\\_Herlev\\_LOW\\_opslag.pdf](http://www.herlevhospital.dk/NR/rdonlyres/74234BCB-4E38-4B84-9742-80FFCDB416AF/0/10988_Biobooster_Herlev_LOW_opslag.pdf) (last access on January 12<sup>th</sup>, 2015)
- 1161 Hijnen WAM., Beerendonk EF Medema GJ. Inactivation credit of UV radiation for viruses, bacteria and  
1162 protozoan (oo)cysts in water: A review. *Water Res* 2006;40:3-22.
- 1163 Joss A, Zabczynski S, Göbel A, Hoffmann B, Löffler D, McArdell CS et al. Biological degradation of  
1164 pharmaceuticals in municipal wastewater treatment: Proposing a classification scheme. *Water Res.*  
1165 2006;40:1686-96.
- 1166 Kajitvichyanukul P, Suntronvipart N. Evaluation of biodegradability and oxidation degree of hospital  
1167 wastewater using photo-Fenton process as the pretreatment method. *J Hazard Mater* 2006;B138:384-  
1168 91.
- 1169 Kimura K, Toshima S, Amy G, Watanabe Y. Rejection of neutral endocrine disrupting compounds (EDCs) and  
1170 the pharmaceutical active compounds (PhACs) by RO membranes. *J Membrane Sci* 2004;245:71-8.
- 1171 Kist LT, Albrech C, Machado ÊL. Hospital laundry wastewater disinfection with catalytic photoozonation.  
1172 *Clean-Soil Air Water* 2008;36:775-80.
- 1173 Kohler C, Venditti S, Igos E, Klepiszewski K, Benetto E, Cornelissen A. Elimination of pharmaceutical residues  
1174 in biologically pre-treated hospital wastewater using advanced UV irradiation technology: A  
1175 comparative assessment. *J Hazard Mater* 2012;239-240:70-7.
- 1176 Korzeniewska E, Korzeniewska A, Harnisz M. Antibiotic resistant *Escherichia coli* in hospital and municipal  
1177 sewage and their emission to the environment. *Ecotox Environ Safe* 2013;91:96-102.
- 1178 Kosma CI, Lambropoulou DA, Albanis TA. Occurrence and removal of PPCPs in municipal and hospital  
1179 wastewaters in Greece. *J Hazard Mater* 2010;179:804-17.
- 1180 Kovalova L, Siegrist H, Singer H, Wittmer A, McArdell CS. Hospital wastewater treatment by membrane  
1181 bioreactor: Performance and efficiency for organic micropollutant elimination. *Environ Sci Technol*  
1182 2012;46:1536-45.
- 1183 Kovalova L, Siegrist H, Von Gunten U, Eugster J, Hagenbuch M, Wittmer A et al. Elimination of  
1184 micropollutants during post-treatment of hospital wastewater with powdered activated carbon, ozone,  
1185 and U. *Environ Sci Technol* 2013;47:7899-908.
- 1186 Kreuzinger N, Clara M, Strenn B, Kroiss H. Relevance of the sludge retention time (SRT) as design criteria for  
1187 wastewater treatment plants for the removal of endocrine disruptors and pharmaceuticals from  
1188 wastewater *Wat Sci Technol* 2004;50:149-156.
- 1189 Kummerer K. Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into  
1190 wastewater by hospital in relation to other sources – a review. *Chemosphere* 2001;45:957–69
- 1191 Kummerer K, Erbe T, Gartiser S, Brinker L. AOX-emissions from hospital into municipal wastewater.  
1192 *Chemosphere* 1998;36:2437–45
- 1193 Lee Y, Von Gunten U. Oxidative transformation of micropollutants during municipal wastewater treatment:  
1194 Comparison of kinetic aspects of selective (chlorine, chlorine dioxide, ferrate<sup>VI</sup>, and ozone) and non-  
1195 selective oxidants (hydroxyl radical). *Water Res* 2010;44:555-66.
- 1196 Lenz K, Koellensperger G, Hann S, Weissenbacher N, Mahnik SN, Fuerhacker M. Fate of cancerostatic  
1197 platinum compounds in biological wastewater treatment of hospital effluents. *Chemosphere*  
1198 2007a;69:1765-74.
- 1199 Lenz K, Mahnik SN, Weissenbacher N, Mader RM, Krenn P, Hann S et al. Monitoring, removal and risk  
1200 assessment of cytostatic drugs in hospital wastewater. *Water Sci Technol* 2007b;56:141-9.

- 1201 Lienert J, Koller M, Konrad, J, McArdell CS, Schuwirth N. Multiple-criteria decision analysis reveals high  
 1202 stakeholder preference to remove pharmaceuticals from hospital wastewater. *Environ Sci Technol*  
 1203 2011;45:3848-57.
- 1204 **Lopez N, Deblonde T, Hartemann Ph. Les effluents liquides hospitaliers. *Hygiènes* 2010;18:405-10**
- 1205 Liu Q, Zhou Y, Chen L, Zheng X. Application of MBR for hospital wastewater treatment in China.  
 1206 *Desalination* 2010;250:605-8.
- 1207 Machado ÊL, Kist LT, Schmidt R, Hoeltz JM, Dalberto D, Alcayaga ELA. Secondary hospital wastewater  
 1208 detoxification and disinfection by advanced oxidation processes. *Environ Technol* 2007;28:1135-43.
- 1209 Mahnik SN, Lenz K, Weissenbacher N, Mader RM, Fuerhacker M. Fate of 5-fluorouracil, doxorubicin,  
 1210 epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and  
 1211 treatment in a membrane-bio-reactor system. *Chemosphere* 2007;66:30-7.
- 1212 Mahvi A, Rajabizadeh A, Fatehizadeh A, Yousefi N, Hosseini H, Ahmadian M. Survey Wastewater Treatment  
 1213 Condition and Effluent Quality of Kerman Province Hospitals. *World Appl Sci J* 2009;7:1521-5.
- 1214 Martins AF, Vasconcelos TG, Henriques DM, Frank CS, König A, Kümmerer K. Concentration of ciprofloxacin  
 1215 in Brazilian hospital effluent and preliminary risk assessment: A case study. *Clean-Soil Air Water*  
 1216 2008;36:264-9.
- 1217 McArdell CS, Kovalova L, Siegrist H. Input and elimination of pharmaceuticals and disinfectants from  
 1218 hospital wastewater. Final report. July 2011
- 1219 Mesdaghinia AR, Naddafi K, Nabizadeh R, Saeedi R, Zamanzadeh M. Wastewater characteristics and  
 1220 appropriate Method for wastewater management in the hospitals. *Iran J Public Health* 2009;38:34-40.
- 1221 Monteiro SC, Boxall ABA. Occurrence and fate of human pharmaceuticals in the environment. *Rev Environ*  
 1222 *Contam T* 2010;202:53-154.
- 1223 Mousaab A, Claire C, Magali C, Christophe D. Upgrading the performances of ultrafiltration membrane  
 1224 system coupled with activated sludge reactor by addition of biofilm supports for the treatment of  
 1225 hospital effluents. *Chem Eng J* 2015;262:456-463.
- 1226 Mullot J, Karolak S, Fontova A, Levi Y. Modeling of hospital wastewater pollution by pharmaceuticals: First  
 1227 results of mediflux study carried out in three French hospitals. *Water Sci Technol* 2010;62: 2912-19.
- 1228 Nardi G, Feretti D, Bracchi U, Dorè F, Francesconi A, Grottole M et al. Acque reflue ospedaliere. Valutazione  
 1229 di un trattamento di disinfezione con biossido di cloro. *Inquinamento* 1995;7:77-83.
- 1230 Nielsen U, Hastrup C, Klausen MM, Pedersen BM, Kristensen GH, Jansen JLC et al. Removal of APIs and  
 1231 bacteria from hospital wastewater by MBR plus O<sub>3</sub>, O<sub>3</sub> + H<sub>2</sub>O<sub>2</sub>, PAC or ClO<sub>2</sub>. *Water Sci Technol*  
 1232 2013;67:854-62.
- 1233 Ort C, Lawrence M, Reungoat J, Eagleham G, Carter S, Keller J. Determination of the fraction of  
 1234 pharmaceutical residues in wastewater originating from a hospital. *Water Res* 2010;44:605–15.
- 1235 Panouillères M, Boillot C, Perrodin Y. Study of the combined effects of a peracetic acid-based disinfectant  
 1236 and surfactants contained in hospital effluents on daphnia magna. *Ecotoxicology* 2007;16:327-40.
- 1237 Pauwels B, Fru Ngwa F, Deconinck S, Verstraete W. Effluent quality of a conventional activated sludge and a  
 1238 membrane bioreactor system treating hospital wastewater. *Environ Technol* 2006;27:395-402.
- 1239 Pauwels B, Verstraete W. The treatment of hospital wastewater: an appraisal. *J Water Health* 2006;4:405–  
 1240 16.
- 1241 Pharmafilter report, Evaluation report Pharmafilter Full scale demonstration in the Reinier de Graaf  
 1242 Gasthuis (Hospital) Delft, ISBN 9789057735936. Available at the web site:  
 1243 <http://nieuwesanitatie.stowa.nl/upload/publicaties/STOWA%202013%2016%20LR.pdf> (last access on  
 1244 January 12<sup>th</sup> 2015)
- 1245 Perrodin Y, Bazin C, Bony S, Devaux A, Bertrand-Krajewski JL, Cren-Olivé C et al. A priori assessment of  
 1246 ecotoxicological risks linked to building a hospital. *Chemosphere* 2013;90:1037-46.
- 1247 PILLS Report 2012. Pharmaceutical residues in the aquatic system: - a challenge for the future, Final report  
 1248 of the European cooperation project PILLS, available at the address: [www.pills-project.eu](http://www.pills-project.eu) (last access on  
 1249 January 5<sup>th</sup> 2015), Gelsenkirchen September 2012.
- 1250 Prado T, Silva DM, Guilayn WC, Rose TL, Gaspar AMC, Miagostovich MP. Quantification and molecular  
 1251 characterization of enteric viruses detected in effluents from two hospital wastewater treatment plants.  
 1252 *Water Res* 2011;45:1287-97.

- 1253 Prayitno, Kusuma Z, Yanuwadi B, Laksmono RW, Kamahara H, Daimon H. Hospital wastewater treatment  
1254 using aerated fixed film biofilter - Ozonation (Af2b/O3). *Adv Environ Biol* 2014;8:1251-9.
- 1255 Rezaee A, Ansari M, Khavanin A, Sabzali A, Aryan MM. Hospital wastewater treatment using an integrated  
1256 anaerobic aerobic fixed film bioreactor. *Am J Exp Sci* 2005;1:259-63.
- 1257 **Rizzo L, Manaia C, merlin C, Schwartz T, Dagot C, Ploy MC, Michael I, Fatta-Kassinou D. Urban wastewater  
1258 treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A  
1259 review. *Sci Tot Environ* 2013;447:345-60**
- 1260 **Rogers HR. Sources, behaviour and fate of organic contaminants during sewage treatment and in sewage  
1261 sludges. *Sci Total Environ* 1996;185:3-26**
- 1262 Santos LHMLM, Gros M, Rodriguez-Mozaz S, Delerue-Matos C, Pena A et al. Contribution of hospital  
1263 effluents to the load of pharmaceuticals in urban wastewaters: Identification of ecologically relevant  
1264 pharmaceuticals. *Sci Total Environ* 2013;461-462:302-16.
- 1265 Sarafraz Sh, Khani MR, Yaghmaeian K. Quality and quantity survey of hospital wastewater in Hormozgan  
1266 Province. *Iran J Environ Health Sci Eng* 2007;4:43-50.
- 1267 Shrestha RR, Haberl R, Laber J. Constructed Wetland technology transfer to Nepal. *Water Sci Technol*  
1268 2001;43:345-50.
- 1269 Siegest H, Joss A. Review on the fate of organic micropollutants in wastewater treatment and water reuse  
1270 with membranes. *Wat Sci Technol* 2012;66:1369-76.
- 1271 Sim WJ, Kim HY, Choi SD, Kwon JH, Oh JE. Evaluation of pharmaceuticals and personal care products with  
1272 emphasis on anthelmintics in human sanitary waste, sewage, hospital wastewater, livestock wastewater  
1273 and receiving water. *J Hazard Mater* 2013;248-249:219-27.
- 1274 Sipibel Report: Effluents hospitaliers et stations d'épuration urbaines : caractérisation, risques et  
1275 traitabilité- Presentation and premiers resultants- June 2014 available at the web site  
1276 <http://www.graie.org/Sipible/publications.html> (last access on January 2nd, 2015)
- 1277 Straub JO. Environmental risk assessment for new human pharmaceuticals in the European Union  
1278 according to the draft guideline/discussion paper of January 2001. *Toxicol Lett* 2002;131:137-43.
- 1279 Suarez S, Lema JM, Omil F. Pre-treatment of hospital wastewater by coagulation-flocculation and flotation.  
1280 *Bioresource Technol* 2009;100:2138-146.
- 1281 Suty H, De Traversay C, Cost M. Application of advanced oxidation processes: present and future. *Water Sci  
1282 Technol* 2004;49:227-33
- 1283 **Tadkaew N, Hai F I, McDonald JA, Khan SJ, Nghiem LD. Removal of trace organics by MBR treatment: The  
1284 role of molecular properties. *Water Res* 2011;45:2439-51.**
- 1285 Vasconcelos TG, Kümmerer K, Henriques DM, Martins AF. Ciprofloxacin in hospital effluent: Degradation by  
1286 ozone and photoprocesses. *J Hazard Mater* 2009;169:1154-8.
- 1287 Venditti S, Köhler C, Arenz-Leufen M, O'Nagy O, Cornelissen A, Klepiszewski K. Membrane bioreactor  
1288 process as pre-treatment for hospital effluents. *Proceedings 8<sup>th</sup> IWA Leading-Edge Conference on Water  
1289 and Wastewater Technologies, Amsterdam, 2011.*
- 1290 Verlicchi P, Al Aukidy M, Galletti A, Petrovic M, Barceló D. Hospital effluent: investigation of the  
1291 concentrations and distribution of pharmaceuticals and environmental risk assessment. *Sci Total  
1292 Environ* 2012a;430:109-18.
- 1293 Verlicchi P, Al Aukidy M, Zambello, E. Occurrence of pharmaceutical compounds in urban wastewater:  
1294 Removal, mass load and environmental risk after a secondary treatment-A review. *Science of the Total  
1295 Environment*, 2012b;429, 123-155.
- 1296 Verlicchi P, Galletti A, Al Aukidy M, Masotti L. New perspectives in wastewater disinfection, In: Nova  
1297 Publisher, editor. *Water Disinfection*; 2011, pp. 77-108.
- 1298 Verlicchi P, Galletti A, Masotti L. Caratterizzazione e trattabilità di reflui ospedalieri: indagine sperimentale  
1299 (con sistemi MBR) presso un ospedale dell'area ferrarese. *Proceedings Sidisa Conference, Florence  
1300 (Italy), June 2008 (in Italian).*
- 1301 Verlicchi P, Galletti A, Masotti L. Management of hospital wastewaters: The case of the effluent of a large  
1302 hospital situated in a small town. *Wat Sci Technol* 2010;61:2507-519.
- 1303 Verlicchi P, Galletti A, Petrovic M, Barceló D. Micro-pollutants in hospital effluent: their fate, risk and  
1304 treatment options. In: Barceló D, Kostianoy AG, editors. *Emerging organic Contaminants and Human  
1305 Health, The Handbook of Environmental Chemistry, Springer; 2012c. p. 139-72.*

1306 Verlicchi P, Zambello E, Al Aukidy M. Removal of Pharmaceuticals by Conventional Wastewater Treatment  
1307 Plants. In: Barcelò D, Petrovic M. editors *Comprehensive Analytical Chemistry*, Elsevier 2013 p. 231- 86.  
1308 von Gunten U. Ozonation of drinking water: Part II. Disinfection and by-product formation. *Water Res*  
1309 2003;37:1469-87.  
1310 Walhberg C, Biorlenius B, Paxeus N. Pharmaceuticals residues in Stockholm Water Environment –  
1311 Occurrence mitigations and treatment of wastewater. 2010 Stockholm Vatten (in Swedish)  
1312 Wang XW, Li J, Guo T, Zhen B, Kong Q., Yi B et al. Concentration and detection of SARS coronavirus in  
1313 sewage from Xiao Tang Shan hospital and the 309th Hospital of the Chinese People's Liberation Army.  
1314 *Wat Sci Technol* 2005;52:213-21.  
1315 Wen X, Ding H, Huang X, Liu R. Treatment of hospital wastewater using a submerged membrane bioreactor.  
1316 *Process Biochem* 2004;39:1427-431.  
1317 Westerhoff P, Yoon Y, Snyder S, Wert E. Fate of endocrine-disruptor, pharmaceutical and personal care  
1318 product chemicals during simulated drinking water treatment processes. *Environ Sci Technol*  
1319 2005;39:6649–63.  
1320 Wilde ML, Montipo S, Martins AF. Degradation of b-blockers in hospital wastewater by means of ozonation  
1321 and Fe<sup>2+</sup>/ozonation. *Water Res* 2014;48:280-95.  
1322 Zwickenpflug B, Böhler M, Sterkele B, Joss A, Siegrist H, Traber J, Gujer W, Behl M, Dorusch F, Hollender J,  
1323 Ternes T, Fink G. Einsatz von Pulveraktivkohle zur Elimination von Mikroverunreinigungen aus  
1324 kommunalem Abwasser. (Final report of the MicroPoll project EAWAG on behalf of the Swiss Federal  
1325 Office for the Environment, Dübendorf, CH (2010) <http://www.eawag.ch/forschung/eng/schwerpunkte/>  
1326 (last access on January 12<sup>th</sup> 2015)

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## TABLES

**Table 1.** Main chemical characteristics of hospital effluent in terms of conventional parameters and pharmaceuticals and other emerging compounds

Parameter	Range of concentrations	Reference
Conductivity, $\mu\text{S}/\text{cm}$	300-1000	Boillot et al., 2008; Verlicchi et al., 2012c
pH	6-9	PILLS Report, 2012, Kosma et al., 2010
Redox potential, mV	850-950	Verlicchi et al., 2010; Boillot et al., 2008
Fat and oil, mg/L	50-210	Al-Hashimia et al., 2013; Verlicchi et al., 2010
Chlorides, mg/L	80-400	Emmanuel et al., 2004; Verlicchi et al., 2012c
Total N, mg N/L	60-98	PILLS Report, 2012, Beyene and Redaie, 2011
$\text{NH}_4$ , mg $\text{NH}_4$ /L	10-68	McArdell et al., 2011, Verlicchi et al., 2012c Wen et al., 2004
Nitrite, mg $\text{NO}_2$ /L	0.1-0.58	Al Hashimia et al., 2013; McArdell et al., 2011
Nitrate, mg $\text{NO}_3$ /L	1-2	Lopez et al., 2010; McArdell et al., 2011, Venditti et al., 2011
Phosphate, mg P- $\text{PO}_4$ /L	6-19	Al-Hashimia et al., 2013; Verlicchi et al., 2010;2012c
Suspended solids, mg/L	120-400	Verlicchi et al., 2012c
COD, mg/L	1350-2480	Kajitvichyanukul and Suntronvipart 2006; Berto et al., 2009
Dissolved COD, mg/L	380-700	McArdell et al., 2011
DOC, mg/L	120-130	McArdell et al., 2011;
TOC, mg/L	31-180	Beier, 2012, Nardi et al., 1995
$\text{BOD}_5$ /COD (biodegradability index)	0.3-0.4	Kajitvichyanukul and Suntronvipart 2006
AOX, $\mu\text{g}/\text{L}$	550-10000	Kummerer et al., 1998; Nardi et al., 1995
Microrganisms MPN/100 mL		
<i>E. coli</i>	$10^3$ - $10^6$	Beier et al., 2012, Nielsen et al., 2013
Enterococci	$10^3$ - $10^6$	Beier et al., 2012
Fecal Coliform	$10^3$ - $10^4$	Beier et al., 2012
Total Coliform	$10^5$ - $10^7$	Lopez et al., 2010; Beyene and Redaie 2011
$\text{EC}_{50}$ ( <i>Daphnia</i> ), TU	9.8-117	Emmanuel et al., 2004; Machado et al., 2007
Total surfactants, mg/L	4-8	Verlicchi et al., 2008, 2010
Total disinfectants, mg/L	2-200	Kummerer, 2001; Verlicchi et al., 2012c
Specific disinfectants:		
BAC_C12-18, $\mu\text{g}/\text{L}$	49	Kovalova et al., 2012
BAC_C12, $\mu\text{g}/\text{L}$	34	Kovalova et al., 2012
DDAC-C10, $\mu\text{g}/\text{L}$	102	Kovalova et al., 2012
Antibiotics, $\mu\text{g}/\text{L}$	30-200	Verlicchi et al., 2012c
Antinflammatories, $\mu\text{g}/\text{L}$	5-1500	Verlicchi et al., 2012c
Lipid regulators, $\mu\text{g}/\text{L}$	1-10	Verlicchi et al., 2012c
Cytostatic agents, $\mu\text{g}/\text{L}$	5-50	Suarez et al., 2009; Verlicchi et al., 2012c
ICM, $\mu\text{g}/\text{L}$	0.2-2600	Verlicchi et al., 2012c

<sup>1</sup>Disinfectants: quaternary ammonia disinfectant: BAC\_C12-18: benzalkonium chloride; DDAC-C10: dimethyldidecylammonium chloride

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65



**Table 2** List of the studies included in the overview together with a brief description of the corresponding investigations and rationale

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Abd El-Gawad and Aly, 2011	Investigation carried out at four hospitals in Egypt to assess hospital effluent quality and quantity, as well as the impact on the environment in terms of common parameters and pollutants when a CAS system is adopted as treatment prior to discharge into surface water.	Suitable HWW management based on standards set for conventional pollutants in UWW.	Conventional parameters: BOD <sub>5</sub> , DO, TSS, total coliform, fecal coliform and trace elements (metals)
Al Hashimia et al., 2013	Investigation carried out on real wastewater collected from a hospital located in Iraq to assess the performance of a lab-scale sequencing anoxic/anaerobic MBR for nutrient removal under different internal recycling time modes between anoxic and anaerobic conditions operating with an SRT = 58.5-116 d, internal recycle rate of 39 L/h, a flux of 15.12 L/(m <sup>2</sup> h).	Enhancement in nutrient removal in hospital effluent.	Conventional parameters: COD, BOD <sub>5</sub> , PO <sub>4</sub> , NH <sub>4</sub> , NO <sub>3</sub> , NO <sub>2</sub> , TSS, oil and grease, total and fecal coliforms
Andersen et al., 2014	Investigation regarding the treatment of the oncological ward effluent by means of a pilot plant consisting in a moving bed biofilm reactor (MBBR) followed by ozonation carried out in Denmark. System performances were provided for six pharmaceutical model substrates each representing different biological and chemical degradation.	Optimization of the removal of selected compounds by means of a MBBR and ozonation.	PhCs: triclosan, mefenamic acid, diclofenac, naproxen, gemfibrozil, ketoprofen, ibuprofen, clofibrac acid
Arslan et al., 2014	Investigation carried out on raw hospital effluent in Turkey. Ozonation, O <sub>3</sub> /UV, O <sub>3</sub> /UV/H <sub>2</sub> O <sub>2</sub> were tested as a pretreatment option in a batch reactor in order to evaluate the removal of COD and UV absorbance and the improvement in biodegradation.	Options in pretreatments	Conventional parameters: COD and absorbance
Azar et al., 2010	Investigation carried out on real HWW collected from two hospitals located in Iran, by means of biological oxidation (aerobic/anaerobic) in an 80-litre pilot plant.	Recommended treatment for hospital effluent in Iran, based on an analysis of conventional parameter removals.	Conventional parameters: COD, BOD <sub>5</sub> , TSS, NO <sub>2</sub> , NO <sub>3</sub> , PO <sub>4</sub> , detergents, oil and grease, total coliform, <i>Escherichia coli</i> , Ag, Hg and Ni
Beier et al., 2010	Investigation carried out at Waldbrol hospital (Germany) by means of nanofiltration (NF) and reverse osmosis (RO) membrane (pilot plant) for the treatment of a (full scale) MBR permeate. The molecular weight cut off (MWCO) of NF membranes was 300-400 Dalton and of RO membranes was 100-150 Dalton. For the tests, the pump pressure was 7 bar for NF and 14 bar for RO and the maximum feed flux to NF/RO modules was between 20 and 36 L/(m <sup>2</sup> h).	Dedicated polishing treatment for HWWs to remove PhCs.	PhCs: bezafibrate, bisoprolol, carbamazepine, clarithromycin, ciprofloxacin, diclofenac, ibuprofen, metronidazole, moxifloxacin, telmisartan, tramadol

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Beier et al., 2011	Investigation carried out at the full-scale MBR in operation at Waldbrol hospital in Germany to assess PhCs removal from hospital wastewater. The permeate is then sent to the municipal WWTP. The main design parameters are: Q = 130 m <sup>3</sup> /d; maximum flow 250 m <sup>3</sup> /d; 5 Kubota EK 400 flat sheet membrane modules, total membrane area 1600 m <sup>2</sup> , cut off value 0.2 µm; biomass concentration in the bioreactor 10-12 g/L; biological reactor volume 56 m <sup>3</sup> . The main average operating parameters: hydraulic retention time 31.3 h, temperature in aerated tank 24.6 °C, biomass concentration 13.6 g/L, flux 10-20 L/(m <sup>2</sup> h).	Separate treatment of HWWs will allow evaluation of the appropriateness of MBR for hospital effluent in high density urban areas, contributing to minimizing the operating and financial expenditure for municipal WWTP.	PhCs: bezafibrate, bisoprolol, carbamazepine, clarithromycin, ciprofloxacin, diclofenac, ibuprofen, metronidazole, moxifloxacin, tramadol.
Beier et al., 2012	Investigation carried out at a hospital in Waldbrol (Germany) to assess the performance of a full-scale wastewater treatment plant equipped with a MBR and to evaluate the characteristics of the activated sludge. For design and operational parameters see Beier et al. (2011).	Evaluation of MBR as a dedicated treatment of HWWs to reduce the environmental input of chemical and microbiological parameters in the environment.	Conventional parameters: COD, TOC, AOX, NH <sub>4</sub> , total P, <i>E. coli</i> and Enterococci
Berto et al., 2009	Investigation carried out at a hospital in Brazil to evaluate the effectiveness of “advanced” pretreatments consisting in a biological (full-scale septic tank, 45 m <sup>3</sup> ) and a chemical stage (lab-scale Fenton reactor) to remove organic matter and pathogenic microbiota from HWW.	Adequate advanced (pre)treatments for hospital effluents to reduce their environmental impact.	Conventional parameters: COD, BOD <sub>5</sub> , P and N compounds, suspended solids, total coliform and thermotolerant coliforms
Beyene and Redaie, 2011	Investigation carried out at Hawassa University Referral Hospital (Ethiopia) to examine the suitability of a series of (full scale) ponds for the treatment of HWW. The treatment train consists of two facultative ponds (each of them: surface area 667 m <sup>2</sup> , depth 1.5 m and retention time 14 d) followed by two maturation ponds (each of them surface area of about 400 m <sup>2</sup> , depth 1.1 m, retention time 3 d) and a final fish pond (surface area 862 m <sup>2</sup> , depth 1.5 m, retention time 9 d).	Evaluation of the risk posed by HWWs in terms of conventional pollutants and a proposal to upgrade existing WWTP in order to reduce it.	Conventional parameters: COD, BOD <sub>5</sub> , P, PO <sub>4</sub> , total Nitrogen, NH <sub>3</sub> , NO <sub>3</sub> , NO <sub>2</sub> TSS, TDS, Cl, S <sub>2</sub> , total coliforms and fecal coliforms
Chiang et al., 2003	Investigation carried out in Taiwan on the disinfection by continuous ozonation of hospital effluent and in particular of the effluent from the kidney dialysis unit and on the increment of hospital effluent biodegradability.	Disinfection effect and improvement in biodegradability of hospital effluent by ozonation	Conventional parameters: COD, BOD, total coliforms
Chitnis et al., 2004	Investigation carried out in India in a pilot plant consisting in preliminary and primary treatments, a conventional activated sludge system, sand filtration and chlorination.	Investigation into the microbiological community and evaluation of the risk of multidrug resistant bacteria spread	Different microbiological parameters: total coliforms, fecal enterococci, staphylococci, <i>Pseudomonas</i> , multidrug resistant bacteria.

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Cruz-Morato et al., 2014	Investigation carried out in Spain in a batch fluidized bed bioreactor (lab scale) under sterile and non-sterile conditions with <i>Trametes versicolor</i> pellets to examine the removal of a wide group of pharmaceutical compounds from HWW. Samples were collected from the main sewer of Girona University Hospital (Spain).	Evaluation of the capacity of a treatment by fungal bioreactor in reducing pharmaceutical concentration from HWW.	99 PhCs of different classes
de Almeida et al., 2013	Investigation carried out at the University hospital of Santa Maria (Brazil) by means of a septic tank and anaerobic filter (full scale).	Environmental risks of PhCs and adequateness of treatment trains.	PhCs: 5 anti-anxiety and anti-epileptic compounds
Emmanuel et al., 2004	Toxicity evaluation after prechlorination (NaClO addition) of the effluent from the infectious and tropical disease department at the hospital in Lyon, France.	Toxicity evaluation due to prechlorination	Conventional parameters: COD, TOC, AOX, chlorides
Gautam et al., 2007	Investigation carried out at the hospital located in Vellore, Tamil Nadu (India), by means of a lab-scale plant consisting of coagulation (by adding FeCl <sub>3</sub> up to 300 mg/L), rapid filtration and disinfection (by adding a bleaching powder solution) steps.	Options for hospital effluent pretreatment before discharge in public sewage.	Conventional parameters: COD, BOD <sub>5</sub> , SS and P.
Grundfos Biobooster, 2012	Report from an on-going project in Denmark to evaluate the best available technologies (BATs) for the separated treatment of hospital effluent. Two sequences are being tested: MBR followed by O <sub>3</sub> , GAC and/or H <sub>2</sub> O <sub>2</sub> and UV, MBR followed by GAC and UV	Evaluation of the BAT for hospital treatment.	.
Kajitvichyanukul and Suntronvipart, 2006	Investigation carried out in Bangkok, Thailand, on the pretreatment of hospital effluent by using a lab-scale photo-Fenton process.	Improvement in biodegradability of hospital effluent by using the photo-Fenton process as a pretreatment.	Conventional parameters: COD, BOD <sub>5</sub> , TOC, turbidity, TSS, conductivity and toxicity
Kist et al., 2008	Investigation carried out on the treatment of wastewater produced in a hospital laundry in the Rio Pardo Valley (Brazil), by means of a (lab scale, 4 L) ramp type reactor for catalytic photoozonation (UV/TiO <sub>2</sub> /O <sub>3</sub> ).	Reduction of the risk posed by hazardous substances occurring in HWWs due to adequate pretreatments	Conventional parameters: COD, BOD <sub>5</sub> , turbidity, surfactants, <i>Escherichia Coli</i> and thermotolerant Coliforms
Kohler et al., 2012	Investigation carried out at the Hospitalier Emil Mayrisch (Luxembourg) by means of a pilot plant (MBR+UV; MBR+H <sub>2</sub> O <sub>2</sub> +UV) to assess the removal of some pharmaceutical compounds. Details of the MBR are reported in Venditti et al., 2011.	Technical and economical feasibility for hospital effluent treatment.	13 PhCs
Kosma et al., 2010	Investigation carried out on the occurrence and removal of PhCs at the hospital (full scale) WWTP (CAS, 600 m <sup>3</sup> , HRT = 6 h) in Ioannina (Greece).	Impact of pharmaceuticals on the environment.	11 PhCs; COD, BOD <sub>5</sub> , NO <sub>3</sub> , PO <sub>4</sub> and TSS

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Kovalova et al., 2012	Investigation carried out in Switzerland, on a pilot-scale primary clarifier+ MBR installed and operated for one year at Cantonal Hospital in Baden. The bioreactor consisted of an anoxic tank (0.5 m <sup>3</sup> ) and an aerobic one (1 m <sup>3</sup> ) equipped with submerged ultrafiltration flat sheet membrane plates (15-30 L/m <sup>2</sup> h, 38 nm pore size, nominal cut-off 150 kDa). Biomass concentrations was 2 g/L, SRT 30-50 d, temperature 29 °C.	Analysis of performance and removal in MBR of many PhCs. Reduction of the spread of multi resistant or pathogenic bacteria, virus, parasite eggs and PhCs.	56 PhCs
Kovalova et al., 2013	Investigation carried out at the Cantonal Hospital in Baden (Switzerland) in a pilot plant consisting in a primary clarifier, MBR (see Kovalova et al., 2012), and five post-treatment technologies: O <sub>3</sub> , O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> , powdered activated carbon (PAC), and low pressure UV light with and without TiO <sub>2</sub> .	Removal of typical pollutants in hospital effluent (disinfectants, pathogens and antibiotic resistant bacteria) by advanced treatments.	56 PhCs
Lenz et al., 2007a	Investigation carried out at a hospital in Vienna (Austria), by means of a pilot MBR (150 L) installed and fed with oncologic in-patient treatment ward effluent. Ultrafiltration membranes (nominal cut-off of 100 kDa) were used	Risk of cancerostatic platinum compounds to humans.	Cancerostatic platinum compounds
Lenz et al., 2007b	Investigation carried out at the oncological ward in a hospital in Vienna (Austria), by means of a pilot MBR (see Lenz et al., 2007a) followed by granular activated carbon (GAC) and UV. Biomass concentration was 12-15 g/L, the average hydraulic load 260 L/d	Environmental risk of cytostatic.	Cancerostatic platinum compounds.
Liu et al., 2010	Investigation carried out in China on operating conditions, MBR efficiency in treating hospital effluent.	To avoid the spread of pathogenic microorganisms and viruses, especially following the outbreak of SARS in 2003.	Conventional parameters: COD, BOD <sub>5</sub> , NH <sub>3</sub> , TSS, Bacteria and fecal coliform
Machado et al., 2007	Investigation carried out in Brazil, on a lab-scale advanced oxidation process (UV/TiO <sub>2</sub> /O <sub>3</sub> ) operating as a tertiary treatment, fed with secondary HWW.	Proposal of a (sustainable) treatment schematic to reduce microorganisms and toxicity from hospital effluent.	Conventional parameters: COD, BOD <sub>5</sub> , turbidity, total nitrogen, total phosphorus, surfactants, thermotolerant coliforms, toxicity and AOX
Mahnik et al., 2007	Occurrence and treatability of cytostatics in the effluent from the oncologic in-patient treatment ward of the Vienna University Hospital was investigated as well as their removal by an MBR (pilot scale, 150 L of aeration tank, hydraulic load 100-200 L/d, HRT = 20-24 h, biomass concentration 12-15 g/L, UF membranes: active area 1 m <sup>2</sup> , nominal cut-off 100kDa)	Pollution level of the effluent from particular hospital wards.	4 PhCs: 5-fluorouracil, doxorubicin, epirubicin and daunorubicin
Mahvi et al., 2009	Analysis of the performance of seven WWTPs (CAS + chlorination) in Kerman Province (Iran) receiving hospital effluent in terms of removal of main conventional parameters and malfunctions.	Malfunctions in WWTPs receiving hospital effluents.	Conventional parameters: COD, BOD <sub>5</sub> , DO, TSS, pH, NO <sub>2</sub> , NO <sub>3</sub> , PO <sub>4</sub> , Cl and SO <sub>4</sub> <sup>2-</sup>

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Martins et al., 2008	Investigation carried out in Brazil into the pretreatment of hospital effluent by using a septic tank and an anaerobic filter. Analysis was referred to occurrence, removal of ciprofloxacin and the resulting risk due to its residue in the treated effluent	Evaluation of the adequateness of specific pretreatment in Brazil	PhC: ciprofloxacin
McArdell et al., 2011	Report including all the details of the investigations described in Kovalova et al. (2012, 2013) and in PILLS Report 2012 referring to the Swiss investigations on MBR and MBR+ AOPs applied to a hospital effluent	Testing and comparing the removal of PhCs from HWW by different technologies	Conventional parameters, PhCs
Mousaab et al., 2015	Investigation into the removal ability of PhCs and conventional pollutants in an upgraded UF membrane system coupled with an activated sludge (AS) reactor by the addition of biofilm support media in the aeration tank in case of hospital effluent treatment. The aeration bioreactor had a volume of 400 L, the UF membrane system consisted of a hollow fiber module (1 m <sup>2</sup> surface area, pore size 0.2 µm). HRT = 22 h and SRT=20 d.	Improvement in PhC removal from hospital effluent and in membrane functioning resulting in a reduction of operation costs.	PhCs
Nardi et al., 1995	Investigation into disinfection of the effluent of an Italian infectious disease ward by means of different doses of ClO <sub>2</sub> and evaluation of AOX production.	Disinfection performance of ClO <sub>2</sub> with respect to NaClO in case of hospital effluent and evaluation of AOX production.	Conventional parameters: COD, TOC, total and fecal coliforms, Streptococci. AOX
Nielsen et al., 2013	Investigation carried out in Denmark with pilot and lab scale plants into the ability of different technologies acting as a secondary (MBR) or a tertiary (O <sub>3</sub> , O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> , ClO <sub>2</sub> , PAC) treatment in removing common PhCs from hospital effluent. The MBR was equipped with ceramic UF membranes (surface area 3.75 m <sup>2</sup> , pore size 60 nm). The average daily flow was 2.2 m <sup>3</sup> /d and 24.6 L/(m <sup>2</sup> h), SRT = 35 d	Risk to human health posed by Hwws during combined sewers overflow.	PhCs; <i>eE. coli</i> , total coliforms, total enterococci.
Pauwels et al., 2006	Investigation carried out in Ghent (Belgium) to compare the performance of two lab-scale plants (CAS and MBR) in treating hospital effluent. The MBR consisted of a 25 L tank equipped with 3 plate membrane modules ( pore size 0.4 µm; total surface area 0.3 m <sup>2</sup> ) HRT = 12 h in both reactors	Potential risk of HWWs- correlation between PhC and conventional parameters removal.	COD, total ammonium nitrogen, total coliforms, fecal coliforms, total aerobic bacteria, total anaerobic bacteria and Enterococci; Ethinylestradiol.
Pharmafilter Report, 2013	Report on the characteristics and the performance of a full-scale system (Pharmafilter) installed and tested in the Reinier de Graaf Gasthuis in Delft (Netherlands) in the period 2010-2012. The system is an integral concept for the optimization of care, processing waste and purifying wastewater in hospitals. It consists in: pretreatment (sieve), biological process (UF MBR), ozonation, GAC filtration. The sludge discharged from the MBR is fed back into the digester and any excess sludge water from the digestate formed in the digester can be transported to the MBR. The fate and removal of about 100	Potential health risk posed by HWWs	Potential health risk posed by HWWs PhCs

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
	PhCs was observed.		
PILLS Report, 2012	Report of the main results achieved within the European PILLS project developed in 2010-2012 involving four research units in different countries that investigated the removal of PhCs from HWW by means of MBR+PAC, MBR+O <sub>3</sub> +moving bed bioreactor, MBR+UV+moving bed bioreactor in Switzerland, MBR+RO, MBR+UV, MBR+ O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> in Luxembourg, MBR+O <sub>3</sub> +sand filtration, MBR+ PAC+sand filtration in Germany, MBR+O <sub>3</sub> +GAC, MBR+GAC+UV/H <sub>2</sub> O <sub>2</sub> +GAC in the Netherlands. Monitored parameters were PhCs and toxicity. See also Kovalova et al. (2012, 2013), Koeler et al. (2011); McArdell et al. (2011)	Effects of pharmaceuticals on environment water and potential measures to reduce their occurrence.	PhCs
Prado et al., 2011	Investigation carried out in Brazil involving detection of some enteric viruses and hepatitis A in hospital effluent and in the effluent from two different full scale treatment plants. The removal efficiencies observed in the two sequences: upflow anaerobic sludge blanket (UASB) +three serial anaerobic filters and CAS system followed by a chlorination tank were investigated and compared.	Quantification of enteric viruses and hepatitis A in the effluent of different hospital WWTPs.	Enteric viruses and hepatitis A
Prayitno et al., 2014	Investigation on a pilot scale plant consisting in an Aerated Fixed Film Biofilter (AF2B reactor) coupled with an ozonation reactor fed by the effluent from Malang City hospital in Indonesia.	Pollution and health problems for humans being caused by the discharge of HWWs.	Conventional pollutants: BOD <sub>5</sub> , phenols, fecal coliform and Pb.
Rezaee et al. 2005	Investigation carried out in Iran on a pilot-scale system consisting in an integrated anaerobic-aerobic fixed film reactor fed with hospital effluent before co-treatment with urban wastewater.	Potential reduction of the organic load in hospital effluent by biological pretreatment before its cotreatment.	Conventional parameters: COD, BOD <sub>5</sub> , NH <sub>4</sub> , Turbidity, Bacteria and <i>Escherchia coli</i> .
Shrestha et al., 2001	Analysis of the removal performance in a full scale two stage constructed wetland (CWs) designed and constructed in Nepal to treat hospital effluent (20 m <sup>3</sup> /d). The system consists in a three chambered septic tank, a horizontal flow bed (140 m <sup>2</sup> ), with 0.65 to 0.75 m depth and a vertical flow bed (120 m <sup>2</sup> ) with 1 m depth. The beds were planted with local reeds ( <i>Phragmites karka</i> ).	Transfer CW technology to developing countries to reduce pollution in aquatic environments.	Conventional parameters: TSS, BOD <sub>5</sub> , COD, NH <sub>4</sub> , PO <sub>4</sub> <sup>2-</sup> , total coliforms, <i>E. coli</i> , Streptococci.
Sim et al., 2013	Investigation carried out at two hospital WWTPs located in Korea to assess the occurrence and removal of selected pharmaceutical and personal care products. The wastewater treatment plants consist of (i) flocculation (FL)+ activated carbon filtration (AC); (ii) flocculation + CAS.	Potential risks of anthelmintics on non-target organisms in the environment and their resistance to biodegradation.	33 PhCs and personal care products

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Suarez et al., 2009	Investigation carried out in Spain into the pretreatment of hospital effluent. The efficacy of coagulation-flocculation (Coag-FL) and flotation (FLO) processes in removing PhCs was investigated in case of two kinds of hospital effluent: one from radiotherapy and outpatient consultation wards and one from hospitalized patients, surgery, laboratories, radiology and general services. Coagulation-flocculation assays were performed in a jar-test device and in a continuous pilot-scale plant. Ferric chloride (FeCl <sub>3</sub> ) and aluminium sulphate (Al <sub>2</sub> (SO <sub>4</sub> ) <sub>3</sub> ) were added.	Potential risk of hospital wastewater to the environment.	13 PhCs and personal care products; TSS, COD, fat
Vasconcelos et al., 2009	Investigation carried out in Brazil into the potential pretreatment of hospital effluent to degrade persistent compounds. In particular the study investigated the performance of a lab-scale photo-induced oxidation, heterogeneous photocatalysis, ozonation and perozone in degrading the antimicrobial ciprofloxacin.	Environmental impact of Ciprofloxacin and analysis of its degradation by ozone and photoprocesses.	Ciprofloxacin, COD.
Venditti et al., 2011	Investigation carried out in Luxembourg on the removal of conventional pollutants and selected PhCs by means of a pilot MBR fed with hospital effluent (2 m <sup>3</sup> /d on average). The bioreactor consists of an anoxic/oxic compartments (0.175 m <sup>3</sup> , 0.515 m <sup>3</sup> respectively) and is equipped with two submerged microfiltration membrane modules (pore size 0.4 μm, total surface area 9.6 m <sup>2</sup> ). Average HRT 8 h, temperature 16-18 °C, biomass concentration 10-13.2 g/L, SRT > 30 d.	Adequateness of MBR as a pretreatment for hospital effluent	10 common PhCs, DOC, COD, BOD <sub>5</sub> , NH <sub>4</sub> , NO <sub>3</sub> , total N total P.
Verlicchi et al., 2010	Investigation carried out at an Italian hospital by means of a pilot-scale MBR equipped with UF membranes.	Hospitals are the main source of PhCs. Guidelines for a full scale plant for hospital effluent	Monitored parameters were COD, BOD <sub>5</sub> , SS, NH <sub>4</sub> , Total P and <i>E. coli</i> .
Wen et al., 2004	Investigation carried out at Haidian community hospital (China), where a full-scale submerged hollow fiber MBR was installed.	Efficiency and operation stability of MBR equipped with microfiltration membranes in treating HWWs.	Monitored pollutants were COD, BOD <sub>5</sub> , NH <sub>4</sub> , turbidity and <i>Escherchia coli</i> .
Wilde et al., 2014	Investigation carried out in Brazil into the degradation of a mixture of beta-blockers in hospital effluent by ozonation and Fenton reaction	Optimization of the operational condition in the degradation of a mixture of PhCs in hospital effluent	Atenolol, propranolol and metoprolol

**Table 3** Dedicated treatment trains for hospital effluent included in the review

Investigated Treatment/treatment train*	Reference
(pre)Disinfection with ozone <sup>1</sup>	Chiang et al., 2003
(pre)Disinfection with chlorine <sup>1</sup>	Emmanuel et al., 2004; Nardi et al., 1995; Liu et al., 2010
(pre)Photo-Fenton <sup>1</sup>	Katjitvichyanukul and Suntronvipart 2006
Coagulation-flocculation; Coagulation-flocculation+flotation	Suarez et al., 2009
Coagulation+filtration + disinfection	Gautam et al., 2007
Screening + O <sub>3</sub> /UV or O <sub>3</sub> /UV/H <sub>2</sub> O <sub>2</sub> (+ biological step) <sup>2</sup>	Arslan et al., 2014
Septic tank+ anaerobic filter	de Almeida et al., 2013; Martins et al., 2008
Septic tank+HSF+VSF	Shrestha et al., 2001
Septic tank + Fenton	Berto et al., 2009
Flocculation + CA	Sim et al., 2013
Flocculation+ CAS	Sim et al., 2013
Anaerobic-aerobic fixed film reactor	Rezaee et al., 2005
Facultative and polishing ponds (II + III) <sup>2</sup>	Beyene and Redaie 2011
Aerated Fixed Film Biofilter+O <sub>3</sub>	Prayitno et al., 2014
CAS	Abd El Gawad and Aly, 2011; Azar et al., 2010
CAS + support media + UF	Mousaab et al., 2015
CAS + chlorination	Kosma et al., 2010; Mahvi et al., 2009; Prado et al., 2011
Fungal bioreactor	Cruz-Morato et al., 2014
UASB+ anaerobic filter	Prado et al., 2011
MBBR + ozonation	Andersen et al., 2014
MBR	Al Hashmia et al., 2013; Beier et al., 2012; Kovalova et al., 2012; Lenz et al., 2007a; Liu et al., 2010; Mahnik et al., 2007; Nielsen et al., 2013; Venditti et al., 2011; Weng et al., 2004
MBR + chlorination	Liu et al., 2010, Nielsen et al., 2013
MBR + GAC	Lenz et al., 2007b
MBR + GAC + O <sub>3</sub> and or H <sub>2</sub> O <sub>2</sub> + UV	Grundfos Biobooster 2012,
MBR + GAC + UV	Lenz et al., 2007b
MBR + H <sub>2</sub> O <sub>2</sub> +UV	Koheler et al., 2011,;Kovalova et al., 2013
MBR + O <sub>3</sub> + GAC	Pharmafilter, 2013
MBR + O <sub>3</sub> + GAC+ UV	Grundfos Biobooster 2012,
MBR + public sewage+ cotreatment	Beier et al., 2011
MBR + UV	Lenz et al., 2007b
MBR+ H <sub>2</sub> O <sub>2</sub>	Koheler et al., 2011
(MBR+) PAC <sup>3</sup>	Kovalova et al., 2013; Nielsen et al., 2013
(MBR+) O <sub>3</sub> <sup>3</sup>	Kovalova et al., 2013; Nielsen et al., 2013



(MBR+) O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> <sup>3</sup>	Nielsen et al., 2013
(MBR+) UV with/without TiO <sub>2</sub> <sup>3</sup>	Kovalova et al., 2013
UV/O <sub>3</sub> / TiO <sub>2</sub>	Kist et al., 2008
(Septic tank+ anaerobic filter+) O <sub>3</sub> , H <sub>2</sub> O <sub>2</sub> /O <sub>3</sub> <sup>3</sup>	Vasconcelos et al., 2009
(Septic tank+ anaerobic filter+) O <sub>3</sub> , Fe <sup>+2</sup> /O <sub>3</sub> <sup>3</sup>	Wilde et al., 2014
(Septic tank+ anaerobic filter+) UV <sup>3</sup>	Vasconcelos et al., 2009
(Septic tank+ anaerobic filter+)TiO <sub>2</sub> /UV <sup>3</sup>	Vasconcelos et al., 2009
NF/RO (polishing) <sup>4</sup>	Beier et al., 2010

<sup>1</sup> (pre): means preliminary treatment

<sup>2</sup> (biological treatment) means that the investigated treatment is upstream of a biological step

<sup>3</sup> Upstream treatments reported in brackets have to better define the step of the treatment considered and reported data on the removal efficiencies of PhCs do not include their contribution in the cited investigations.

<sup>4</sup> (II+III) means a series of secondary and tertiary ponds

**Table 4.** Main operational parameter in the UV reactors included in this study

Unit→	Austria	Switzerland	Luxembourg
↓Parameter			
Plant type	Pilot	pilot	Pilot
Lamp	LP	LP	LP and MP
Actual Fluence, J/m <sup>2</sup>	110000	800, 2400, 7200	7400-29700 (LP) 10125-506250 (MP), λ=200-280 nm 5400-270000 (MP), λ =280-315 nm 4725-236250 (MP), λ =200-280 nm and 315-400 nm
Residence time, s	120	18, 54,162	18-71 (LP), 1.3-64 (MP)

**Table 5** Disinfection performance by means of AOPs

Method	Secondary effluent thermotolerant Coliforms Machado et al., 2007	Laundry effluent thermotolerant Coliforms Kist et al., 2008
Secondary effluent	1.1 10 <sup>6</sup>	9 10 <sup>6</sup>
UV/O <sub>3</sub>	17 000	110
UV	9000	
TiO <sub>2</sub>	170	
O <sub>3</sub>	170	
O <sub>3</sub> /TiO <sub>2</sub>	120	1700
UV/TiO <sub>2</sub>	40	20
UV/TiO <sub>2</sub> /O <sub>3</sub>	< 2	< 20

**Table 6. Removal efficiencies expected for the different groups of compounds**

<b>Group</b>	<b>PAC</b>	<b>AOP</b>	<b>UV</b>	<b>Cl<sub>2</sub>/ClO<sub>2</sub></b>	<b>Coag/Floc</b>
Antibiotics	40-90	20-90	40-90	20-90	<20
Antidepressants	70-90	20-90	40-90	20-70	<20-40
Analgesics/Anti-inflammatory	>90	20-90	70-90	20-70	<20
Lipid regulator	>90		>90	20-70	<20
X-ray contrast media	70-90	70-90	20-90	20-70	<20-40
Disinfectants/detergents	>90	>90	40-90	>20	<20-40

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Table 7. Investment and O&M costs for hospital effluent treatment by different technologies

Author	Kajitvichyanukul and Suntronvipart 2006	Liu et al. 2010	Verlicchi et al. 2010	Beier et al. 2012	Pills project 2012				Kovalova et al. 2013	Nielsen et al. 2013								
Place	Thailand	China	Italy	Germany	Netherlands			Switzerland		Denmark								
Type of treatment	Photo-Fenton	MBR	MBR+O <sub>3</sub> +UV	MBR	MBR	MBR + GAC	MBR + O <sub>3</sub> + GAC	MBR +UV/H <sub>2</sub> O <sub>2</sub> + GAC	MBR + PAC	MBR + O <sub>3</sub>	O <sub>3</sub>	O <sub>3</sub>	O <sub>3</sub> +H <sub>2</sub> O <sub>2</sub>	O <sub>3</sub> +H <sub>2</sub> O <sub>2</sub>	PAC	PAC	ClO <sub>2</sub>	MBR+O <sub>3</sub>
Investment cost (€/m <sup>3</sup> )			3.6		3.25	3.35	3.5	3.65										
O&M cost (€/m <sup>3</sup> )	0.38 <sup>1</sup>	0.45-0.163 <sup>1</sup>			1.45	1.65	1.75	1.85			0.22	0.4	0.34	1.08	0.31	1.06	0.3	1
Total cost €/m <sup>3</sup>				4.1	4.7	5	5.3	5.5	2.7	2.4								

<sup>1</sup>Exchange rate refers to December 20<sup>th</sup> 2014

# What have we learned from worldwide experiences on the management and treatment of hospital effluent?– An overview and a discussion on perspectives.


Verlicchi P.\*°, Al Aukidy M.\* Zambello E.\*

\*Department of Engineering, University of Ferrara, Via Saragat 1, I-44122 Ferrara, Italy

° Terra&Acqua Tech Technopole of the University of Ferrara, Via Borsari 46, 44123 Ferrara, Italy

[paola.verlicchi@unife.it](mailto:paola.verlicchi@unife.it), [mustafakether.alaukidi@unife.it](mailto:mustafakether.alaukidi@unife.it), [elena.zambello@unife.it](mailto:elena.zambello@unife.it)

## Graphical abstract



## Abstract

This study overviews lessons learned from experimental investigations on dedicated treatment systems of hospital effluent carried out worldwide in the last twenty years. It includes 48 peer reviewed papers from 1995 to 2015 assessing the efficacy of different treatment levels (preliminary, primary, secondary and polishing) of hospital wastewater in removing a wide spectrum of pharmaceutical compounds as well as conventional contaminants. Moreover, it highlights the rationale and the reasons for each study: reducing the discharge of micropollutants in surface water, improving existing wastewater treatment technologies, reducing the risk of spread of pathogens causing endemic diseases and finally, it offers a critical analysis of the conclusions and suggestions of each study. The most investigated technologies are membrane bioreactors equipped with ultrafiltration membranes in the secondary step, ozonation followed by

24 activated carbon filtration (in powder and in granules) in the polishing step. Interesting research projects  
1  
25 deal with photo-Fenton processes acting as primary treatments to enhance biodegradation before  
2  
326 biological treatment, and as a polishing step, thus further reducing micro-contaminant occurrence.  
4  
527 Investment and operational costs are also presented and discussed for the different treatment  
6  
728 technologies tested worldwide, in particular membrane bioreactors and various advanced oxidation  
8  
929 processes.

10  
1130 This study also discusses the need for further research to evaluate toxicity resulting from advanced  
12  
1331 oxidation processes as well as the need to develop an accurate feasibility study that encompasses  
14  
1542 technical, ecotoxicological and economic aspects to identify the best available treatment in the different  
16  
1733 situations from a global view point.

18  
1934 **Keywords:** advanced oxidation processes; environmental risk assessment; hospital effluent; pharmaceutical  
20  
2136 removal; toxicity; treatment costs.

22  
23

## 24 2537 **Abbreviations**

2638 AOP = advanced oxidation process; AOX = adsorbable organic compounds; ARB = antibiotic resistant  
27  
2839 bacteria; ARG = antibiotic resistant genes; AS = activated sludge; BAT = best available technology; CAS =  
29  
3040 conventional activated sludge; Chlorin = chlorination; Coag = coagulation; CPCs = cancerogenic platinum  
31  
3241 compounds; CWs= constructed wetlands; D617 = N-dealkylverapamil;  $D_{ow}$  = octanol water distribution  
33  
3442 coefficient; DNA = deoxyribonucleic acid; DO = Dissolved oxygen; DOC = dissolved organic carbon; EE2 =  
35  
3643 ethinyl estradiol or 17- $\alpha$  ethinyl estradiol; EQS = environmental quality standard; FL = flocculation; FLO =  
37  
3844 flotation; GAC = granular activated carbon; HDPE = high density polyethylene; HRT = hydraulic retention  
39  
4045 time; H-SSF = horizontal subsurface flow; HWW = hospital wastewater; ICM = iodinated contrast media;  $K_a$   
41  
4246 = dissociation constant;  $k_{biol}$  = biological degradation rate;  $K_{ow}$  = octanol water partition coefficient; LP = low  
43  
4447 pressure; MBBR = moving bed biofilm reactor; MBR = membrane biological reactor; MCWO = molecular  
45  
4648 weight cut off; MP = medium pressure; NF = nanofiltration; O&M = maintenance and operation; PAC =  
47  
4849 powdered activated carbon; PhC = pharmaceutical compound; RO = reverse osmosis; SARS = severe acute  
49  
5050 respiratory syndrome; SRT = sludge retention time; T = temperature; TDS = total dissolved solids; TOC=  
51  
5251 total organic carbon; TSS = total suspended solids; UASB = upflow anaerobic sludge blanket; UF =  
53  
5452 ultrafiltration; UV = ultraviolet; UWW = urban wastewater;  $v_f$  = filtration velocity; V-SSF = vertical  
55  
5653 subsurface flow; WWTP = wastewater treatment plant

55  
56  
57

## 5855 **1. Introduction**

5956 In recent years, hospital effluent has been the object of study and research in various countries throughout  
60  
6157 the world facing different issues. The specific driving and inspiring force has been to improve the

62  
63  
64  
65

58 knowledge of the chemical and physical characterization of such wastewater for conventional parameters,  
1  
2 59 namely BOD<sub>5</sub>, COD, TSS, N and P compounds, pH and T (Sarafraz et al., 2007; Verlicchi et al., 2012a); the  
3  
4 60 microbiological load of hospital effluent and also the risk of the spread of antibiotic resistant bacteria  
5  
6 61 (Boillot et al., 2008; Chitnis et al., 2004); differences in composition between hospital effluent and urban  
7  
8 62 wastewater (UWW) (Verlicchi et al., 2010); seasonal variation of hospital effluent compositions (Verlicchi et  
9  
10 63 al., 2012a, 2012c); strategies in their management (co-treatment or dedicated treatment with UWW)  
11  
12 64 (Pauwels and Verstraete, 2006, Verlicchi et al., 2010), evaluation of the adequacy of adopted treatment  
13  
14 65 strategies with respect to the removal of specific contaminants (Mesdaghinia et al., 2009, Beier et al.,  
15  
16 66 2010); technical and economic feasibility of dedicated treatment trains for hospital wastewater (HWW)  
17  
18 67 (PILLS report, 2012); contribution of hospital effluent to the influent of a municipal wastewater treatment  
19  
20 68 plant (WWTP) (Verlicchi et al., 2012a; Santos et al., 2013).

21 69 On occasion, the occurrence of disease outbreaks due to pathogens occurring in sewage, such as SARS  
22  
23 70 (severe acute respiratory syndrome) in China in 2003, has led scientists to develop specific research  
24  
25 71 projects to identify safety measures to rapidly adopt in existing WWTPs, in particular in plants receiving  
26  
27 72 hospital effluent, not only to deal with the current emergency, but also to prevent further ones (Wang et  
28  
29 73 al., 2005).

30 74 Quite rarely, national (or regional) legal regulations have been established to define how to manage and  
31  
32 75 treat hospital effluent before its disposal (discharge in public sewage for treatment at a municipal WWTP or  
33  
34 76 discharge into a surface water body) (Boillot et al., 2008; Verlicchi et al., 2010). Indeed, hospital effluent  
35  
36 77 was and (still) is generally considered of the same pollutant nature as UWW and thus it is commonly  
37  
38 78 discharged in public sewage systems, conveyed to an urban WWTP where it is subjected to conventional  
39  
40 79 treatment, often consisting in primary clarification, activated sludge process and sometimes disinfection.  
41  
42 80 This practice is very common although recent studies (Verlicchi et al., 2010; Santos et al., 2013, McArdell et  
43  
44 81 al., 2011) highlighted that higher concentrations of pharmaceuticals (PhCs), disinfectants, X-ray contrast  
45  
46 82 media occur in hospital effluent as well as a microbiological load exhibiting a higher resistance to treatment  
47  
48 83 (Chitnis et al., 2004).

49 84 Municipal WWTPs were conceived and, in some cases, recently upgraded to guarantee a high removal  
50  
51 85 efficiency of carbon, nitrogen and phosphorus compounds, as well as microorganisms (mainly bacteria):  
52  
53 86 pollutants regularly arriving with and occurring in the WWTP influent at concentrations in the order of units  
54  
55 87 (P compounds), tens (NH<sub>4</sub>, TKN) and hundreds (COD, BOD<sub>5</sub>) of mg/L and thousands of MPN/100 mL  
56  
57 88 (*Escherichia coli*).

58 89 Commonly adopted treatments at municipal WWTPs include: preliminary treatments, (sometimes) primary  
59  
60 90 clarification, secondary biological (usually consisting in a conventional activated sludge –CAS - process), and  
61  
62 91 polishing treatments (chemical disinfection or sometimes rapid filtration followed by UV disinfection).  
63  
64 92 Unfortunately, these WWTPs are not adequate enough to reach high removal efficiencies for the wide  
65

93 spectrum of micropollutants (PhCs, adsorbable organic compounds commonly known with the acronym  
1  
94 AOX) commonly present in hospital effluent. They are also among the main sources of antibiotic release  
2  
3  
95 into the environment and thus they may promote the selection of antibiotic resistant genes (ARG) and  
4  
5  
96 antibiotic resistant bacteria (ARB), as deeply investigated in Rizzo et al. (2013). Moreover, in some  
6  
7  
97 circumstances, conventional treatments have been adopted for HWW, but they are not well managed and  
8  
98 very low efficiencies are achieved even for common parameters, namely BOD<sub>5</sub>, COD, TSS and Total coliform  
9  
10  
99 (Mesdaghinia et al., 2009). Sometimes, a simple primary treatment is adopted for hospital effluent (primary  
11  
12  
100 clarification, prechlorination) but it is not efficient (Martins et al., 2008).

13  
14  
101 In other cases, no treatment is adopted at all and direct discharge of raw HWW into surface rivers is  
15  
16  
102 common practice (Liu et al., 2010).

17  
103 The main focus of this study is to present and discuss lessons learned from previous investigations and  
18  
19  
104 studies carried out on dedicated treatment of HWW in the different countries worldwide. It offers a critical  
20  
21  
105 analysis of data collected from lab, pilot and full scale treatment plants acting as primary, secondary and  
22  
23  
106 tertiary steps. Attention is paid to the removal efficiencies observed for contaminants, including  
24  
25  
107 conventional parameters but in particular emerging ones: mainly PhCs, detergents and disinfectants. The  
26  
27  
108 analysis also compares the assessment of investment and operational costs for each applied technology.

28  
29  
30

## 31 **2. Object and framework of the survey**

32  
33  
110 This study is based on 48 publications regarding investigations into the *dedicated* treatment of hospital  
34  
35  
112 effluent in lab, pilot and full scale plants acting as primary, secondary or tertiary steps. They were carried  
36  
37  
113 out in 24 different countries all over the world between 1995 and 2015.

38  
39  
114 Collected data that are presented and discussed herein mainly refer to observed removal efficiencies for  
40  
41  
115 108 PhCs belonging to 17 different classes: analgesics and anti-inflammatories (20), anaesthetics (1),  
42  
43  
116 anthelmintics (5), antibiotics (23), antifungals (1), antihypertensives (6), antineoplastics (6), antiseptics (1),  
44  
45  
117 antivirals (5), beta-blockers (6), contrast media (9), fragrances (3), hormones (4), lipid regulators (4),  
46  
47  
118 psychiatric drugs (12), receptor antagonists (1), stimulants (1). Table SD-2 in Supplementary Data compiles  
48  
49  
119 all the selected compounds grouped according to their class. Moreover, conventional pollutants (BOD<sub>5</sub>,  
50  
51  
120 COD, SS, N and P compounds, microorganisms...) are also reported and discussed.

52  
53  
121 In discussing removal efficiencies of selected PhCs observed for the different treatment technologies and  
54  
55  
122 steps, particular attention is paid to the potential capacity of each technology in retaining/degrading  
56  
57  
123 specific compounds and, when possible, to the operational conditions which could maximize them. Data  
58  
59  
124 are presented in graphs in the manuscript and further details are provided in Tables in Supplementary  
60  
61  
125 Data.

62  
63  
126 All removal values reported and discussed (in the following graphs and tables) must be considered with the  
64  
65  
127 necessary caution, bearing in mind their origin and that they may be affected by many factors, namely:

- 128 • influent characteristics (macro- and micropollutant concentrations),
- 129 • operational conditions (sludge concentration, sludge retention time SRT, hydraulic retention time
- 130 HRT, pH, temperature T, feeding mode, dosage of ozone, H<sub>2</sub>O<sub>2</sub>, UV irradiation, catalyst type and
- 131 contact time),
- 132 • reactor types (conventional activated sludge system or membrane bioreactor MBR;
- 133 compartmentalization),
- 134 • environmental conditions (temperature, irradiation)
- 135 • water sampling mode and frequency.

136 Before discussing the main results derived from these studies, a snapshot of the main chemical, physical  
 137 and microbiological characteristics of HWW is provided in Table 1. References are also provided for each  
 138 compiled parameter or class of compounds of PhCs.

139 To ease the reading of the manuscript, a brief presentation of each investigation is reported in Table 2 and  
 140 the list of all the investigated treatment trains is provided in Table 3 with the corresponding references.

142 **Table 1.**

### 144 3. Technologies and treatment trains for HWW under review

145 Table 2 reports the main characteristics of the studies included in this review referring to the dedicated  
 146 treatment of hospital effluent and the *rationale* behind each one.

147 A rapid glance at Table 2 points out that hospital effluent was subjected to different treatment levels: just a  
 148 preliminary/primary (potential or actual) dedicated treatment before its co-treatment with UWW at a  
 149 municipal WWTP, sometimes conventional secondary biological treatments (CAS) or modified CAS  
 150 processes that are systems combining attached and suspended biomass, but also MBRs, and advanced  
 151 oxidation processes (AOPs). In some countries AOPs were investigated as preliminary-primary treatments  
 152 in order to enhance biodegradation in the stream.

153 In order to help in the reading of this review, Table 3 lists all the types of investigated technologies and  
 154 treatment trains with the corresponding references. Their distribution in the different countries in the  
 155 world can be found in the graphical abstract, as well as on a larger scale in Fig SD-1 in the Supplementary  
 156 Data.

157 Most of the investigations referred to pilot/lab scale plants (69%) and the remaining 31% to full scale  
 158 dedicated facilities (see Table SD-1 in the Supplementary data). The latter include the following treatment  
 159 trains: septic tank followed by an anaerobic filter (Brazil, de Almeida et al., 2013, Martins et al., 2008),  
 160 UASB + anaerobic filters (Brazil, Prado et al., 2011); series of maturation and facultative ponds (Ethiopia,  
 161 Beyene and Redaie, 2011); septic tank + constructed wetlands (H-SSF + V-SSF beds) (Nepal, Shrestha et al.,  
 162 2001); MBR (in Germany, Beier et al., 2011, 2012; in China: Liu et al., 2010, Wen et al., 2004); CAS+



163 chlorination (in Greece, Kosma et al., 2010; in Brazil, Prado et al., 2011; in Iran, Mahvi et al., 2009); MBR+  
164 chlorination (in China, Liu et al., 2010); flocculation+activated carbon or flocculation+CAS (Republic of  
165 Korea, Sim et al., 2013), MBR+O<sub>3</sub>+UV (Italy, Verlicchi et al., 2010), MBR+O<sub>3</sub> or PAC and then sand filtration  
166 (in Germany, PILLS Project Report 2012), MBR+O<sub>3</sub>+GAC (a full scale demo plant called Pharmaphilter  
167 operating in the Netherlands, Pharmafilter report, 2013), MBR+GAC+O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub> and MBR+GAC+UV (Denmark,  
168 Grundfoss biobooster, 2012).

169 Moreover, 53% of the studies were carried out in European countries (Austria, Belgium, Denmark, France,  
170 Germany, Greece, Italy, Luxembourg, Netherlands, Switzerland and Turkey), 27% in Asiatic countries  
171 (China, India, Indonesia, Iran, Iraq, Nepal, Republic of Korea, Thailandia and Taiwan), 16% in South America  
172 (Brazil) and 4% in Africa (Egypt and Ethiopia). PhCs were detected and removal efficiencies evaluated in  
173 60% of the studies included, whereas the remaining ones only refer to conventional parameters. All the  
174 studies developed in Europe investigated PhCs with the only exception of Nardi et al., 1995 (referring to  
175 prechlorination of raw hospital effluent), and Arslan et al., 2014 regarding AOPs applied on a raw HWW.

176  
177 It is worth noting that often in Asian countries, the main reason for investigating hospital effluent  
178 treatment is the need to guarantee “safe” treatment for this kind of wastewater and to evaluate the  
179 possibility of directly reusing the treated effluent due to water scarcity for various requirements, in  
180 particular for irrigation (Al Hashimia et al., 2013). As discussed below, although it is highly appreciable that  
181 this problem has been tackled, their common conclusion, based on an analysis of conventional  
182 contaminants whereby a secondary biological treatment followed by chlorination may be considered  
183 adequate treatment even in case of direct reuse, is not backed up by comprehensive research into  
184 micropollutants or ecotoxicology.

185 In European countries, the main reason for research is generally an awareness of the potential risk posed  
186 by the occurrence of PhC residues in secondary effluent and the need to reduce the PhC load discharged  
187 into the environment via WWTP effluent. There is a lively debate on the need to adopt dedicated and  
188 proper treatments for hospital effluents (Ort et al., 2010, Verlicchi et al., 2012a, Santos et al., 2013) based  
189 on the evaluation of the contribution of the health care structure and the corresponding catchment area in  
190 the discharge of PhCs.

191  
192 **Table 2**

193  
194  
195 **Table 3**

196  
197

198

199

200

201

202

203

204

205

206

207

197 **4. Results and Discussion**

198 The following sections present and discuss collected data on the removal efficiencies of selected PhCs as  
2  
199 well as conventional parameters from HWW by different systems acting as primary, secondary and tertiary  
4  
200 steps. A specific section is devoted to the removal ability of microorganisms observed in the different  
5  
201 technologies and on measures suggested to reduce the spread of pathogens and also of antibiotic resistant  
7  
202 bacteria. Supplementary Data provides a brief overview on the main reactions taking place during AOPs  
9  
203 and might help in reading the following discussion.

11  
204  
12  
13  
205 **4.1. Preliminary and primary treatments –Pharmaceutical removal**

206 Preliminary treatments are generally adopted and tested with the aim of removing rough and coarse  
16  
207 material from raw wastewater, thus protecting mechanical and electrical parts in the downstream  
18  
208 treatment steps. Specific treatments have also been tested in lab and pilot plants to reduce the toxicity of  
19  
209 chemical mixtures occurring in hospital effluent and to enhance biodegradability (namely to increase the  
21  
210 BOD<sub>5</sub>/COD ratio) and to improve downstream biological processes.

23  
241 Coagulation-flocculation and flotation are processes that satisfy the first objective as they promote the  
25  
212 removal of suspended solids and colloids from wastewater which do not settle spontaneously (Gautam et  
26  
27  
213 al., 2007; Suarez et al., 2009), whereas ozonation (Chiang et al., 2003) and AOPs (Kajitvichyanukul and  
28  
29  
214 Suntronvipart, 2006) satisfy the second objective.

30  
315 COD removal was found greater than 70% when 200 mg/L of ferric chloride was added to raw hospital  
32  
316 effluent and removal increased to over 98% if the coagulant was added to settled HWW. A following step of  
34  
317 disinfection by calcium hydrochloride not only reduces microorganisms, but also COD. It was found that  
35  
36  
318 with a contact time of 30 minutes, the Ca(ClO)<sub>2</sub> break point dose is 20 mg/L (Gautam et al., 2007).

37  
38  
319 A few studies have been carried out on the effectiveness of coagulation, flocculation and flotation in  
39  
40  
420 removing PhCs from hospital effluent (Suarez et al., 2009; Martins et al., 2008). Figure 1 shows the main  
41  
421 results when common coagulants Al<sub>2</sub>(SO<sub>4</sub>)<sub>3</sub> and FeCl<sub>3</sub> at a dosage of 25 mg/L are added to the raw  
42  
43  
422 wastewater, with and without flotation. These processes are not particularly efficient in removing PhCs,  
44  
45  
423 confirming the considerations reported in Verlicchi et al. (2012b). In fact, only diclofenac and some  
46  
47  
424 fragrances are removed by more than 60%. Figure 1 also reports the somewhat modest removal efficiency  
48  
49  
425 (17%) observed for ciprofloxacin using a septic tank followed by an anaerobic filter fed with raw effluent  
50  
51  
526 from a hospital in Brazil (Martins et al., 2008).

52  
527 Attempts to improve COD removal and increase biodegradability in *raw* hospital effluent were made by  
53  
54  
528 applying ozonation, O<sub>3</sub>/UV and O<sub>3</sub>/UV/H<sub>2</sub>O<sub>2</sub> as a pretreatment (Arslan et al., 2014). Based on lab scale tests  
55  
56  
529 on effluent from a diagnostic centre, nuclear medicine, oncology, radiology and medical genetics  
57  
58  
530 departments, it was found that the highest COD removal (47.5%) was obtained in a system O<sub>3</sub>/UV/H<sub>2</sub>O<sub>2</sub>  
59  
60  
531 operating at pH 6.0, O<sub>3</sub> concentration 10 mg/L, monochromatic UV lamp (254 nm) and dosage of H<sub>2</sub>O<sub>2</sub> 1.8  
61  
62  
532 mL within 60 min. As for absorbance removal, the best AOP is O<sub>3</sub>/UV: in fact the addition of H<sub>2</sub>O<sub>2</sub> led to a

233 scavenger effect on hydroxyl radicals resulting in a lower removal efficiency (see Supplementary Data for  
234 more details).

235 The results achieved from the ozonation of effluent from a kidney dialysis unit are quite interesting: at a  
236 dose of 25 mg/L of ozone and a contact time of 20 min, COD was reduced from 132 mg/L to 97 mg/L and  
237 the ratio BOD<sub>5</sub>/COD increased from 0.15 to 0.26 confirming a consistent increment in the biodegradability  
238 of the stream (Chiang et al., 2003).

239 Another option to improve biodegradability is achieved using photo-Fenton processes (see Supplementary  
240 Data for the main reactions involved). It was found that in hospital effluent of average pollutant strength  
241 (COD 1350-2250 mg/L, BOD<sub>5</sub>/COD 0.30) with a dosage ratio COD:H<sub>2</sub>O<sub>2</sub>:Fe<sup>+2</sup> equal to 1:4:0.1, a reaction pH  
242 of 3 and a reaction time of 2 h, the removal efficiencies for BOD<sub>5</sub>, COD and TOC were: 61%, 77% and 52%  
243 and the BOD<sub>5</sub>/COD ratio increased from 0.30 to 0.52. It was also found that for higher COD values,  
244 optimum reaction conditions have to be tested to guarantee good mineralization of organic compounds  
245 and to enhance biodegradability (Kajitvichyanukul and Suntronvipart, 2006). The increased biodegradability  
246 of the wastewater was also confirmed by batch experiments on raw and pretreated effluent subjected to a  
247 biological process using activated sludge. It was found that in the case of pretreated wastewater, the  
248 removal of COD amounted to 90% after a 72 h treatment time, whereas it was only 30% in the case of raw  
249 hospital effluent (Kajitvichyanukul and Suntronvipart, 2006).

250 A Fenton process may also act as a disinfectant step: in fact it greatly removes total coliforms and  
251 thermotolerant coliforms as documented by Berto et al. (2009). The cases of complete removal observed in  
252 their investigation were ascribed to acidic conditions and the occurrence of hydroxyl radicals. Low pH  
253 values would cause bacteria death and HO• would assure DNA denaturation.

254 These studies led to suggest ozonation, Fenton as well as photo-Fenton processes as suitable solutions for  
255 the preliminary treatment of hospital wastewater from a technical viewpoint. An economic analysis would  
256 be necessary to assess investment, operational and maintenance costs. Moreover, the adequateness of  
257 adopting these advanced technologies as “pretreatment” also needs to be confirmed from a toxicological  
258 view point, but unfortunately, there is no available research to investigate.

## 261 **Figure 1**

### 263 **4.2. Secondary treatments – Pharmaceutical removal**

264 Most of the studies investigated the capacity of MBRs as a biological stage for the treatment of HWW.  
265 Other systems analyzed include: CAS systems in Iran (Mahvi et al., 2009), Greece (Kosma et al., 2010), Egypt  
266 (Abd El-Gawad and Aly, 2011) and Belgium (Pauwels et al., 2006), an anaerobic-aerobic fixed film  
267 bioreactor in Iran (Rezaee et al., 2005), an aerated fixed film biofilter in Indonesia (Prayitno et al., 2014), a  
268 moving bed biofilm reactor in Denmark (Andersen et al., 2014), ultrafiltration membranes coupled with a  
269 modified CAS reactor by addition of biofilm supports in France (Mousaab et al., 2015), maturation and

270 polishing ponds in Ethiopia (Beyene and Redaie, 2011), horizontal and vertical subsurface flow systems in  
271 Nepal (Shrestha et al., 2001), and a fungal bioreactor in Spain (Cruz-Morato et al., 2014). In the first part of  
272 this section MBRs and CAS are critically analyzed and compared, the remaining systems are analyzed and  
273 compared in the second part.

274  
275 *MBR – Lessons learned from the reviewed studies, carried out all over the world, regarding the efficacy of*  
276 *MBRs applied to UWW in the removal of macro- and micropollutants (Verlicchi et al., 2012b) are certainly*  
277 *useful in an analysis of the performance of an MBR fed with hospital effluent. As regards this type of*  
278 *wastewater, special attention must be paid to evaluate the potential inhibition effect on the biological*  
279 *activities of PhCs, heavy metals, disinfectants, detergents that occur at higher concentrations in HWW*  
280 *rather than UWW thus, the risk that they could negatively affect the degradation processes of micro*  
281 *contaminants has to be assessed.*

282 In the studies included herein, hospital effluent is generally subjected to a coarse screening (2 mm),  
283 sometimes through a fine screen or a sieve (0.5-1 mm), whereas a primary clarifier is only rarely adopted  
284 (HRT 2-10 h). Adequate pretreatments are extremely useful in guaranteeing continuous operation of MBRs.  
285 As reported in the investigation by Verlicchi et al. (2008), the raw HWW may contain rags, filaments, pieces  
286 of cardboard that can adversely interfere with moving parts within the WWTPs or clog membranes and  
287 thus they have to be efficiently removed at the start of the treatment train. This is in agreement with  
288 suggestions by Gabarron et al. (2013) which investigated different pretreatment processes to find the most  
289 adequate technology that would consistently contribute in minimizing the ragging impact over MBR  
290 performance.

291 A storage/equalization tank before an MBR guarantees homogeneous feeding, avoids damage to the  
292 membrane units and may also promote sorption removal mechanisms due to the contact between solid  
293 particles and micropollutants. This is the case of cancerogenic platinum compounds (CPCs), such as  
294 cisplatin, that show a high affinity for suspended solids (Lenz et al. 2007a). In this study, the feed from the  
295 oncological ward, was first collected in a tank (24 h residence time), then processed through a sieve (1 μm,  
296 to separate suspended solids from the liquid phase) and finally sent to an MBR treatment. The CPC  
297 concentration was significantly reduced after passing through the sieve and the membranes due to particle  
298 and biomass sorption onto the surface.

299 A biological reactor usually consists in an anoxic/oxic compartments to promote complete nitrification and  
300 denitrification. P removal, when necessary, is achieved by a co-precipitation with FeCl<sub>2</sub>. Biomass  
301 concentration in the aerated compartment varied between 2 and 20 g/L, the sludge retention time ranged  
302 between 20 and 100 d with the only exception of an MBR operating in parallel with a CAS system whose  
303 SRTs were 12-15 d in each (Pauwels et al., 2006).

305 Ultrafiltration membranes (tubular or flat sheet, 0.03-0.06  $\mu\text{m}$ ) were more frequently investigated (Nielsen  
306 et al., 2013; Lenz et al., 2007a, PILLS report 2012 – at the Swiss, German and Dutch units within the project)  
307 than microfiltration membranes (sheet, 0.4  $\mu\text{m}$ ; Pauwels et al., 2006; Beier et al., 2011; Luxembourg unit  
308 within the PILLS project – PILLS report 2012). Submerged membrane modules integrated in the bioreactor  
309 was the most commonly adopted configuration; side stream modules were equipped only in the Dutch unit  
310 within the PILLS project and in the Austrian investigation where the MBR was fed by the oncological ward  
311 effluent (Lenz et al., 2007a).

312  
313 A rapid glance at the macro pollutant removal observed in the different MBRs shows that notably high  
314 values were found (94% for DOC, 99% for COD, 93-99% for  $\text{NH}_4^+$ , around 85% for nitrates) resulting in a  
315 high quality permeate, with reduced variability intervals for the different pollutants: DOC 6-11 mg/L, COD  
316 20-30 mg/L, total N 3-17 mg/L with a few exceptions (McArdell et al., 2011; Wen et al., 2004).

317 Good biological activity was in general guaranteed and maintained throughout each observation period in  
318 the different investigations. Chemical or physical parameter shocks could occasionally occur resulting in  
319 disturbances at the biological reactors and, from a macroscopic point of view, reduced removal of macro  
320 pollutants, namely COD, SS, N compounds, from a microscopic point of view changes, modification or  
321 disintegration of the activated sludge flocks (Pauwels et al., 2006; McArdell et al., 2011).

322 In this context, quaternary ammonia disinfectants are potential critical parameters, as their consumption  
323 may greatly vary from one hospital to another as remarked by Kovalova et al. (2012). As for the common  
324 quaternary ammonia disinfectant BAC C12, tolerable concentrations may reach up to 150  $\mu\text{g/L}$  without  
325 inducing negative effects on the biomass (Kovalova et al., 2012, McArdell et al., 2011).

326 Moreover, hospital laundrette effluent represents a hotspot for certain pollutants (Kist et al., 2008). A  
327 sudden increase in formic acid concentrations may occur as reported by Pauwels et al. (2006), leading to a  
328 pH shock (2.5) in the bioreactor. This results in a process performance decrease due to the disintegration of  
329 the sludge and consequently in a dramatic decrease in COD removal.

330 Figures 2 and 3 report all collected data on removal of PhCs in hospital effluent by an MBR operating at  
331 different SRT values.

332 As underlined by different studies (Clara et al., 2005; Verlicchi et al., 2012a, 2012b, Monteiro and Boxall  
333 2010), SRT greatly affects the removal performance of many PhCs. Long SRT values promote adaptation of  
334 different kinds of microorganisms and the presence of slower growing species which could have a greater  
335 capacity for removing more recalcitrant compounds while simultaneously improving suspended solid  
336 separation (Kreuzinger et al., 2004). Based on data shown in Figures 2 and 3 involving removal efficiencies  
337 of compounds observed at different sludge ages, it emerges that an SRT equal to 20-25 d promotes the  
338 removal of atenolol and clarithromycin, slightly higher values (around 30 d) enhance diclofenac and  
339 erythromycin removal and around 50 d a larger number of compounds are better removed: naproxen,  
340 lidocaine, ciprofloxacin, sulfamethoxazole and cyclophosphamide.

341 Very good removal efficiencies of over 90% were in general observed at a SRT greater than 30 d for many of  
342 the selected compounds.

343 Modest removal efficiencies (< 50%) were observed for metoprolol, iopamidol, carbamazepine, gabapentin,  
344 ritanilic acid.

345 Unfortunately, removal efficiency was always scarce (< 25%) for various PhCs, namely: indomethacin,  
346 phenazone, roxithromycin, D617 (N-dealkylverapamil, a metabolite of Verapamil), cyclophosphamide,  
347 oseltamivir carboxylate, propranolol, sotalol, iodixinal, iohexol, iomeprol, ioversol, oxazepam.

348 The antineoplastic agents included in the CPC group show a higher removal efficiency with respect to  
349 cyclophosphamide, due to their higher affinity to sorbing onto particles and activated sludge flocks within  
350 the MBR (Lenz et al., 2007a,b).

351  
352

353 **Fig. 2**

354  
355

356 **Fig. 3**

357  
358

358 Releases sometimes occur for diclofenac, phenazone, ciprofloxacin, clarithromycin, sulfadiazine,  
359 sulfamethoxazole, propranolol, iopamidol, carbamazepine, probably due to deconjugation during biological  
360 treatment (Kovalova et al., 2012, Nielsen et al., 2013). These are not reported in the graph in Figures 2 and  
361 3. An in-depth discussion of the potential release of many PhCs is reported in Verlicchi et al. (2012b) as well  
362 as in Monteiro and Boxall (2010).

363 Based on the Swiss research carried out within the PILLS project involving 56 compounds of different  
364 therapeutic classes, it emerged that an MBR (SRT equal to 30-50 days) is able to remove up to 90% of  
365 pharmaceuticals and metabolite *load* (X-ray contrast media excluded), although removal of some of the  
366 selected compounds was very poor (in particular, clindamycin, diclofenac and furosemide). Only 2% of the  
367 influent contrast media load was removed in the investigated MBR.

368 An MBR is not a satisfactory treatment process for the removal of AOX compounds: in the permeate, AOXs  
369 occur in the range of 0.56-0.85 mg/L (Beier et al., 2011; McArdell et al., 2011) and further advanced  
370 treatment is necessary to reduce their content in the final effluent (Machado et al., 2007).

371 The absence of suspended solids in the MBR effluent represents a strength as it is the most important  
372 condition required by many advanced technologies in the removal of trace contaminants, as suspended  
373 solids may negatively interfere with the removal performance of said technologies.

374 An MBR appears to be an adequate secondary treatment for hospital effluent as it produces very good  
375 quality and stable effluent throughout the running time, and is thus suitable for advanced technologies  
376 (Venditti et al., 2011; Beier et al., 2011), including NF/RO and AOPs. Full scale MBRs have been adopted for  
377 the treatment of HWW in Italy (Verlicchi et al., 2010), Germany (PILLS report 2012) and China (Liu et al.,  
378 2010).

379  
380 CAS – Only two research projects were found dealing with the removal of PhCs from hospital effluent  
381 involving “dedicated” CAS systems: one lab scale (Pauwels et al., 2006) and one full scale (Kosma et al.,  
382 2010). Pretreatment was only reported in the second case, consisting in a grit removal and mixing tank.  
383 Biological reactors had anoxic/aerobic compartments in the first case and only aerobic in the second. In the  
384 research by Kosma et al., 2010 removal efficiencies were provided for PhCs after CAS (HRT 6 h)+  
385 chlorination.

386 Only 10 PhCs were monitored in these dedicated CAS systems. High removal efficiencies were observed for  
387 ibuprofen (92%), salicylic acid (79%) and caffeine (75%), naproxen, gemfibrozil, paracetamol and ethynyl  
388 estradiol (EE2) were moderately removed (67%, 63%, 61% and 43% respectively), whereas scant removal  
389 was found for carbamazepine and phenazone (30% and 13% respectively). A modest release (-17%) was  
390 observed for diclofenac.

391  
392 *Comparison between CAS and MBR* - In the research by Pauwels et al. (2006), CAS and an MBR were  
393 operating in parallel, fed with the same hospital effluent (spiked with EE2 up to 1 mg/L). With respect to  
394 the MBR, the CAS system exhibited a slower start up and was more prone to bulking. Moreover, COD  
395 removal was worse in the CAS system (88% in CAS vs. 93% in an MBR) as was the removal of various  
396 bacterial groups: total coliforms, fecal coliforms and total anaerobic bacteria (about 2 log units less) and  
397 total aerobic bacteria (1.4 log units less). No differences were found in the removal of EE2 between CAS  
398 and MBR.

399 The higher removal efficiencies observed for some bacterial groups in the MBR permeate is due to  
400 membrane retention. Their occurrence in the MBR effluent may instead be explained by unavoidable  
401 bacteria regrowth from the effluent vessel into the permeate collecting tube and also by the absence of  
402 proper membrane cleaning while the system was running, as disinfection was not applied (Pauwels et al.,  
403 2006).

404 Lessons learned from previous studies on removal of PhCs by means of CAS and an MBR fed with UWW  
405 (Verlicchi et al., 2012a,b) highlighted that in the MBR, the combination of higher biomass concentration in  
406 the aerated basin, development of different bacterial species within the biomass, smaller sludge flocks that  
407 may enhance sorption on the surface of different contaminants, higher SRTs and higher removal of  
408 suspended solids, greatly contribute to the removal of PhCs from the stream. Moreover, as discussed  
409 below, passage through ultrafiltration membranes guarantees disinfection of the wastewater, thus  
410 reducing the risk of spread of pathogenic bacteria and of multi drug resistant bacteria.

411  
412 *MBR upgrade* - Recently, an upgrade of the MBR system was researched by Mousaab et al. (2015) with the  
413 aim of improving PhC removal efficiencies and membrane function. The system consisted in an activated  
414 sludge basin coupled with an external ultrafiltration membrane module (0.2 µm), operating at a SRT 20 d,

415 HRT 22 h, T 18-20 °C and pH 6.8-7.9. In the first 75 d, it worked under “usual” conditions. Then, HDPE  
416 support media were added to the biological reactor (specific area: 600 m<sup>2</sup>/m<sup>3</sup>; diameter: 12.2 mm; length:  
417 12 mm, density: 0.95-0.98 kg/m<sup>3</sup>) promoting the development of a hybrid (attached and suspended)  
418 biomass and a longer SRT of fixed organisms. In the modified bioreactor, higher removal efficiencies were  
419 observed for soluble COD (91.8% vs. 86.9%), TSS (100% vs. 99.6%) and VSS (93.2%vs. 87.9%) and removal  
420 efficiencies greater than 95% for codeine, pravastatin, ketoprofen, diclofenac, roxithromycin, gemfibrozil  
421 and iohexol, whereas in the unmodified MBR their removal was either absent or very low. The presence of  
422 biofilm supports also enhanced particle sorption and improved effluent quality, thus offering better  
423 protection of the membranes against fouling and reducing cleaning operations.  
424 Enhanced removal of P compounds from hospital effluent could be obtained by sequencing  
425 anoxic/anaerobic MBRs. Al –Hashimia et al. (2013) found that the optimal phase for this type of system is  
426 operating with an internal recycling mode of 2 h anoxic followed by 2 h anaerobic. These conditions  
427 provide an optimal simultaneous removal efficiency of 93% for N compounds and 83% for P compounds  
428 (expressed as P-PO<sub>4</sub><sup>-</sup>).

429 *Other investigated biological systems* -In Nepal, in 1997 a dedicated treatment plant was built for hospital  
430 effluent. It consists of a three chambered septic tank (16.7 m<sup>3</sup>) providing pretreatment, followed by CW  
431 systems: a horizontal subsurface flow bed (140 m<sup>2</sup>, 0.65 m deep and 0.75 m high, filled with 5 mm crushed  
432 gravel) and a vertical flow bed (120 m<sup>2</sup>, 1 m deep, filled with clean sand) as a secondary step. Very good  
433 removal efficiencies were observed for TSS and BOD<sub>5</sub> (97-99%), COD (94-97%), N-NH<sub>4</sub> (80-99%), total  
434 coliform 99.87-99.999%), *E. coli* (99.98-99.999%) and *Streptococcus* (99.3-99.99%) (Shrestha et al., 2001)  
435 In Ethiopia, a series of waste stabilisation ponds (2 facultative ponds, 2 maturation ponds and 1 fish pond  
436 covering an area of about 3000 m<sup>2</sup> with a total retention time of 43 d) was found to be reasonably efficient  
437 in the removal of BOD<sub>5</sub>, COD, sulphide, suspended solids and N compounds from hospital effluent (Beyene  
438 and Redaie, 2011). Despite the satisfactory removal of total and fecal coliform (99.7 and 99.4%  
439 respectively), their final concentrations do not fulfil WHO recommendations for restricted and unrestricted  
440 irrigation. Options to improve the quality of the final effluent were considered: for instance adoption of (i)  
441 constructed wetlands; (ii) two successive lagoons followed by infiltration into the land, (iii) MBR advanced  
442 oxidation treatment to better remove all the parameters as well as pharmaceuticals, (iv) photo-Fenton  
443 process to reduce toxicity. Only the first option was considered feasible, whereas the second could lead to  
444 groundwater contamination and the applicability of the remaining options was found difficult in terms of  
445 cost, installation, operation and maintenance.

446 In Iran, hospital effluents are generally discharged into a public sewage system and then co-treated with  
447 urban effluents. Usually they are subjected to a secondary treatment; disinfection is mandatory in case of  
448 disease outbreaks and in critical periods (in the summer and autumn due to reduced river water flow)  
449 (Mahvi et al., 2009). The most common malfunctions are due to operator inexperience at the WWTP and



451 negligent WWTP management by the authorities. Investigations were carried out on pilot plants with the  
452 aim of evaluating (i) proper pretreatment of hospital effluent before discharge into a public sewage system  
453 followed by co-treatment (Rezaee et al., 2005) and (ii) a (co)-treatment train able to respect Iranian legal  
454 requirements for physical, chemical and microbiological parameters for direct discharge into the surface  
455 body, disposal to wells and reuse in agriculture (Azar et al., 2010). These investigations found that an  
456 integrated anaerobic/aerobic fixed film bioreactor can greatly remove organic and nitrogen compounds  
457 from raw hospital wastewater and when followed by co-treatment consisting in primary treatment, an  
458 aerobic/anaerobic activated sludge reactor fulfils the legal requirements for conventional parameters.  
459 These conclusions however do not consider any kind of more recalcitrant compounds (pharmaceuticals,  
460 contrast agents, disinfectants) whose removal is poor in the investigated biological systems.  
461 Another treatment train was investigated in Indonesia consisting in an aerated fixed film biofilter followed  
462 by an ozone reactor. Satisfactory removal efficiencies were observed for BOD<sub>5</sub> (97.5%), fecal coliform  
463 (99.23%), Pb and phenol (100%), but there was no chemical analysis involving pharmaceuticals,  
464 disinfectants or detergents (Prayitno et al. 2014).  
465 As for preliminary treatments, in addition to what has already been reported in section 4.1, chemical  
466 flocculation followed by a CAS process represents an efficient barrier for anthelmintic drugs (albendazole  
467 and flubendazole) considering that overall removal is in the range of 67-75% (Sim et al., 2013).  
468  
469 Modifications to biological reactors to enhance micropollutant removal have undergone in-depth analysis  
470 during the last years. This is the case of Andersen et al. (2014) where on a pilot scale, the combination of a  
471 moving bed biofilm reactor followed by an ozonation stage was investigated. A biological system was  
472 developed (called a staged MBBR) to attempt to improve the creation of fixed biofilms where slow-growing  
473 bacteria would stand a better chance of development (these bacteria are very efficient in removing  
474 pharmaceuticals) compared to biomass developed in CAS systems. Higher removal efficiencies were  
475 observed for ketoprofen and gemfibrozil and occasionally for diclofenac and clofibric acid.  
476  
477 Interesting and promising results were observed for many PhCs in a batch fluidized bed bioreactor under  
478 sterile and non sterile conditions with *Trametes versicolor* pellets (Cruz-Morato et al., 2014) fed with  
479 hospital effluent, operating at pH 4.5, T 25 °C, 1.4 g dry weight biomass per litre and with a continuous  
480 addition of glucose and ammonium tartrate as a nutrient source for the biomass. Sterile conditions showed  
481 that *T. versicolor* is responsible of the removal of the detected compounds. Very good removal efficiencies  
482 were observed for analgesics and anti-inflammatory drugs after 1 day and complete removal of most was  
483 observed after 8 d, with the only exception of salicylic acid and dexamethasone. Although antibiotics were  
484 partially removed and required longer times (5 d against 1 d for analgesics), the fungal treatment achieved  
485 better results than conventional activated sludge (CAS) processes (Verlicchi et al., 2012a,b) for the most  
486 part. This is the case of ciprofloxacin (69% and 99% in sterile and non sterile conditions respectively, vs. 58-

487 78% in CAS) and clarithromycin (80% in non-sterile conditions vs. 46-62% in CAS). Higher removal  
488 efficiencies were also observed for the anti-hypertensives: valsartan (90 and 95% after 8 d in sterile and  
489 non-sterile conditions), irbesartan (73 and 98% in sterile and non-sterile conditions), diuretic furosemide  
490 (100% and 80% in sterile and non-sterile conditions vs. 33-54 % in CAS). As for diclofenac, complete  
491 removal was observed. This is an important result as it is one of the most persistent compounds in CAS and  
492 also a potential candidate for regulation by European legislation. On the other hand, a disadvantage of this  
493 process is that after treatment, pH neutralization is necessary as secretion of organic acids by the fungus  
494 lowers the overall pH.

495 As concerns the investigations carried out in Iran, Iraq and Indonesia, it is important to underline that final  
496 effluent from treatment trains including CAS or ponds generally should not be directly reused for irrigation  
497 purposes due to the occurrence of residues of PhCs and other emerging contaminants. AOPs should be  
498 included in the treatment trains and in any case, further research into the ecotoxicological characteristics  
499 of the final effluent should be carried out.

### 501 **4.3. Tertiary treatments – Pharmaceutical removal**

#### 502 **4.3.1. Filtration through powdered or granular activated carbon (PAC and GAC)**

503 Filtration through PAC and GAC has undergone in-depth investigation by different European research  
504 groups. Figures 4 and 5 report all the collected data. In all cases included in this study, PAC/GAC treatment  
505 followed an MBR fed only with hospital effluent. In the permeate DOC was in the range of 6-8 mg/L, TOC  
506 around 20 mg/L (McArdell et al., 2011; Nielsen et al., 2013).

507 The adsorbent used in the Swiss research was PAC (McArdell et al., 2011) with a surface area of 1300 m<sup>2</sup>/g,  
508 a particle size d<sub>50</sub> 15µm, a zero surface charge point pH<sub>PZC</sub> equal to 8.8 (this last value represents the pH at  
509 which on the carbon surface there are as many positively as negatively charged functional groups; below  
510 this value the carbon surface is positively charged). In the PAC reactor, good mixing guaranteed a constant  
511 concentration of the adsorbent, its retention time was 2 days as a few differences were found with longer  
512 times. Good separation between loaded PAC and treated effluent was achieved by *filtration* through UF  
513 membrane flat sheets (pore size 0.04 µm) in the PILLS project plants (McArdell et al., 2011, PILLS report  
514 2012) and through a 1 µm glass fibre filter in the Dutch research (Nielsen et al., 2013). Nanofiltration  
515 opposed to ultrafiltration would certainly be convenient from a technical view point (improved PhC  
516 removal), but not from an economic one, as nanofiltration concentrate would require dedicated treatment  
517 due to the high concentrations of micropollutants. Another option could be pumping the loaded activated  
518 carbon from the PAC reactor to the MBR for recycling: a consistent improvement in the removal of  
519 contaminants could result. But neither of these processes were researched.

520 The investigated doses of PAC ranged between 8-23 mg/L in the Swiss and German research study (PILLS  
521 2012) and between 150 and 450 mg/L in Dutch studies (Nielsen et al., 2013). The former range, which is

522 absolutely more sustainable from an economic view point, was defined on the basis of costs and  
523 reasonable removal rates for a wide spectrum of micropollutants (56 compounds), the latter was based on  
524 a Swedish study on the removal of micropollutants in aquatic environments (Wahlberg et al., 2010).  
525 In the PAC filter effluent, DOC occurred at about 4-4.5 mg/L (PAC dose 8 mg/L), 2.7-3.7 (PAC dose 23 mg/L)  
526 and about 2 mg/L (PAC dose 43 mg/L)  
527 Within the Swiss campaigns, at the applied PAC dose of 8 mg/L, 25 out of the 56 investigated  
528 pharmaceuticals were subjected to high removal efficiencies (> 80%) whereas 10 compounds exhibited  
529 removal efficiencies below 20%; at the intermediate value of 23 mg/L a removal efficiency greater than  
530 80% was observed for 36 compounds and less than 20% for only two contrast media (diatrizoate and  
531 ioxitalamic acid). When 43 mg/L of PAC were dosed, 38 compounds had high removal efficiencies (> 80%)  
532 and the same two contrast agents still had scant removal efficiencies (< 20%).  
533 A rapid glance at the results achieved within the Dutch research (Nielsen et al., 2013) shows that no  
534 significant differences were observed in the removal of the 30 selected pharmaceuticals by applying 150  
535 mg/L or 450 mg/L of PAC.  
536 A comparison between the Dutch campaign and the PILLS project, referring only to the 24 compounds  
537 monitored in all the cited studies, highlights that only for 5 PhCs a higher removal efficiency was achieved  
538 with the (extremely high) Dutch dosages. This occurred for the antibiotics sulfadiazine (40% vs. 78% at both  
539 high doses), sulfamethoxazole (62% vs. 71% and 99% at the two doses), trimethoprim (83% vs. 99.9% at  
540 both doses), the contrast agent ifosfamide (60 vs. 96%), and the beta blocker atenolol (88 vs. 99%).  
541 Attempts to correlate the observed removal efficiency of PhCs by using PAC and their sorption potential  
542 expressed in terms of  $K_{ow}$  or  $D_{ow}$  (also accounting for acid-base speciation) were done by the Swiss research  
543 group (Kovalova et al., 2013; McArdell et al., 2011). As regards neutral (i.e. not charged) compounds at pH  
544 8.8 (namely carbamazepine, oxazepam, 4-acetamidoantipyrine, cyclophosphamide, iomeprol, iopamidol,  
545 iopromide, metronidazole, phenazone and primidone), it was found that the higher the  $D_{ow}$  value, the  
546 higher the observed removal by sorption. On the contrary there is no agreement between experimental  
547 data and prediction from Log  $D_{ow}$  of sorption removal for *charged* compounds.  
548 These results confirm that removal mechanisms consist in nonspecific dispersive interactions and  
549 electrostatic interactions as well between the charged adsorbent surface and ionic adsorbate. Moreover,  
550 not only Log  $D_{ow}$  influences the behaviour of a pharmaceutical, but also its  $pK_a$ , molecular size and  
551 aromaticity/aliphaticity potential as well the presence of functional groups. As regards PAC, effective  
552 removal mechanisms depend on surface area, pore size and texture, surface chemistry (in particular  
553 functional groups and point of zero charge) and mineral matter content.  
554 As a rule of thumb, adsorption is most effective for compounds which are uncharged and apolar.  
555 An interesting analysis and discussion of the behaviour of many compounds is reported in Kovalova et al.  
556 (2013) and McArdell et al. (2011).

557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
60  
61  
62  
63  
64  
65

**Fig. 4.**

A consistent improvement in the removal of contrast media may be achieved by recycling PAC to biological treatment as documented in the MicroPoll projects (Zwickenpflug et al., 2010)

*GAC filter*

GAC filtration was investigated at the Netherlands research unit within the PILLS project (PILLS report, 2012) and also in Austria where the oncological ward effluent in a hospital was subjected first to an MBR then to GAC treatment (Lenz et al., 2007b). In the first case, the filter bed had a height of 3.0 m and an empty bed contact time of 51 min. It was fed by MBR permeate (TOC equal to 8.7 mg/L). After GAC filtration, all investigated pharmaceuticals were found below their detection limits. Also sulfamethoxazole, reluctant to PAC sorption, was removed by more than 96%. Unfortunately data referring to contrast agents were not collected.

In the second case, the GAC filter had a height of 36.7 cm, a cross surface of 19.6 cm<sup>2</sup> and a flow rate of 7.6 L/h. Antineoplastic compounds (the cancerostatic platinum compounds CPC cisplatin, carboplatin, oxaliplatin and 5-fluorouracil) were monitored in the GAC influent (corresponding to an MBR permeate) and effluent. Referring to total Pt content, it was observed that GAC contributed to a removal rate of about 50%. As discussed below, a combination of UV with GAC leads to a lesser removal rate of total Pt. This may be due to the fact that the photodegradation products of CPCs exhibit lower affinity to activated carbon than the parent compounds.

It is interesting to observe that with PAC and GAC no byproducts occur, with respect to all oxidation processes (ozonation and AOPs in general) where oxidation and photodegradation compounds are unavoidable and often they have ecotoxicological effects.

**Figure 5.**

**4.3.2. Ozonation**

In ozonation investigations, the influent to each ozone reactor was always an MBR permeate (McArdell et al., 2011, Nielsen et al., 2013), with a COD ranging from 12 and 30 mg/L, a DOC ranging from 6 to 11 mg/L, pH 8-8.5, T 20-22 °C (Kovalova et al., 2012). Contact time within the ozone reactor was between 12 and 23 min and the applied dose of ozone was between 0.45 and 2 g O<sub>3</sub>/g DOC (PILLS Project) and between 4.1 and 7.8 g O<sub>3</sub>/g TOC in the study by Nielsen et al. (2013). Higher concentrations of ozone were not tested as they would lead to the formation of potentially toxic bromates, according to literature (von Gunten 2003). As is clearly shown in Figures 6 and 7, the higher the applied ozone dose, the greater the number of compounds with a removal efficiency > 90%. At the lowest tested value of 0.45 g O<sub>3</sub>/g DOC (German unit

596 within the PILLS project, PILLS report, 2012), 3 out of the 11 investigated compounds were efficiently  
597 removed (namely diclofenac, sulfamethoxazole and erythromycin), the number increases to 26 out of the 48  
598 selected compounds at 0.64 g O<sub>3</sub>/g DOC (Kovalova et al., 2013), to 28 out of 49 at 0.89 and 29 out of 49 at  
599 1.08 g O<sub>3</sub>/g DOC (Kovalova et al., 2013).

600  
601 **Figure 6.**

602  
603 **Figure 7.**

604  
605  
606 The classes of cytostatics and contrast agents were quite reluctant to removal by ozonation: the average  
607 removal efficiencies observed were always lower than those observed for other classes. At medium-high  
608 ozone doses, only some compounds of these two classes were removed by about 50-60%. This occurred to  
609 cyclophosphamide, ifosfamide, iopamidol and iopromide at doses of about 1.1 g O<sub>3</sub>/g DOC and 4.1-7.8 g  
610 O<sub>3</sub>/g TOC (Nielsen et al., 2013). The most reluctant compounds to be removed by ozone were the contrast  
611 agents diatrizoate and ioxitalamic acid, the antibiotic metronidazole and the anthelmintic flubendazole  
612 whose average observed removal efficiencies were between 13 and 27%.

613 This treatment did not consistently decrease COD and DOC as ozonation does not *eliminate* (that is,  
614 *mineralize*) organic matter and micropollutants but rather transforms them into other more degradable  
615 compounds also measured as COD and DOC.

616 It is quite interesting to point out that ozonation seems to be a quite promising treatment for the  
617 abatement of most of the micropollutant load in hospital effluent. It is important to bear in mind one of the  
618 lessons learned by the PILLS Project: based on a Swiss research referring to the top 100 administered  
619 pharmaceuticals in the investigated large hospital (McArdell et al., 2011), a removal efficiency of 90% was  
620 observed for all the PhC and metabolite *load* (ICM excluded) by ozone (1.08 g O<sub>3</sub>/g DOC, pH 8.5, T = 22 °C).  
621 This removal reduces to 50% if contrast agents are included. This could lead to the consideration that  
622 sewage conveying radiological ward effluent could be separated and treated by a dedicated WWTP, so it  
623 could also be possible to recover iodine.

624  
625 The main disadvantages in adopting ozonation, and more in general AOPs, is the formation of oxidation  
626 byproducts (like bromates) due to the matrix compounds (for instance bromides). As these products could  
627 have ecotoxicological effects, it is advisable to adopt a biological step (namely a sand filter or an MBBR)  
628 that will act as a barrier. In the Swiss research, the concentration of bromide in the permeate was 30-40  
629 µg/L and after the addition of the highest dose of ozone (1.08 g O<sub>3</sub>/g DOC, corresponding to 7 mg O<sub>3</sub>/L),  
630 bromate was found at a concentration of 1 µg/L, well below the Swiss drinking water standard set at 10  
631 µg/L.

633 Ozonation reactions were due to the very selective attack of ozone to specific functional moieties of  
634 organic substances and to the less selective attacks of hydroxyl radicals ( $\text{HO}^\cdot$ ), formed during ozone  
635 decomposition, to a wider spectrum of functional groups within the molecules. Ozone decomposition is  
636 favoured by the presence of hydroxyl ions ( $\text{OH}^-$ ) at alkaline pH ( $\text{pH} > 9$ )

637 The following rules of thumb could lead to a rough prediction of the efficacy of ozonation in removing  
638 different types of micropollutants resulting from studies on the kinetics of ozonation reactions and on the  
639 potential correlation between molecular structure (presence of moieties within the molecule) of a  
640 compound and its reactivity with ozone (Lee and Gunten 2010):

- 641 (i) olefin, phenol, aniline, thiophenol, thiol and tertiary amine exhibit a high reactivity with ozone,
- 642 (ii) secondary amines, thioester and anisole an intermediate reactivity,
- 643 (iii) primary amines and nitro group a slow reactivity and (iv) amides do not react with ozone.

644 Compounds with a high reactivity to ozone are already removed to a high extent at the lowest dose of 0.64  
645 g  $\text{O}_3/\text{g DOC}$ . For compounds with intermediate reactivity, such as benzotriazole and ritalinic acid, higher  
646 removal efficiencies were observed with higher ozone doses. Lowest removal efficiency was found in  
647 contrast agents without moieties.

#### 648 649 **4.3.3. UV radiation**

650 Only a few investigations (within the PILLS Project (PILLS report 2012) and at the oncologic ward in a  
651 hospital in Vienna (Lenz et al., 2007b), dealt with the ability and the contribution of an UV irradiation  
652 process in the removal of PhCs from (pretreated) hospital effluent: in each one, the UV reactor was always  
653 fed by an MBR permeate ( $\text{DOC} = 6\text{-}8 \text{ mg/L}$ ). The main characteristics of the tested equipment are reported  
654 in table 4 (PILLS, 2012, McArdell et al., 2011, Lenz et al., 2007b): in particular different fluence values were  
655 tested and, in the Luxembourg unit, low and medium pressure (LP, MP) UV lamps were used and for some  
656 runs, a polychromatic light was applied to the water stream. The collected data are reported in Figures 8  
657 and 9 referring to the lamp type and the applied fluence.

658 Observed removal efficiencies for the investigated compounds were always less than 50% when the UV  
659 fluence of  $800 \text{ J/m}^2$  was applied. At  $2400 \text{ J/m}^2$ , 12 out of 31 PhCs were removed at more than 50% and with  
660  $7200 \text{ J/m}^2$ , 18 out of 31 compounds exceeded the 50% removal threshold. If the UV is irradiated at higher  
661 fluence values, removal increases (for instance at  $29700 \text{ J/m}^2$  or  $47250 \text{ J/m}^2$ ). When MP lamps were used, a  
662 polychromatic light was produced and all the seven investigated compounds were successfully removed.  
663 Figures 8 and 9 clearly show, with the exception of cyclophosphamide ( $\eta = 58\%$ ), that the removal  
664 efficiency of the other compounds ranged between 81 and 98%, on average 83%.

665 Compounds with the highest removal efficiencies were: 4-acetamidoantipyrine (99% with LP and  $7200$   
666  $\text{J/m}^2$ ), diclofenac (99% with LP lamp and  $29700$  and  $47250 \text{ J/m}^2$ ), diclofenac and 4-formylaminoantipyrine  
667 (98%, with LP and  $7200 \text{ J/m}^2$ ), sulfamethoxazole (98% with LP lamp and  $47250 \text{ J/m}^2$ ), diatrizoate (97% with

668 LP and 7200 J/m<sup>2</sup>), sotalol (95% with LP and 7200 J/m<sup>2</sup>) and the remaining X ray contrast media (iomeprol  
669 90%, iopamidol, iopromide and ioxitalamic acid 92% with LP and 7200 J/m<sup>2</sup>). This last result is quite  
670 interesting, as the UV process seems to be the most effective treatment to remove these from the  
671 wastewater.

672  
673 **Table 4.**

674  
675 **Fig. 8**

676  
677 **Fig. 9**

678  
679  
680 The contribution of an UV process in the removal of antineoplastic compounds was found to be negligible.  
681 This was concluded by Lenz et al. (2007b) who monitored the cancerostatic platinum compounds (CPCs)  
682 cisplatin, carboplatin, oxaliplatin and 5-fluoracil in the effluent of a hospital oncological ward. They found  
683 that oxidation of CPC by UV leads to a marginal reduction of total Pt as, even if the substances are  
684 transformed by oxidation, the total amount of Pt remains the same. As for cyclophosphamide, removal  
685 efficiency was found higher in the case of medium pressure UV lamps than in the case of LP lamps (58% vs.  
686 3%)

687  
688 It was observed that UV irradiation is a promising technology in the removal of X-ray contrast media. Very  
689 appreciable results were observed when a fluence of 7200 J/cm<sup>2</sup> was applied. At higher values the removal  
690 of different analgesics, antibiotics, beta-blockers increased (Kovalova et al., 2013).

691 Transmission of UV in water is strictly correlated to water turbidity. Very low turbidity is recommended in  
692 order to greatly reduce potential interferences with the water matrix. Excessive dosages of chemical  
693 oxidisers may act as a scavenger thus inhibiting contaminant destruction efficiency.

694 UV transmission is subject to decrease due to lamp fouling. To reduce lamp fouling, adequate  
695 pretreatments are necessary, insoluble oil and grease concentrations should be minimized and heavy metal  
696 ion concentration should be maintained at a concentration less than 10 mg/L

#### 697 698 **4.3.4. Advanced oxidation processes (AOPs)**

##### 699 **4.3.4.1. Removal of pharmaceuticals**

700 Advanced oxidation processes include different technologies aiming to completely oxidize and/or destroy  
701 different kinds of organic pollutants in water and wastewater streams into H<sub>2</sub>O, CO<sub>2</sub> and mineral salts.

702 Each one is characterized by a variety of *radical reactions* due to highly reactive species (mainly hydroxyl  
703 radicals HO•, but also superoxide radical anions O<sub>2</sub><sup>-•</sup>, hydroperoxyl radicals HO<sub>2</sub>•, ROO<sup>-</sup>), generated on site  
704 in different ways, involving combinations of chemical agents (namely ozone, hydrogen peroxide, transition  
705 metals, metal oxides) and auxiliary energy sources (namely UV irradiation, electronic current, γ-radiation

706 and ultrasound). This study includes combinations between O<sub>3</sub> and H<sub>2</sub>O<sub>2</sub> as chemical agents and UV  
707 irradiation as an energy source.

708 HO• is the primary oxidant in AOPs and unlike many other radicals it is non-selective, it readily reacts with  
709 many organic pollutants occurring in the water, converting them into more hydrophilic compounds than  
710 the original ones.

711 A brief presentation of each, including the main reactions occurring during AOPs is reported in the  
712 Supplementary Data, whereas below, the results obtained in the different investigations into AOPs applied  
713 to hospital effluents as polishing treatments are presented (Figure 10) and discussed.

714 In the experimental setup tested in Switzerland within the PILLS project (McArdell et al., 2011), the  
715 photocatalysis process UV/TiO<sub>2</sub> was compared to the UV process alone. This setup includes a reaction  
716 column containing four conical cartridges, consisting in a photocatalytic fibre (titanium-dispersed silica-  
717 based fibre with a sintered anatase-TiO<sub>2</sub> layer on the surface), around a low pressure UV lamp (254 nm, 220  
718 V, 100-400 W overall energy consumption, 10 mW/cm<sup>2</sup> nominal fluence rate). To protect the fibre from  
719 particle contamination, two pre-filters with a mesh width of 25 and 5 µm were installed. The elimination  
720 rate was evaluated after 1, 3 and 9 cycles with the photocatalytic chamber (UV/TiO<sub>2</sub>) and with UV only.  
721 Removal obtained with one cycle was marginal.

722  
723 Another interesting investigation was carried out by Vasconcelos et al. (2009), aiming to compare the  
724 degradation of just ciprofloxacin in hospital effluent by ozonation, UV irradiation, UV/TiO<sub>2</sub> and O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub>. As  
725 to TiO<sub>2</sub>/UV lab scale equipment was used and TiO<sub>2</sub> was added as a suspension (400 mgTiO<sub>2</sub>/700 mL) to the  
726 hospital effluent set at pH = 3 to enhance photocatalyst activity (see Supplementary Data for process  
727 details). After the treatment, the samples were filtered through a 0.22 µm membrane to separate TiO<sub>2</sub>  
728 particles from the solution. Complete removal of ciprofloxacin was observed after 60 min within the  
729 photocatalytic reactor. The same result was obtained after 300 min in an UV reactor (equipped with a 125  
730 W medium pressure mercury lamp).

731 UV/TiO<sub>2</sub> exhibited a better removal than UV only for a few compounds, in particular for 4- aminoantipyrine,  
732 4-methylaminoantipyrine and sulfapyridine. In general the removal efficiencies increased by a factor of two  
733 for most of the compounds without a photocatalyst.

734 An increment in the cycles slightly improved the removal of contaminants. Only X-ray contrast agents  
735 achieved higher removal efficiencies than in the other post-treatments (20-70%). These results led to the  
736 consideration that direct phototransformation with UV dominated the micropollutant removal and indirect  
737 phototransformation due to the presence of the embedded TiO<sub>2</sub> did not occur.

738 Generally the removal efficiencies observed with TiO<sub>2</sub>/UV in 9 cycles were observed in only 3 cycles when  
739 using UV alone.

740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765



740 The lower removal efficiency observed by UV/TiO<sub>2</sub> might also be due to the fact that photocatalytic fibre  
741 could have adsorbed UV light and shaded part of the reaction chamber, thus the water could have been  
742 exposed to less UV irradiation.

743  
744  
745 **Figure 10.**

746  
747  
748 An improvement in the removal of PhCs was observed when H<sub>2</sub>O<sub>2</sub> was added to the UV reactor. No  
749 consistent differences were found between a dosage of 0.56 g/L and 1.11 g/L (Kohler et al., 2012). It was  
750 also found that the optimum light wavelength for the UV/H<sub>2</sub>O<sub>2</sub> system is 254 nm as it guarantees the  
751 lowest background absorbance of the investigated water and high H<sub>2</sub>O<sub>2</sub> absorbance resulting in an efficient  
752 generation of hydroxyl radicals. As a consequence, LP lamps are recommended as about 90% of their  
753 irradiated light is emitted at 254 nm, whereas MP lamps emit 254 nm light for 5-10% of the total emission.  
754 The good results obtained with LP UV irradiation in AOPs lead to the consideration that for many PhCs,  
755 degradation processes are mainly due to chemical oxidation (between the molecule and the generated  
756 radicals) rather than to direct photolysis (Kohler et al., 2012).

757 Wilde et al. (2014) achieved promising results thanks to the degradation of a mixture of beta-blockers  
758 (atenolol, propranolol and metoprolol) in hospital effluent (pretreated in a septic tank followed by an  
759 anaerobic filter) by O<sub>3</sub> and Fe<sup>+2</sup>/O<sub>3</sub>: they showed that, in 120 min, complete degradation of the parent  
760 compounds was observed but not their complete elimination. The degradation process was found strictly  
761 correlated to pH. Alkaline pH values promote the removal of metoprolol and propranolol, whereas acidic  
762 values enhance the removal of organic load (expressed as COD). The investigation also highlighted the risk  
763 of undesired byproducts due to ozonolysis with a more intense degree of recalcitrance with respect to their  
764 parent compounds. This lead to better investigated ecotoxicological characteristics of the polished effluent.

765  
766 A slight increment in the removal of micropollutants was observed by adding H<sub>2</sub>O<sub>2</sub> into the system. H<sub>2</sub>O<sub>2</sub>  
767 accelerates the decomposition of ozone and partially increases the amount of hydroxyl radicals. Two  
768 different application modes were tested within the PILLS Project (McArdell et al., 2011):

- 769 - addition of H<sub>2</sub>O<sub>2</sub> into the ozone reactor influent;
- 770 - pre-ozonation of the MBR permeate with 1.2 g O<sub>3</sub>/g DOC, addition of 2.5 mg/L H<sub>2</sub>O<sub>2</sub> to half of the  
771 treated wastewater and both parts again treated with 0.7 g O<sub>3</sub>/g DOC.

772 Differences were observed of about ± 20% which were not considered significant because within  
773 experimental error, in agreement with data already published confirming that little improvement was  
774 found especially in water with relatively high DOC (Acero and von Gunten, 2001) and that hydroxyl radicals  
775 attack is less effective than O<sub>3</sub> attack.

776 A significant removal efficiency is observed if very high doses of ozone and H<sub>2</sub>O<sub>2</sub> are applied to the  
777 permeate as tested by Nielsen et al. (2013) (130 mgO<sub>3</sub>/L and 60 mgH<sub>2</sub>O<sub>2</sub>/L 5 min; 450 mgO<sub>3</sub>/L and 200 mg  
778 H<sub>2</sub>O<sub>2</sub>/L 15 min): in these operational conditions with few exceptions (sulfamethoxazole) all the selected  
779 micropollutants were removed below their PNEC/EQS (environmental quality standard) value.

780  
781 In order to guarantee a clear, polished effluent, sometimes a “trap” step follows the AOP reactor. In this  
782 context, the effluent of a PAC reactor was filtered through UF membrane flat sheets (pore size 0.04 μm)  
783 (Switzerland, McArdeall et al., 2011). Moreover within the PILLS Project units, a moving bed bioreactor (HRT  
784 = 0.3-1 d) was used following PAC, O<sub>3</sub> or TiO<sub>2</sub>/UV and a sand filter (filtration velocity v<sub>f</sub> < 12 m/h) was  
785 equipped after ozone or the PAC unit.

#### 786 787 **4.3.4.2. Removal of microorganisms**

788 Disinfection efficiency is strictly correlated to the applied technologies. Table 5 reports the efficacy of 7  
789 different treatments applied to a secondary hospital effluent (Machado et al., 2007) or a secondary hospital  
790 laundry effluent (Kist et al., 2008) carried out in Brazil:

791 The main influent characteristics to the disinfection step were: 25 °C, pH = 9.5, upstream treatments: septic  
792 tank + anaerobic/aerobic treatment fed with hospital/laundry effluent. A dose of 12 mgO<sub>3</sub>/L was applied  
793 and equipped with a UV lamp with an emission at 254 and 365 nm, radiating an energy of 31.9 J/cm<sup>2</sup>.  
794 Catalyst fixation was obtained by preparing a suspension of TiO<sub>2</sub> in CHCl<sub>3</sub> (10% m/v) and by spreading it on  
795 a plate (2.96 mg TiO<sub>2</sub>/cm<sup>2</sup>). The contact time was 60 min for each.

#### 796 797 **Table 5**

798  
799 The best disinfection efficiency was observed for the combination UV/TiO<sub>2</sub>/O<sub>3</sub>, that also provides very good  
800 turbidity removal (from 234 to 36.5 NTU), surfactants (8.0 10<sup>6</sup> mg/L to < detection limit) and toxicity (EC<sub>50</sub>  
801 *Daphnia Magna* from 65 to 100). A contact time of 10 min will result in a concentration of 330 MPN/100  
802 mL and of 30 min of about 70 MPN/100 mL.

803 The disinfection performance is due to damage of the microorganism’s cell wall and cytoplasmatic  
804 membrane. Thus cell permeability increases allowing intracellular content to flow through the membrane  
805 leading to cell death.

#### 806 807 **4.3.5. Nanofiltration and reverse osmosis**

808 Nanofiltration (NF) and reverse osmosis (RO) processes are considered potential polishing treatments for  
809 hospital effluent, pretreated in an MBR from a technical view point. Residues of PhCs, still present in the  
810 permeate, may be retained due to molecular weight and size, sorption onto the membrane and also  
811 charge. Each membrane is characterized by a molecular weight cut off (MWCO) that represents the weight  
812 of those substances retained between 60 and 90%. Sorption is a potential removal mechanism for poorly

813 soluble non-polar compounds, negatively charged compounds are rejected by NF/RO membranes due to  
814 electrostatic repulsion between the compounds and the negatively charged membrane surface (Kimura et  
815 al., 2004). Moreover, water characteristics such as pH, ionic strength, hardness, organic matter and  
816 membrane biofouling also have an influence on solute rejection.

817 In the study by Beier et al. (2010) the permeate of an MBR (COD < 30 mg/L, 5-10 mgN/L) equipped with  
818 microfiltration membranes was then subjected to NF and RO processes, characterized by a MWCO of 300-  
819 400 da and 100-150 da, respectively. It was found that RO exhibited a higher removal for all selected PhCs  
820 with respect to NF. However, RO presents major disadvantages due to the limited yield and the retentates  
821 that have to be properly disposed of. However, no suitable prediction model has been developed up to  
822 now as the rejection of the different micropollutants in NF/RO processes is specific for each membrane  
823 (Siegest and Joss, 2012).

824  
825

#### 825 **4.3.6. Chlorination**

826 Only a few data are available regarding the removal efficiency of PhCs observed after a final chlorination.  
827 These are reported in Fig. 11 and refer to the investigation carried out by Nielsen et al. (2013). The added  
828 amount of ClO<sub>2</sub> was 60 mg/L in each run, and two different contact times were adopted: 15 min and 60  
829 min. Ciprofloxacin showed higher concentrations in the effluent rather than in the influent to the  
830 treatment. In addition, chlorination seems to be able to remove diclofenac: in the study by Nielsen et al.  
831 (2013), its concentration in the influent (MBR permeate) was quite low (< 5 ng/L) and in the effluent it was  
832 1 ng/L (15 min as contact time). But it was found that under lab scale controlled chlorination with surface  
833 water, diclofenac exhibited a large degree of reactivity and its final concentration was below detection limit  
834 (Westerhoff et al., 2005)

835  
836

837 **Fig. 11.**

838

839

840

#### 840 **4.4. Disinfection performance**

841 In some countries disinfection is mandatory for the effluent generated in infectious disease wards or in  
842 health care specialized in infectious diseases (Nardi et al., 1995; Emmanuel et al., 2004). Fecal and total  
843 coliforms were found in the ranges 10<sup>2</sup>- 10<sup>4</sup> MPN/100 mL and 10<sup>4</sup>-10<sup>6</sup> MPN/100 mL respectively (Table 1).  
844 These values are lower than those usually found in raw urban wastewater (Verlicchi et al., 2012a), probably  
845 due to the antimicrobial activity of antibiotic and disinfectant residues present in the infectious disease  
846 ward effluent.

847

848

849

850

851

852

853

854

855

849 Predisinfection of raw hospital effluent is still an issue of great concern: based on a theoretical hypothesis,  
850 Korzeniewska et al. (2013) recommend a preliminary disinfection of the hospital effluent before its  
851 immission into public sewage in order to minimize the spread of antibiotic resistant bacteria, on the other  
852 hand, research by Emmanuel et al. (2004) found that disinfection by means of NaOCl of the effluent from  
853 infectious and tropical disease departments can reduce the content of microorganisms, but at the same  
854 time it has toxic effects on aquatic organisms.

855  
856 In many countries, including China, direct chlorination or primary treatment followed by chlorination  
857 represent the most widely used methods to treat and, in particular, disinfect hospital effluent in order to  
858 prevent the spread of pathogenic microorganisms (Liu et al., 2010). Despite the fact that chlorine  
859 disinfection has a broad spectrum of activities against bacteria, virus and fungi and it is simple to use, it  
860 may produce toxic byproducts, its performance depends on the water quality and only a low removal  
861 efficiency is achieved for viruses as they have a greater tolerability against chlorine compounds than  
862 bacteria. As a consequence, a high excess of disinfectant is generally applied to guarantee a (rough)  
863 disinfection of the hospital effluent, but inevitably extremely high concentrations of residual chloride (as  
864 high as 100-130 mg/L) will occur, resulting in serious pollution problems to the receiving aquatic  
865 environment, as remarked by Emmanuel et al. (2004) who investigated the effect of the addition of NaClO  
866 to hospital effluent: it can greatly reduce bacteria population, but it has toxic effects on aquatic organisms.  
867 In China, to avoid an excessive use of chlorine, the removal of different types of microorganisms from  
868 hospital effluent is dealt with by means of an MBR, mostly employing submerged membranes (pore size  
869 about 0.2-0.4  $\mu\text{m}$ ), followed by a chlorination step with a dosage of NaClO of 1-2 mg/L as free chlorine with  
870 a contact time of 1.5 min. Since 2000, many plants based on membrane technologies have been built for  
871 the treatment of hospital effluent, with a capacity ranging between 20 and 2000  $\text{m}^3/\text{d}$ , in compliance with  
872 the severe limits of 50 PFU/100 ml such as *E. coli* (Liu et al., 2010).

873  
874 While a (UF) MBR followed by a specific disinfection step may be considered a viable option for the removal  
875 of a wide group of bacteria occurring in hospital effluent, studies into their performance in reducing  
876 pathogenic viruses are still scarce. The removal of viruses in an MBR is substantially due to three  
877 mechanisms: virus rejection depending on the cake generating on the membrane surface, viral inactivation  
878 of the biomass, and adsorption onto the surface of suspended solids which makes these microorganisms  
879 more stable.

880 In a Brazilian investigation (Prado et al., 2011) the removal of some enteric viruses (Rotavirus A, human  
881 adenovirus, norovirus genogroup I and II and hepatitis A viruses) was compared in two different treatment  
882 trains: an anaerobic one including a UASB followed by three anaerobic filters and an aerobic one consisting  
883 of a conventional activated sludge process followed by chlorination. It was found that both systems are not

884 suited to their removal. Their frequencies of detection and quantification results varied according to the  
885 virus type and effluents coming from different health care structures.

886 An MBR, equipped with ultrafiltration membranes is able to remove groups of bacteria as reported above  
887 mainly due to membrane retention, reducing the spread of multiple antibiotic resistant strains, usually  
888 occurring in hospital effluent. But specific disinfection is advisable, in order to avoid regrowth of (survival)  
889 bacteria as discussed in Pauwels et al. (2006). For inactivation of pathogens and possible removal of  
890 antibiotic resistant bacteria, UV and ozonation are more efficient with respect to PAC and GAC.

891 In wastewater disinfection, the fluence to apply depends on the required microorganism limits (Verlicchi et  
892 al., 2010). For instance 100 J/m<sup>2</sup> are applied if the aim is to guarantee 1000 MPN/100 mL of total coliforms,  
893 750-850 J/m<sup>2</sup> if a concentration of 23 MPN/100 mL of total coliform has to be guaranteed and finally a  
894 fluence greater than 1000 J/m<sup>2</sup> if the residual concentration of total coliform is < 2.2 MPN/100 mL, thus  
895 allowing an unrestricted irrigation of the disinfected effluent (Crites and Tchobanoglous, 1998).

896 To inactivate specific microorganisms, oocysts or viruses, the requested fluence could be higher. To  
897 inactivate 3 log of Adenovirus type 40, a fluence of 1670 J/m<sup>2</sup> is required, whereas to inactivate up to 3 log  
898 of Cryptosporidium and Giardiasis, a fluence of 120 J/m is required (Hijen et al., 2006).

899 These considerations lead to the consideration that when ozonation, UV, AOPs in general are applied to  
900 hospital effluent to remove recalcitrant compounds, at the same time it is disinfected to a very high degree.  
901 But in order to guarantee safe reuse of the disinfected effluent for unrestricted irrigation, a higher fluence  
902 is required (as well as further studies into the ecotoxicologic characteristics of the water)

903

#### 904 905 **4.5. Comparison between the different treatments**

906 A comparison of the performance of the different analyzed secondary and tertiary dedicated treatments  
907 for HWW is depicted in Figure 12 in terms of number of investigated compounds and the number of  
908 compounds exhibiting a removal efficiency greater than 80%. It is based on all the data collected about  
909 PhCs in the peer reviewed papers included in this manuscript. What clearly emerges is that the most  
910 investigated technologies are MBR, PAC, ozonation and UV. The best results were performed by MBR  
911 (secondary step) and PAC (tertiary step).

912 Moreover Table SD-3 in Supplementary Data compiles compounds that exhibited a removal efficiency  
913 greater than 80% during secondary and tertiary treatment, with the corresponding references.

914 An in-depth analysis of the comparison of pairs of treatment is performed in Kovalova et al. (2013) with  
915 respect to the different classes of PhCs. They found that iodinated contrast media were better removed by  
916 MBR+UV (66% of the total influent load), all the selected PhCs except iodinated contrast media by  
917 MBR+PAC or MBR +UV (99%).

918

919

920

921

922

923

924

925

918 Lessons learned from these campaigns led to consider 1.08 g O<sub>3</sub>/g DOC, 23 mg/L PAC and 2400 J/m<sup>2</sup> UV the  
919 values that best satisfy the two following choice criteria: relatively good abatement for most  
920 micropollutants and reasonable running costs (Kovalova et al., 2013).

921 Table 6 reports a rough estimation of the global removal of the different kind of classes with respect to  
922 different technologies, based on all the collected data.

923  
924 **Table 6.**

925 It is important to observe that the choice of the best technologies for treatment of hospital effluent should  
926 not necessarily lead to the complete removal of specific parent compounds, but to the removal of the  
927 estrogenic activity of the effluent itself, or more generally, a reduction in its ecotoxicological effects.

928 Bearing this concept in mind, processes including TiO<sub>2</sub> photocatalysis seem to be promising technologies as  
929 they are able to remove estrogenic activity of 17-β-estradiol (Byrne et al., 1998), 17-α-ethinylestradiol  
930 (Coleman et al., 2000).

931 AOPs seem to be the most promising technologies as they can be effective in removing compounds not  
932 affected by other technologies as discussed above, reactions are generally fast, resulting in more compact  
933 reactors, finally (no or) low chemical doses are required leading to (no or) lower residuals, but they may  
934 have undesirable drawbacks, namely: unselective hydroxyl radicals, production of more hydrophiles and  
935 more difficult to treat byproducts than the original ones; as have been clearly listed by Suty et al. (2004).

936  
937 **Figure 12.**

938  
939  
940  
941 The spread of disease due to pathogens and of specific strains of antibiotic resistant bacteria can be  
942 countered by a disinfection step (Korzeniewska et al., 2013). Some laws and regulations (including the  
943 Italian Deliberation by the Inter-ministerial Committee dated 4 February 1977) require treatment of the  
944 effluent from health care structures, blood analysis laboratories, and in particular, for the effluent from  
945 infectious disease wards. As an example, the effluent produced by the very large laboratory for blood  
946 analysis in Pievesestina (Cesena, North Italy, effluent flow-rate about 10<sup>3</sup> m<sup>3</sup>/year) is subjected to  
947 ozonation and filtration through activated carbon prior to being immitted into the public sewage system  
948 and is then co-treated at the municipal WWTP. Alternatively, the addition of 10 mg/L of ClO<sub>2</sub> and a contact  
949 time of 30 min, guarantee an efficient removal of fecal and total coliform, with a negligible increment of  
950 AOX (Nardi et al., 1995). This increment is consistent if the applied disinfectant is NaClO (Emmanuel et al.,  
951 2004).

952 Due to the different nature of pollutants that may be present in hospital effluent (residues of PhCs, their  
953 metabolites, disinfectants and antiseptics, heavy metals, radio-elements, pathogens), the risk posed by this  
954 effluent may be toxic, radioactive and infectious.

955 Proper management of hospital effluent has to be considered and must include measures to mitigate the  
956 consequences at a WWTP level as well as towards the environment.

957  
958

#### 958 **4.6. Removal efficiencies vs. physical-chemical properties of investigated compounds**

959 Many studies were developed in order to investigate potential correlations between observed  
960 pharmaceutical removal efficiencies achieved by the different wastewater treatments and pharmaceutical  
961 molecular properties (among them Cunningham, 2008; Joss et al., 2006, Rogers, 1996; Tadkaew et al.,  
962 2011). They underlined that it is always very difficult to find reliable correlations, because many factors (i.e.  
963 operational and environmental conditions) affect removal mechanisms of such complex molecules thus a  
964 wide range of variability is generally observed for the removal of a specific compound during a treatment.  
965 Studies referring to UWW led to rules of thumb that try to correlate the behavior of a specific molecule on  
966 the basis of its properties:  $k_{biol}$ ,  $K_d$ ,  $K_{ow}$ ,  $pK_a$ , as discussed and reported in Tadkaew et al. (2011) and Verlicchi  
967 et al. (2013). Lessons learned from UWW may be also useful in making a rough prediction of efficacy of  
968 specific treatments in HWW managing.

969 Moreover attempts to correlate the behavior of common parameters, such as COD or SS, and specific  
970 pharmaceuticals during hospital wastewater treatment were carried out, but unfortunately they did not  
971 suggest any reliable relationship (Emmanuel et al., 2004, Pauwels et al., 2006, Vasconcelos et al., 2009,  
972 Wilde et al., 2014).

973  
974

#### 974 **5. Hospital effluent toxicity and Environmental risk assessment**

975 Interesting and useful research has been accomplished dealing with hospital effluent toxicity and  
976 assessment of the environmental risk posed by pharmaceutical residues in treated hospital effluent (Boillot  
977 et al., 2008; Perrodin et al., 2013; Emmanuel et al., 2004). This is quite a complex problem and is beyond  
978 the aim of this manuscript, but some lessons learned from published studies are discussed herein to point  
979 out concerns that merit further research.

980 It is well known that hospital effluent is 5-15 more toxic than urban wastewater due to the high  
981 concentrations of detergent and disinfectants, often containing chlorine or aldehydes (such as sodium  
982 hypochlorite and glutaraldehyde), iodinated contrast media that lead to the generation of AOX in the  
983 drainage network, heavy metals (namely silver used in radiology departments), radio-elements injected or  
984 administered in nuclear medicine studies and completely excreted in urine, PhC residues. That being said,  
985 hospital effluent can inhibit the activity of the biomass in the aeration tank of a sewage facility by 7-8% as  
986 documented in Boillot et al. (2008) and Panouillères et al. (2007).

987 Investigations are often based on Microtox and acute *Daphnia magna* tests (Emmanuel et al., 2004; Boillot  
988 et al., 2008), but also to batteries including different kinds of test (Perrodin et al., 2013).

989  
990  
991  
992  
993  
994  
995

989 Lessons learned from these studies suggest that different pollutants may induce or contribute to toxicity:  
990 namely free chlorine, AOX (Emmanuel et al., 2004), ethanol, propanol, metals including Zn, Cu, As, Pb  
991 (Boillot et al., 2008).  
992 Environmental risk assessment of hospital wastewater is generally based on the risk quotient  $RQ$ , defined  
993 as the ratio between PhC concentration in the effluent and its predicted non- effect concentration (PNEC).  
994 According to the classification that was adopted in many studies (Straub, 2002; Verlicchi et al., 2012a;  
995 Santos et al., 2013) the risk is classified high if  $RQ \geq 1$ , medium if  $1 < RQ < 0.1$  and low if  $RQ \leq 0.1$ .  
996 Based on *measured* effluent concentrations Verlicchi et al. (2012a) and Santos et al. (2013) found that in  
997 raw hospital effluent a high risk is posed by azithromycin, clarithromycin, erythromycin, ofloxacin,  
998 sulfamethoxazole, metronidazole, fluoxetine, ibuprofen, acetaminophen and iopromide. This fact pinpoints  
999 that adequate treatment is necessary for hospital wastewater to reduce its negative effect on the  
1000 environment. Bearing this in mind, the frameworks provided by Al Aukidy et al. (2014), Emmanuel et al.  
1001 (2005), Escher et al., (2011), Lienert et al., 2011, Mullot et al., 2010 might help in evaluating and comparing  
1002 the efficacy of different treatment trains.

1003 *Antibiotic resistance bacteria* - Another source of risk in hospital effluent is correlated to the occurrence of  
1004 antibiotics and consists in the potential development and release of antibiotic-resistant bacteria (ARB) and  
1005 genes (ARG). The PILLS project pinpoints that the risk of the spread of resistance to specific antibiotic  
1006 molecules is higher in hospital effluent than in urban WW. The efficiency of advanced biological and  
1007 chemical processes varies in the range of 1-5 log units. Ultrafiltration MBRs guarantee a consistent  
1008 reduction of this risk, whereas a following step including ozonation, sand or PAC filtration does not  
1009 contribute to further reduction.

## 1012 6. Costs

1013 A summary of the investment and operational and maintenance (O&M) costs for the different scenarios are  
1014 reported in Table 7 referring to economic evaluations carried out in the cited studies in a design step.  
1015 Unfortunately they are not homogeneous and not always investment and operational and maintenance  
1016 data are available. The investments are amortized over 10 or 15 years depending on the investigations.  
1017 Table 7 just offers a rapid comparison of the different technologies and of the order of magnitude of the  
1018 different treatment trains.  
1019 Many considerations may arise from these reported values. For example, it emerged from previous  
1020 discussion of collected removal data of PhCs that activated carbon seems a promising technology in  
1021 reducing their occurrence in the final effluent. But activated carbon requires expensive maintenance  
1022 operations in order to guarantee proper performance. In this context, investment cost for an activated  
1023 carbon filter is lower than that of another AOP treatment, but if DOC levels in the stream fed to the carbon



1024 filter are above 10 mg/L, carbon treatment could become uncompetitive against AOPs, due to frequent  
1025 change out, regeneration and disposal of the exhausted carbon. Moreover, GAC and PAC do not destroy  
1026 microcontaminants, but they allow their transfer from a liquid phase to a solid one. Operational costs  
1027 should also include costs of final disposal of GAC and PAC.

1028  
1029 To have an idea of the potential cost of dedicated treatment of hospital effluent, total costs range between  
1030 4.1 €/m<sup>3</sup> and 5.5 €/m<sup>3</sup> in case of secondary treatment by means of an MBR and polishing AOPs with the  
1031 exception of Kovalova et al. (2013) that reported lower total costs ranging around 2.4-2.7 €/m<sup>3</sup>. These  
1032 differences were not commented by the two research groups within the PILLS projects.

1033  
1034  
1035 **Table 7.**  
1036  
1037

## 1038 **7. Current strategies and future perspectives in the treatment of hospital effluent -** 1039 **Conclusions**

1040 Management and treatment of hospital effluent greatly vary in different countries. In developed ones they  
1041 may be completely absent, meaning that HWW is directly discharged into a surface water body or they  
1042 consist in simple chlorination, or primary clarification followed by a chlorination or primary and secondary  
1043 treatments followed by chemical disinfection (Prayitno et al., 2014).

1044 Various research projects have been carried out in these countries, aiming to evaluate the suitability of  
1045 some (simple) treatment trains for hospital effluent. They generally refer to a discussion of the observed  
1046 removal efficiencies of *conventional* contaminants and microorganisms, and the possibilities to directly re-  
1047 use this reclaimed water for irrigation purposes as they have to face problems arising from water shortage  
1048 (among them Chitnis et al., 2004; Shetha et al., 2001; Beyene and Redaie, 2011, Abd-El-Gawad and Aly,  
1049 2011). Suggestions to improve the adopted treatment are also provided with a view to their applicability in  
1050 terms of land requirement, footprint, costs, installation, operation and maintenance. Some case studies are  
1051 reported herein. Direct reuse of reclaimed water should be evaluated, including the risk posed by  
1052 persistent emerging contaminants and their (acute and chronic) effects on the environment and human  
1053 health.

1054 In European countries efforts are made to improve removal of these persistent compounds by means of  
1055 end-of pipe treatments and in this context, AOP technologies are the most researched ones. Studies  
1056 generally refer to occurrence and removal of a consistent number of PhCs, as well as ecotoxicological  
1057 evaluation by means of the risk quotient ratio, i.e. the ratio between maximum measured concentrations  
1058 and predicted no-effect concentration (Verlicchi et al., 2012a,; Escher et al., 2011). Different full scale  
1059 WWTPs have already been constructed for the dedicated treatment of hospital effluent. Each one consists  
1060 in preliminary treatment, MBR (Beier et al., 2011), MBR followed by ozonation and UV (Verlicchi et al.,  
1061  
1062  
1063  
1064  
1065

1061 2010), ozonation and PAC (PILLS report, 2012), ozonation and GAC (Pharmafilter, 2013;Grundfos  
1062 Biobooster, 2012).

1063 An interesting approach has been adopted in France to manage and treat the effluent of the Centre  
1064 Hospitalier Alpes Lemon in Annemasse. Thanks to dedicated piping, the HWW is conveyed to the near  
1065 municipal WWTP where it is treated in a specific line and subjected to continuous monitoring to improve  
1066 the removal of persistent compounds. This was a decision taken by the local authorities who have even  
1067 drawn up a specific law for this site (Sibipel Report, 2014).

1068 The best option in the management and treatment of hospital effluent is strictly correlated to hospital size  
1069 and catchment area dimension and must be defined on the basis of a technical and economical feasibility  
1070 study that would focus on the most appropriate measures able to reduce the (macro and micro) pollutant  
1071 load discharged into the surface water environment. Dedicated treatments for hospital effluent are  
1072 recommended by many authors worldwide, segregation and special treatment seems adequate for specific  
1073 effluent including effluent generated in radiology wards, containing ICMs, the most recalcitrant  
1074 compounds, at extremely high concentrations, but also for the effluent from laundries, oncological wards  
1075 and clinical analysis laboratories, as in the case of the large and centralized Italian lab services discussed  
1076 above. In any case, dilution with surface water should not represent the proper action to mitigate potential  
1077 adverse negative effects of PhC residues in the environment.

1078 A final remark is suggested by studies promoting the implementation of energy-intensive systems with  
1079 indirect solar energy by aggregating photovoltaic cells for the generation of electrical energy. This may  
1080 result in energy storage and in a balanced use of energy during periods in which light incidence is lower.

1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165

## 8. Supplementary Data

The Supplementary Data includes figures and tables referring to: worldwide distribution of all treatment trains and technologies, investigated in lab, pilot and full scale plants, included in this study together with the corresponding reference; list of pharmaceuticals included in this study; reactions involved in AOPs processes, list of compounds exhibiting a removal higher than 80 % in secondary and tertiary treatment steps, according to studies examined in this review study.

## References

- Abd El-Gawad HA, Aly AM. Assessment of aquatic environmental for wastewater management quality in the hospitals: A case study. *Aust J Basic & Appl Sci* 2011;5:474-82.
- Acero JL, Von Gunten U. Characterization of oxidation processes: ozonation and the AOP O-3/H2O2, *J Am Water Works Ass* 2001;93:90-100.
- Al Aukidy M, Verlicchi P, Voulvoulis N. A framework for the assessment of the environmental risk posed by pharmaceuticals originating from hospital effluents. *Sci Total Environ* 2014;493:54-64.
- Al-Hashimia M, Abbas TR, Jasema YI. Performance of sequencing anoxic/anaerobic membrane bioreactor (SAM) system in hospital wastewater treatment and reuse. *Eur Sci J* 2013;9:169-180.

- 1099 Andersen HR, Chhetri RK, Hansen MS, Christensson M, Sundmark K, Sund C et al. Staged MBBR optimized  
1100 for pharmaceutical biodegradation and ozonation of hospital wastewater. Poster presentation at the  
1101 8th World Water Congress, Lisbon, 2014.
- 1102 Arslan A, Veli S, Bingol D. Use of response surface methodologies for pretreatment of hospital wastewater  
1103 by O<sub>3</sub>/UV and O<sub>3</sub>/UV/H<sub>2</sub>O<sub>2</sub> processes. *Separ Purif Method* 2014;132:561-7.
- 1104 Azar AM, Jelogir AG, Bidhendi GN, Mehrdadi N, Zaredar N, Poshtegal MK. Investigation of optimal method  
1105 for hospital wastewater treatment. *J Food Agric Environ* 2010;8:1199-1202.
- 1106 Beier S, Cramer C, Köster S, Mauer C, Palmowski L, Schröder HFr et al. Full scale membrane bioreactor  
1107 treatment of hospital wastewater as forerunner for hot-spot wastewater treatment solutions in high  
1108 density urban areas. *Water Sci Technol* 2011;63:66-71.
- 1109 Beier S, Cramer C, Mauer C, Köster S, Schröder HFr, Pinnekamp J. MBR technology: A promising approach  
1110 for the (pre-)treatment of hospital wastewater. *Water Sci Technol* 2012;65:1648-53.
- 1111 Beier S, Köster S, Veltmann K, Schröder HFr, Pinnekamp J. Treatment of hospital wastewater effluent by  
1112 nanofiltration and reverse osmosis. *Water Sci Technol* 2010;61:1691-8.
- 1113 Berto J, Rothenbach GC, Barreiros MAB, Corrêa AXR, Peluso-Silva S, Radetski CM. Physico-chemical,  
1114 microbiological and ecotoxicological evaluation of a septic tank/Fenton reaction combination for the  
1115 treatment of hospital wastewaters. *Ecotox Environ Safe* 2009;72:1076-81.
- 1116 Beyene H, Redaie G. Assessment of waste stabilization ponds for the treatment of hospital wastewater: The  
1117 case of hawassa university referral hospital. *World Appl Sci J* 2011;15:142-150.
- 1118 Boillot C, Bazin C, Tissot-Guerraz F, Droguet J, Perraud M, Cetre JC et al. Daily physicochemical,  
1119 microbiological and ecotoxicological fluctuations of a hospital effluent according to technical and care  
1120 activities. *Sci Total Environ* 2008;403:113-29.
- 1121 Byrne JA, Eggins BR, Brown NMD, McKinney B, Rouse M. Immobilisation of TiO<sub>2</sub> powder for the treatment  
1122 of polluted water. *Appl Catal B-Environ* 1998;17:25-36.
- 1123 Chiang CF, Tsai CT, Lin ST, Huo CP, Lo KW. Disinfection of Hospital wastewater by continuous ozonation. *J*  
1124 *Environ Sci Heal A* 2003, A38, 12, 2895-908.
- 1125 Chitnis V, Chitnis S, Vaidya K, Ravikant S, Patil S, Chitnis DS. Bacterial population changes in hospital effluent  
1126 treatment plant in central india. *Water Res* 2004;38:441-7.
- 1127 Clara M, Strenn B, Gans O, Martinez E, Kreuzinger N, Kroiss H. Removal of selected pharmaceuticals,  
1128 fragrances and endocrine disrupting compounds in a membrane bioreactor and conventional  
1129 wastewater treatment plants. *Water Res*, 2005;39:4797-807.
- 1130 Coleman HM, Eggins BR, Byrne JA, Palmer FL, King E. Photocatalytic degradation of 17-β-oestradiol on  
1131 immobilised TiO<sub>2</sub>. *Appl Catal B-Environ* 2000;24:L1-L5.
- 1132 Crites RW, Tchobanoglous G. Small and decentralized wastewater management systems, WCB/McGraw-Hill  
1133 Editor. New York 1998.
- 1134 Cruz-Morato C, Lucas D, Llorca M, Rodriguez-Mozaz S, Gorga M, Petrovic, M et al. Hospital wastewater  
1135 treatment by fungal bioreactor: Removal efficiency for pharmaceuticals and endocrine disruptor  
1136 compounds. *Sci Total Environ* 2014;493:365-76.
- 1137 Cunningham VL. Special Characteristics of Pharmaceuticals related to Environmental fate. In: Kummerer K,  
1138 editor. *Pharmaceutical in the environment - Sources, fate, effects and risks*, III ed., Springer Berlin  
1139 Heidelberg; 2008 p, 23-34.
- 1140 De Almeida CAA, Brenner CGB, Minetto L, Mallmann CA, Martins AF. Determination of anti-anxiety and  
1141 anti-epileptic drugs in hospital effluent and a preliminary risk assessment. *Chemosphere* 2013;93:2349-  
1142 55.
- 1143 Emmanuel E, Keck G, Blanchard JM, Vermande P, Perrodin Y. Toxicological effects of disinfections using  
1144 sodium hypochlorite on aquatic organisms and its contribution to AOX formation in hospital  
1145 wastewater. *Environ Int* 2004;30:891-900.
- 1146 Emmanuel E, Perrodin Y, Keck G, Blanchard J, Vermande P. Ecotoxicological risk assessment of hospital  
1147 wastewater: A proposed framework for raw effluents discharging into urban sewer network. *J Hazard*  
1148 *Mater* 2005;117:1-11.
- 1149 Escher BI, Baumgartner R, Koller M, Treyer K, Lienert J, McArdell CS. Environmental toxicology and risk  
1150 assessment of pharmaceuticals from hospital wastewater. *Water Res* 2011;45:75-92.

- 1151 Gabarron S, Gómez M, Monclús H, Rodríguez-Roda I, Comas J. Ragging phenomenon characterisation and  
1152 impact in a full-scale MBR. *Water Sci Technol* 2013;67:810-6.
- 1153 Gautam AK, Kumar S, Sabumon PC. Preliminary study of physico-chemical treatment options for hospital  
1154 wastewater. *J Environ Manage* 2007;83:298-306.
- 1155 Grundfos biobooster, Wastewater Treatment at Herlev Hospital, Denmark, 2012, available at the web site:  
1156 [http://www.herlevhospital.dk/NR/rdonlyres/74234BCB-4E38-4B84-9742-  
1157 80FFCDB416AF/0/10988\\_Biobooster\\_Herlev\\_LOW\\_opslag.pdf](http://www.herlevhospital.dk/NR/rdonlyres/74234BCB-4E38-4B84-9742-80FFCDB416AF/0/10988_Biobooster_Herlev_LOW_opslag.pdf) (last access on January 12<sup>th</sup>, 2015)
- 1158 Hijnen WAM., Beerendonk EF Medema GJ. Inactivation credit of UV radiation for viruses, bacteria and  
1159 protozoan (oo)cysts in water: A review. *Water Res* 2006;40:3-22.
- 1160 Joss A, Zabczynski S, Göbel A, Hoffmann B, Löffler D, Mc Ardell CS et al. Biological degradation of  
1161 pharmaceuticals in municipal wastewater treatment: Proposing a classification scheme. *Water Res.*  
1162 2006;40:1686-96.
- 1163 Kajitvichyanukul P, Suntronvipart N. Evaluation of biodegradability and oxidation degree of hospital  
1164 wastewater using photo-Fenton process as the pretreatment method. *J Hazard Mater* 2006;B138:384-  
1165 91.
- 1166 Kimura K, Toshima S, Amy G, Watanabe Y. Rejection of neutral endocrine disrupting compounds (EDCs) and  
1167 the pharmaceutical active compounds (PhACs) by RO membranes. *J Membrane Sci* 2004;245:71-8.
- 1168 Kist LT, Albrecht C, Machado ÊL. Hospital laundry wastewater disinfection with catalytic photoozonation.  
1169 *Clean-Soil Air Water* 2008;36:775-80.
- 1170 Kohler C, Venditti S, Igos E, Klepyszewski K, Benetto E, Cornelissen A. Elimination of pharmaceutical residues  
1171 in biologically pre-treated hospital wastewater using advanced UV irradiation technology: A  
1172 comparative assessment. *J Hazard Mater* 2012;239-240:70-7.
- 1173 Korzeniewska E, Korzeniewska A, Harnisz M. Antibiotic resistant *Escherichia coli* in hospital and municipal  
1174 sewage and their emission to the environment. *Ecotox Environ Safe* 2013;91:96-102.
- 1175 Kosma CI, Lambropoulou DA, Albanis TA. Occurrence and removal of PPCPs in municipal and hospital  
1176 wastewaters in Greece. *J Hazard Mater* 2010;179:804-17.
- 1177 Kovalova L, Siegrist H, Singer H, Wittmer A, Mc Ardell CS. Hospital wastewater treatment by membrane  
1178 bioreactor: Performance and efficiency for organic micropollutant elimination. *Environ Sci Technol*  
1179 2012;46:1536-45.
- 1180 Kovalova L, Siegrist H, Von Gunten U, Eugster J, Hagenbuch M, Wittmer A et al. Elimination of  
1181 micropollutants during post-treatment of hospital wastewater with powdered activated carbon, ozone,  
1182 and U. *Environ Sci Technol* 2013;47:7899-908.
- 1183 Kreuzinger N, Clara M, Strenn B, Kroiss H. Relevance of the sludge retention time (SRT) as design criteria for  
1184 wastewater treatment plants for the removal of endocrine disruptors and pharmaceuticals from  
1185 wastewater *Wat Sci Technol* 2004;50:149-156.
- 1186 Kummerer K. Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into  
1187 wastewater by hospital in relation to other sources – a review. *Chemosphere* 2001;45:957–69
- 1188 Kummerer K, Erbe T, Gartiser S, Brinker L. AOX-emissions from hospital into municipal wastewater.  
1189 *Chemosphere* 1998;36:2437–45
- 1190 Lee Y, Von Gunten U. Oxidative transformation of micropollutants during municipal wastewater treatment:  
1191 Comparison of kinetic aspects of selective (chlorine, chlorine dioxide, ferrate<sup>VI</sup>, and ozone) and non-  
1192 selective oxidants (hydroxyl radical). *Water Res* 2010;44:555-66.
- 1193 Lenz K, Koellensperger G, Hann S, Weissenbacher N, Mahnik SN, Fuerhacker M. Fate of cancerostatic  
1194 platinum compounds in biological wastewater treatment of hospital effluents. *Chemosphere*  
1195 2007a;69:1765-74.
- 1196 Lenz K, Mahnik SN, Weissenbacher N, Mader RM, Krenn P, Hann S et al. Monitoring, removal and risk  
1197 assessment of cytostatic drugs in hospital wastewater. *Water Sci Technol* 2007b;56:141-9.
- 1198 Lienert J, Koller M, Konrad, J, Mc Ardell CS, Schuwirth N. Multiple-criteria decision analysis reveals high  
1199 stakeholder preference to remove pharmaceuticals from hospital wastewater. *Environ Sci Technol*  
1200 2011;45:3848-57.
- 1201 Lopez N, Deblonde T, Hartemann Ph. Les effluents liquids hospitaliers. *Hygiènes* 2010;18:405-10
- 1202 Liu Q, Zhou Y, Chen L, Zheng X. Application of MBR for hospital wastewater treatment in China.  
1203 *Desalination* 2010;250:605-8.

- 1204 Machado ÊL, Kist LT, Schmidt R, Hoeltz JM, Dalberto D, Alcayaga ELA. Secondary hospital wastewater  
1205 detoxification and disinfection by advanced oxidation processes. *Environ Technol* 2007;28:1135-43.
- 1206 Mahnik SN, Lenz K, Weissenbacher N, Mader RM, Fuerhacker M. Fate of 5-fluorouracil, doxorubicin,  
1207 epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and  
1208 treatment in a membrane-bio-reactor system. *Chemosphere* 2007;66:30-7.
- 1209 Mahvi A, Rajabizadeh A, Fatehizadeh A, Yousefi N, Hosseini H, Ahmadian M. Survey Wastewater Treatment  
1210 Condition and Effluent Quality of Kerman Province Hospitals. *World Appl Sci J* 2009;7:1521-5.
- 1211 Martins AF, Vasconcelos TG, Henriques DM, Frank CS, König A, Kümmerer K. Concentration of ciprofloxacin  
1212 in Brazilian hospital effluent and preliminary risk assessment: A case study. *Clean-Soil Air Water*  
1213 2008;36:264-9.
- 1214 McArdell CS, Kovalova L, Siegrist H. Input and elimination of pharmaceuticals and disinfectants from  
1215 hospital wastewater. Final report. July 2011
- 1216 Mesdaghinia AR, Naddafi K, Nabizadeh R, Saeedi R, Zamanzadeh M. Wastewater characteristics and  
1217 appropriate Method for wastewater management in the hospitals. *Iran J Public Health* 2009;38:34-40.
- 1218 Monteiro SC, Boxall ABA. Occurrence and fate of human pharmaceuticals in the environment. *Rev Environ*  
1219 *Contam T* 2010;202:53-154.
- 1220 Mousaab A, Claire C, Magali C, Christophe D. Upgrading the performances of ultrafiltration membrane  
1221 system coupled with activated sludge reactor by addition of biofilm supports for the treatment of  
1222 hospital effluents. *Chem Eng J* 2015;262:456-463.
- 1223 Mullot J, Karolak S, Fontova A, Levi Y. Modeling of hospital wastewater pollution by pharmaceuticals: First  
1224 results of mediflux study carried out in three French hospitals. *Water Sci Technol* 2010;62: 2912-19.
- 1225 Nardi G, Feretti D, Bracchi U, Dorè F, Francesconi A, Grottolo M et al. Acque reflue ospedaliere. Valutazione  
1226 di un trattamento di disinfezione con biossido di cloro. *Inquinamento* 1995;7:77-83.
- 1227 Nielsen U, Hastrup C, Klausen MM, Pedersen BM, Kristensen GH, Jansen JLC et al. Removal of APIs and  
1228 bacteria from hospital wastewater by MBR plus O<sub>3</sub>, O<sub>3</sub> + H<sub>2</sub>O<sub>2</sub>, PAC or ClO<sub>2</sub>. *Water Sci Technol*  
1229 2013;67:854-62.
- 1230 Ort C, Lawrence M, Reungoat J, Eagleham G, Carter S, Keller J. Determination of the fraction of  
1231 pharmaceutical residues in wastewater originating from a hospital. *Water Res* 2010;44:605–15.
- 1232 Panouillères M, Boillot C, Perrodin Y. Study of the combined effects of a peracetic acid-based disinfectant  
1233 and surfactants contained in hospital effluents on daphnia magna. *Ecotoxicology* 2007;16:327-40.
- 1234 Pauwels B, Fru Ngwa F, Deconinck S, Verstraete W. Effluent quality of a conventional activated sludge and a  
1235 membrane bioreactor system treating hospital wastewater. *Environ Technol* 2006;27:395-402.
- 1236 Pauwels B, Verstraete W. The treatment of hospital wastewater: an appraisal. *J Water Health* 2006;4:405–  
1237 16.
- 1238 Pharmafilter report, Evaluation report Pharmafilter Full scale demonstration in the Reinier de Graaf  
1239 Gasthuis (Hospital) Delft, ISBN 9789057735936. Available at the web site:  
1240 <http://nieuwesanitatie.stowa.nl/upload/publicaties/STOWA%202013%2016%20LR.pdf> (last access on  
1241 January 12<sup>th</sup> 2015)
- 1242 Perrodin Y, Bazin C, Bony S, Devaux A, Bertrand-Krajewski JL, Cren-Olivé C et al. A priori assessment of  
1243 ecotoxicological risks linked to building a hospital. *Chemosphere* 2013;90:1037-46.
- 1244 PILLS Report 2012. Pharmaceutical residues in the aquatic system: - a challenge for the future, Final report  
1245 of the European cooperation project PILLS, available at the address: [www.pills-project.eu](http://www.pills-project.eu) (last access on  
1246 January 5<sup>th</sup> 2015), Gelsenkirchen September 2012.
- 1247 Prado T, Silva DM, Guilayn WC, Rose TL, Gaspar AMC, Miagostovich MP. Quantification and molecular  
1248 characterization of enteric viruses detected in effluents from two hospital wastewater treatment plants.  
1249 *Water Res* 2011;45:1287-97.
- 1250 Prayitno, Kusuma Z, Yanuwadi B, Laksmono RW, Kamahara H, Daimon H. Hospital wastewater treatment  
1251 using aerated fixed film biofilter - Ozonation (Af2b/O<sub>3</sub>). *Adv Environ Biol* 2014;8:1251-9.
- 1252 Rezaee A, Ansari M, Khavanin A, Sabzali A, Aryan MM. Hospital wastewater treatment using an integrated  
1253 anaerobic aerobic fixed film bioreactor. *Am J Exp Sci* 2005;1:259-63.
- 1254 Rizzo L, Maniaia C, merlin C, Schwartz T, Dagot C, Ploy MC, Michael I, Fatta-Kassinos D. Urban wastewater  
1255 treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A  
1256 review. *Sci Tot Environ* 2013;447:345-60

- 1257 Rogers HR. Sources, behaviour and fate of organic contaminants during sewage treatment and in sewage  
1258 sludges. *Sci Total Environ* 1996;185:3-26
- 1259 Santos LHMLM, Gros M, Rodriguez-Mozas S, Delerue-Matos C, Pena A et al. Contribution of hospital  
1260 effluents to the load of pharmaceuticals in urban wastewaters: Identification of ecologically relevant  
1261 pharmaceuticals. *Sci Total Environ* 2013;461-462:302-16.
- 1262 Sarafraz Sh, Khani MR, Yaghmaeian K. Quality and quantity survey of hospital wastewater in Hormozgan  
1263 Province. *Iran J Environ Health Sci Eng* 2007;4:43-50.
- 1264 Shrestha RR, Haberl R, Laber J. Constructed Wetland technology transfer to Nepal. *Water Sci Technol*  
1265 2001;43:345-50.
- 1266 Siegrest H, Joss A. Review on the fate of organic micropollutants in wastewater treatment and water reuse  
1267 with membranes. *Wat Sci Technol* 2012;66:1369-76.
- 1268 Sim WJ, Kim HY, Choi SD, Kwon JH, Oh JE. Evaluation of pharmaceuticals and personal care products with  
1269 emphasis on anthelmintics in human sanitary waste, sewage, hospital wastewater, livestock wastewater  
1270 and receiving water. *J Hazard Mater* 2013;248-249:219-27.
- 1271 Sipibel Report: Effluents hospitaliers et stations d'épuration urbaines : caractérisation, risques et  
1272 traitabilité- Presentation and premiers resultants- June 2014 available at the web site  
1273 <http://www.graie.org/Sipible/publications.html> (last access on January 2nd, 2015)
- 1274 Straub JO. Environmental risk assessment for new human pharmaceuticals in the European Union  
1275 according to the draft guideline/discussion paper of January 2001. *Toxicol Lett* 2002;131:137-43.
- 1276 Suarez S, Lema JM, Omil F. Pre-treatment of hospital wastewater by coagulation-flocculation and flotation.  
1277 *Bioresource Technol* 2009;100:2138-146.
- 1278 Suty H, De Traversay C, Cost M. Application of advanced oxidation processes: present and future. *Water Sci*  
1279 *Technol* 2004;49:227-33
- 1280 Tadkaew N, Hai F I, McDonald JA, Khan SJ, Nghiem LD. Removal of trace organics by MBR treatment: The  
1281 role of molecular properties. *Water Res* 2011;45:2439-51.
- 1282 Vasconcelos TG, Kümmerer K, Henriques DM, Martins AF. Ciprofloxacin in hospital effluent: Degradation by  
1283 ozone and photoprocesses. *J Hazard Mater* 2009;169:1154-8.
- 1284 Venditti S, Köhler C, Arenz-Leufen M, O'Nagy O, Cornelissen A, Klepiszewski K. Membrane bioreactor  
1285 process as pre-treatment for hospital effluents. *Proceedings 8<sup>th</sup> IWA Leading-Edge Conference on Water*  
1286 *and Wastewater Technologies, Amsterdam, 2011.*
- 1287 Verlicchi P, Al Aukidy M, Galletti A, Petrovic M, Barceló D. Hospital effluent: investigation of the  
1288 concentrations and distribution of pharmaceuticals and environmental risk assessment. *Sci Total*  
1289 *Environ* 2012a;430:109-18.
- 1290 Verlicchi P, Al Aukidy M, Zambello, E. Occurrence of pharmaceutical compounds in urban wastewater:  
1291 Removal, mass load and environmental risk after a secondary treatment-A review. *Science of the Total*  
1292 *Environment*, 2012b;429, 123-155.
- 1293 Verlicchi P, Galletti A, Al Aukidy M, Masotti L. New perspectives in wastewater disinfection, In: Nova  
1294 Publisher, editor. *Water Disinfection*; 2011, pp. 77-108.
- 1295 Verlicchi P, Galletti A, Masotti L. Caratterizzazione e trattabilità di reflui ospedalieri: indagine sperimentale  
1296 (con sistemi MBR) presso un ospedale dell'area ferrarese. *Proceedings Sidisa Conference, Florence*  
1297 *(Italy), June 2008 (in Italian).*
- 1298 Verlicchi P, Galletti A, Masotti L. Management of hospital wastewaters: The case of the effluent of a large  
1299 hospital situated in a small town. *Wat Sci Technol* 2010;61:2507-519.
- 1300 Verlicchi P, Galletti A, Petrovic M, Barcelò D. Micro-pollutants in hospital effluent: their fate, risk and  
1301 treatment options. In: Barcelò D, Kostianoy AG, editors. *Emerging organic Contaminants and Human*  
1302 *Health, The Handbook of Environmental Chemistry, Springer; 2012c. p. 139-72.*
- 1303 Verlicchi P, Zambello E, Al Aukidy M. Removal of Pharmaceuticals by Conventional Wastewater Treatment  
1304 Plants. In: Barcelò D, Petrovic M. editors *Comprehensive Analytical Chemistry, Elsevier* 2013 p. 231- 86.
- 1305 von Gunten U. Ozonation of drinking water: Part II. Disinfection and by-product formation. *Water Res*  
1306 2003;37:1469-87.
- 1307 Walkberg C, Biorlenius B, Paxeus N. Pharmaceuticals residues in Stockholm Water Environment –  
1308 Occurrence mitigations and treatment of wastewater. 2010 Stockholm Vatten (in Swedish)

1309 Wang XW, Li J, Guo T, Zhen B, Kong Q., Yi B et al. Concentration and detection of SARS coronavirus in  
1310 sewage from Xiao Tang Shan hospital and the 309th Hospital of the Chinese People's Liberation Army.  
1311 *Wat Sci Technol* 2005;52:213-21.  
1312 Wen X, Ding H, Huang X, Liu R. Treatment of hospital wastewater using a submerged membrane bioreactor.  
1313 *Process Biochem* 2004;39:1427-431.  
1314 Westerhoff P, Yoon Y, Snyder S, Wert E. Fate of endocrine-disruptor, pharmaceutical and personal care  
1315 product chemicals during simulated drinking water treatment processes. *Environ Sci Technol*  
1316 2005;39:6649–63.  
1317 Wilde ML, Montipo S, Martins AF. Degradation of b-blockers in hospital wastewater by means of ozonation  
1318 and Fe<sup>2+</sup>/ozonation. *Water Res* 2014;48:280-95.  
1319 Zwickenspflug B, Böhler M, Sterkele B, Joss A, Siegrist H, Traber J, Gujer W, Behl M, Dorusch F, Hollender J,  
1320 Ternes T, Fink G. Einsatz von Pulveraktivkohle zur Elimination von Mikroverunreinigungen aus  
1321 kommunalem Abwasser.(Final report of the MicroPoll project EAWAG on behalf of the Swiss Federal  
1322 Office for the Environment, Dübendorf, CH (2010) <http://www.eawag.ch/forschung/eng/schwerpunkte/>  
1323 (last access on January 12<sup>th</sup> 2015)

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## TABLES

**Table 1.** Main chemical characteristics of hospital effluent in terms of conventional parameters and pharmaceuticals and other emerging compounds

Parameter	Range of concentrations	Reference
Conductivity, $\mu\text{S}/\text{cm}$	300-1000	Boillot et al., 2008; Verlicchi et al., 2012c
pH	6-9	PILLS Report, 2012, Kosma et al., 2010
Redox potential, mV	850-950	Verlicchi et al., 2010; Boillot et al., 2008
Fat and oil, mg/L	50-210	Al-Hashimia et al., 2013; Verlicchi et al., 2010
Chlorides, mg/L	80-400	Emmanuel et al., 2004; Verlicchi et al., 2012c
Total N, mg N/L	60-98	PILLS Report, 2012, Beyene and Redaie, 2011
$\text{NH}_4$ , mg $\text{NH}_4$ /L	10-68	McArdell et al., 2011, Verlicchi et al., 2012c Wen et al., 2004
Nitrite, mg $\text{NO}_2$ /L	0.1-0.58	Al Hashimia et al., 2013; McArdell et al., 2011
Nitrate, mg $\text{NO}_3$ /L	1-2	Lopez et al., 2010; McArdell et al., 2011, Venditti et al., 2011
Phosphate, mg P- $\text{PO}_4$ /L	6-19	Al-Hashimia et al., 2013; Verlicchi et al., 2010;2012c
Suspended solids, mg/L	120-400	Verlicchi et al., 2012c
COD, mg/L	1350-2480	Kajitvichyanukul and Suntronvipart 2006; Berto et al., 2009
Dissolved COD, mg/L	380-700	McArdell et al., 2011
DOC, mg/L	120-130	McArdell et al., 2011;
TOC, mg/L	31-180	Beier, 2012, Nardi et al., 1995
BOD <sub>5</sub> /COD (biodegradability index)	0.3-0.4	Kajitvichyanukul and Suntronvipart 2006
AOX, $\mu\text{g}/\text{L}$	550-10000	Kummerer et al., 1998; Nardi et al., 1995
Microrganisms MPN/100 mL		
<i>E. coli</i>	$10^3$ - $10^6$	Beier et al., 2012, Nielsen et al., 2013
Enterococci	$10^3$ - $10^6$	Beier et al., 2012
Fecal Coliform	$10^3$ - $10^4$	Beier et al., 2012
Total Coliform	$10^5$ - $10^7$	Lopez et al., 2010; Beyene and Redaie 2011
EC <sub>50</sub> ( <i>Daphnia</i> ), TU	9.8-117	Emmanuel et al., 2004; Machado et al., 2007
Total surfactants, mg/L	4-8	Verlicchi et al., 2008, 2010
Total disinfectants, mg/L	2-200	Kummerer, 2001; Verlicchi et al., 2012c
Specific disinfectants:		
BAC_C12-18, $\mu\text{g}/\text{L}$	49	Kovalova et al., 2012
BAC_C12, $\mu\text{g}/\text{L}$	34	Kovalova et al., 2012
DDAC-C10, $\mu\text{g}/\text{L}$	102	Kovalova et al., 2012
Antibiotics, $\mu\text{g}/\text{L}$	30-200	Verlicchi et al., 2012c
Antinflammatories, $\mu\text{g}/\text{L}$	5-1500	Verlicchi et al., 2012c
Lipid regulators, $\mu\text{g}/\text{L}$	1-10	Verlicchi et al., 2012c
Cytostatic agents, $\mu\text{g}/\text{L}$	5-50	Suarez et al., 2009; Verlicchi et al., 2012c
ICM, $\mu\text{g}/\text{L}$	0.2-2600	Verlicchi et al., 2012c



---

Beta-blockers, µg/L

0.4-25

Verlicchi et al., 2012c

---

<sup>1</sup>Disinfectants: quaternary ammonia disinfectant: BAC\_C12-18: benzalkonium chloride; DDAC-C10: dimethyldidecylammonium chloride

**Table 2** List of the studies included in the overview together with a brief description of the corresponding investigations and rationale

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Abd El-Gawad and Aly, 2011	Investigation carried out at four hospitals in Egypt to assess hospital effluent quality and quantity, as well as the impact on the environment in terms of common parameters and pollutants when a CAS system is adopted as treatment prior to discharge into surface water.	Suitable HWW management based on standards set for conventional pollutants in UWW.	Conventional parameters: BOD <sub>5</sub> , DO, TSS, total coliform, fecal coliform and trace elements (metals)
Al Hashimia et al., 2013	Investigation carried out on real wastewater collected from a hospital located in Iraq to assess the performance of a lab-scale <i>sequencing</i> anoxic/anaerobic MBR for nutrient removal under different internal recycling time modes between anoxic and anaerobic conditions operating with an SRT = 58.5-116 d, internal recycle rate of 39 L/h, a flux of 15.12 L/(m <sup>2</sup> h).	Enhancement in nutrient removal in hospital effluent.	Conventional parameters: COD, BOD <sub>5</sub> , PO <sub>4</sub> , NH <sub>4</sub> , NO <sub>3</sub> , NO <sub>2</sub> , TSS, oil and grease, total and fecal coliforms
Andersen et al., 2014	Investigation regarding to the treatment of the oncological ward effluent by means of a pilot plant consisting in a moving bed biofilm reactor (MBBR) followed by ozonation carried out in Denmark. System performances were provided for six pharmaceutical model substrates each representing different biological and chemical degradation.	Optimization of the removal of selected compounds by means of a MBBR and ozonation.	PhCs: triclosan, mefenamic acid, diclofenac, naproxen, gemfibrozil, ketoprofen, ibuprofen, clofibrac acid
Arslan et al., 2014	Investigation carried out on raw hospital effluent in Turkey. Ozonation, O <sub>3</sub> /UV, O <sub>3</sub> /UV/H <sub>2</sub> O <sub>2</sub> were tested as a <i>pretreatment</i> option in a batch reactor in order to evaluate the removal of COD and UV absorbance and the improvement in biodegradation.	Options in pretreatments	Conventional parameters: COD and absorbance
Azar et al., 2010	Investigation carried out on real HWW collected from two hospitals located in Iran, by means of biological oxidation (aerobic/anaerobic) in an 80-litre pilot plant.	Recommended treatment for hospital effluent in Iran, based on an analysis of conventional parameter removals.	Conventional parameters: COD, BOD <sub>5</sub> , TSS, NO <sub>2</sub> , NO <sub>3</sub> , PO <sub>4</sub> , detergents, oil and grease, total coliform, <i>Escherichia coli</i> , Ag, Hg and Ni
Beier et al., 2010	Investigation carried out at Waldbrol hospital (Germany) by means of nanofiltration (NF) and reverse osmosis (RO) membrane (pilot plant) for the treatment of a (full scale) MBR permeate. The molecular weight cut off (MWCO) of NF membranes was 300-400 Dalton and of RO membranes was 100-150 Dalton. For the tests, the pump pressure was 7 bar for NF and 14 bar for RO and the maximum feed flux to NF/RO modules was between 20 and 36 L/(m <sup>2</sup> h).	Dedicated polishing treatment for HWWs to remove PhCs.	PhCs: bezafibrate, bisoprolol, carbamazepine, clarithromycin, ciprofloxacin, diclofenac, ibuprofen, metronidazole, moxifloxacin, telmisartan, tramadol

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Beier et al., 2011	Investigation carried out at the full-scale MBR in operation at Waldbrol hospital in Germany to assess PhCs removal from hospital wastewater. The permeate is then sent to the municipal WWTP. The main design parameters are: Q = 130 m <sup>3</sup> /d; maximum flow 250 m <sup>3</sup> /d; 5 Kubota EK 400 flat sheet membrane modules, total membrane area 1600 m <sup>2</sup> , cut off value 0.2 µm; biomass concentration in the bioreactor 10-12 g/L; biological reactor volume 56 m <sup>3</sup> . The main average operating parameters: hydraulic retention time 31.3 h, temperature in aerated tank 24.6 °C, biomass concentration 13.6 g/L, flux 10-20 L/(m <sup>2</sup> h).	Separate treatment of HWWs will allow evaluation of the appropriateness of MBR for hospital effluent in high density urban areas, contributing to minimizing the operating and financial expenditure for municipal WWTP.	PhCs: bezafibrate, bisoprolol, carbamazepine, clarithromycin, ciprofloxacin, diclofenac, ibuprofen, metronidazole, moxifloxacin, tramadol.
Beier et al., 2012	Investigation carried out at a hospital in Waldbrol (Germany) to assess the performance of a full-scale wastewater treatment plant equipped with a MBR and to evaluate the characteristics of the activated sludge. For design and operational parameters see Beier et al. (2011).	Evaluation of MBR as a dedicated treatment of HWWs to reduce the environmental input of chemical and microbiological parameters in the environment.	Conventional parameters: COD, TOC, AOX, NH <sub>4</sub> , total P, <i>E. coli</i> and Enterococci
Berto et al., 2009	Investigation carried out at a hospital in Brazil to evaluate the effectiveness of “advanced” pretreatments consisting in a biological (full-scale septic tank, 45 m <sup>3</sup> ) and a chemical stage (lab-scale Fenton reactor) to remove organic matter and pathogenic microbiota from HWW.	Adequate advanced (pre)treatments for hospital effluents to reduce their environmental impact.	Conventional parameters: COD, BOD <sub>5</sub> , P and N compounds, suspended solids, total coliform and thermotolerant coliforms
Beyene and Redaie, 2011	Investigation carried out at Hawassa University Referral Hospital (Ethiopia) to examine the suitability of a series of (full scale) ponds for the treatment of HWW. The treatment train consists of two facultative ponds (each of them: surface area 667 m <sup>2</sup> , depth 1.5 m and retention time 14 d) followed by two maturation ponds (each of them surface area of about 400 m <sup>2</sup> , depth 1.1 m, retention time 3 d) and a final fish pond (surface area 862 m <sup>2</sup> , depth 1.5 m, retention time 9 d).	Evaluation of the risk posed by HWWs in terms of conventional pollutants and a proposal to upgrade existing WWTP in order to reduce it.	Conventional parameters: COD, BOD <sub>5</sub> , P, PO <sub>4</sub> , total Nitrogen, NH <sub>3</sub> , NO <sub>3</sub> , NO <sub>2</sub> TSS, TDS, Cl, S <sub>2</sub> , total coliforms and fecal coliforms
Chiang et al., 2003	Investigation carried out in Taiwan on the disinfection by continuous ozonation of hospital effluent and in particular of the effluent from the kidney dialysis unit and on the increment of hospital effluent biodegradability.	Disinfection effect and improvement in biodegradability of hospital effluent by ozonation	Conventional parameters: COD, BOD, total coliforms
Chitnis et al., 2004	Investigation carried out in India in a pilot plant consisting in preliminary and primary treatments, a conventional activated sludge system, sand filtration and chlorination.	Investigation into the microbiological community and evaluation of the risk of multidrug resistant bacteria spread	Different microbiological parameters: total coliforms, fecal enterococci, staphylococci, <i>Pseudomonas</i> , multidrug resistant bacteria.

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Cruz-Morato et al., 2014	Investigation carried out in Spain in a batch fluidized bed bioreactor (lab scale) under sterile and non-sterile conditions with <i>Trametes versicolor</i> pellets to examine the removal of a wide group of pharmaceutical compounds from HWW. Samples were collected from the main sewer of Girona University Hospital (Spain).	Evaluation of the capacity of a treatment by fungal bioreactor in reducing pharmaceutical concentration from HWW.	99 PhCs of different classes
de Almeida et al., 2013	Investigation carried out at the University hospital of Santa Maria (Brazil) by means of a septic tank and anaerobic filter (full scale).	Environmental risks of PhCs and adequateness of treatment trains.	PhCs: 5 anti-anxiety and anti-epileptic compounds
Emmanuel et al., 2004	Toxicity evaluation after prechlorination (NaClO addition) of the effluent from the infectious and tropical disease department at the hospital in Lyon, France.	Toxicity evaluation due to prechlorination	Conventional parameters: COD, TOC, AOX, chlorides
Gautam et al., 2007	Investigation carried out at the hospital located in Vellore, Tamil Nadu (India), by means of a lab-scale plant consisting of coagulation (by adding FeCl <sub>3</sub> up to 300 mg/L), rapid filtration and disinfection (by adding a bleaching powder solution) steps.	Options for hospital effluent pretreatment before discharge in public sewage.	Conventional parameters: COD, BOD <sub>5</sub> , SS and P.
Grundfos Biobooster, 2012	Report from an on-going project in Denmark to evaluate the best available technologies (BATs) for the separated treatment of hospital effluent. Two sequences are being tested: MBR followed by O <sub>3</sub> , GAC and/or H <sub>2</sub> O <sub>2</sub> and UV, MBR followed by GAC and UV	Evaluation of the BAT for hospital treatment.	.
Kajitvichyanukul and Suntronvipart, 2006	Investigation carried out in Bangkok, Thailand, on the pretreatment of hospital effluent by using a lab-scale photo-Fenton process.	Improvement in biodegradability of hospital effluent by using the photo-Fenton process as a pretreatment.	Conventional parameters: COD, BOD <sub>5</sub> , TOC, turbidity, TSS, conductivity and toxicity
Kist et al., 2008	Investigation carried out on the treatment of wastewater produced in a hospital laundry in the Rio Pardo Valley (Brazil), by means of a (lab scale, 4 L) ramp type reactor for catalytic photoozonation (UV/TiO <sub>2</sub> /O <sub>3</sub> ).	Reduction of the risk posed by hazardous substances occurring in HWWs due to adequate pretreatments	Conventional parameters: COD, BOD <sub>5</sub> , turbidity, surfactants, <i>Escherichia Coli</i> and thermotolerant Coliforms
Kohler et al., 2012	Investigation carried out at the Hospitalier Emil Mayrisch (Luxembourg) by means of a pilot plant (MBR+UV; MBR+H <sub>2</sub> O <sub>2</sub> +UV) to assess the removal of some pharmaceutical compounds. Details of the MBR are reported in Venditti et al., 2011.	Technical and economical feasibility for hospital effluent treatment.	13 PhCs
Kosma et al., 2010	Investigation carried out on the occurrence and removal of PhCs at the hospital (full scale) WWTP (CAS, 600 m <sup>3</sup> , HRT = 6 h) in Ioannina (Greece).	Impact of pharmaceuticals on the environment.	11 PhCs; COD, BOD <sub>5</sub> , NO <sub>3</sub> , PO <sub>4</sub> and TSS

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Kovalova et al., 2012	Investigation carried out in Switzerland, on a pilot-scale primary clarifier+ MBR installed and operated for one year at Cantonal Hospital in Baden. The bioreactor consisted of an anoxic tank (0.5 m <sup>3</sup> ) and an aerobic one (1 m <sup>3</sup> ) equipped with submerged ultrafiltration flat sheet membrane plates (15-30 L/m <sup>2</sup> h, 38 nm pore size, nominal cut-off 150 kDa). Biomass concentrations was 2 g/L, SRT 30-50 d, temperature 29 °C.	Analysis of performance and removal in MBR of many PhCs. Reduction of the spread of multi resistant or pathogenic bacteria, virus, parasite eggs and PhCs.	56 PhCs
Kovalova et al., 2013	Investigation carried out at the Cantonal Hospital in Baden (Switzerland) in a pilot plant consisting in a primary clarifier, MBR (see Kovalova et al., 2012), and five post-treatment technologies: O <sub>3</sub> , O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> , powdered activated carbon (PAC), and low pressure UV light with and without TiO <sub>2</sub> .	Removal of typical pollutants in hospital effluent (disinfectants, pathogens and antibiotic resistant bacteria) by advanced treatments.	56 PhCs
Lenz et al., 2007a	Investigation carried out at a hospital in Vienna (Austria), by means of a pilot MBR (150 L) installed and fed with oncologic in-patient treatment ward effluent. Ultrafiltration membranes (nominal cut-off of 100 kDa) were used	Risk of cancerostatic platinum compounds to humans.	Cancerostatic platinum compounds
Lenz et al., 2007b	Investigation carried out at the oncological ward in a hospital in Vienna (Austria), by means of a pilot MBR (see Lenz et al., 2007a) followed by granular activated carbon (GAC) and UV. Biomass concentration was 12-15 g/L, the average hydraulic load 260 L/d	Environmental risk of cytostatic.	Cancerostatic platinum compounds.
Liu et al., 2010	Investigation carried out in China on operating conditions, MBR efficiency in treating hospital effluent.	To avoid the spread of pathogenic microorganisms and viruses, especially following the outbreak of SARS in 2003.	Conventional parameters: COD, BOD <sub>5</sub> , NH <sub>3</sub> , TSS, Bacteria and fecal coliform
Machado et al., 2007	Investigation carried out in Brazil, on a lab-scale advanced oxidation process (UV/TiO <sub>2</sub> /O <sub>3</sub> ) operating as a tertiary treatment, fed with secondary HWW.	Proposal of a (sustainable) treatment schematic to reduce microorganisms and toxicity from hospital effluent.	Conventional parameters: COD, BOD <sub>5</sub> , turbidity, total nitrogen, total phosphorus, surfactants, thermotolerant coliforms. toxicity and AOX
Mahnik et al., 2007	Occurrence and treatability of cytostatics in the effluent from the oncologic in-patient treatment ward of the Vienna University Hospital was investigated as well as their removal by an MBR (pilot scale, 150 L of aeration tank, hydraulic load 100-200 L/d, HRT = 20-24 h, biomass concentration 12-15 g/L, UF membranes: active area 1 m <sup>2</sup> , nominal cut-off 100kDa)	Pollution level of the effluent from particular hospital wards.	4 PhCs: 5-fluorouracil, doxorubicin, epirubicin and daunorubicin
Mahvi et al., 2009	Analysis of the performance of seven WWTPs (CAS + chlorination) in Kerman Province (Iran) receiving hospital effluent in terms of removal of main conventional parameters and malfunctions.	Malfunctions in WWTPs receiving hospital effluents.	Conventional parameters: COD, BOD <sub>5</sub> , DO, TSS, pH, NO <sub>2</sub> , NO <sub>3</sub> , PO <sub>4</sub> , Cl and SO <sub>4</sub> <sup>2-</sup>

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Martins et al., 2008	Investigation carried out in Brazil into the pretreatment of hospital effluent by using a septic tank and an anaerobic filter. Analysis was referred to occurrence, removal of ciprofloxacin and the resulting risk due to its residue in the treated effluent	Evaluation of the adequateness of specific pretreatment in Brazil	PhC: ciprofloxacin
McArdell et al., 2011	Report including all the details of the investigations described in Kovalova et al. (2012, 2013) and in PILLS Report 2012 referring to the Swiss investigations on MBR and MBR+ AOPs applied to a hospital effluent	Testing and comparing the removal of PhCs from HWW by different technologies	Conventional parameters, PhCs
Moussaab et al., 2015	Investigation into the removal ability of PhCs and conventional pollutants in an upgraded UF membrane system coupled with an activated sludge (AS) reactor by the addition of biofilm support media in the aeration tank in case of hospital effluent treatment. The aeration bioreactor had a volume of 400 L, the UF membrane system consisted of a hollow fiber module (1 m <sup>2</sup> surface area, pore size 0.2 µm). HRT = 22 h and SRT=20 d.	Improvement in PhC removal from hospital effluent and in membrane functioning resulting in a reduction of operation costs.	PhCs
Nardi et al., 1995	Investigation into disinfection of the effluent of an Italian infectious disease ward by means of different doses of ClO <sub>2</sub> and evaluation of AOX production.	Disinfection performance of ClO <sub>2</sub> with respect to NaClO in case of hospital effluent and evaluation of AOX production.	Conventional parameters: COD, TOC, total and fecal coliforms, Streptococci. AOX
Nielsen et al., 2013	Investigation carried out in Denmark with pilot and lab scale plants into the ability of different technologies acting as a secondary (MBR) or a tertiary (O <sub>3</sub> , O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> , ClO <sub>2</sub> , PAC) treatment in removing common PhCs from hospital effluent. The MBR was equipped with ceramic UF membranes (surface area 3.75 m <sup>2</sup> , pore size 60 nm). The average daily flow was 2.2 m <sup>3</sup> /d and 24.6 L/(m <sup>2</sup> h), SRT = 35 d	Risk to human health posed by Hwws during combined sewers overflow.	PhCs; <i>eE. coli</i> , total coliforms, total enterococci.
Pauwels et al., 2006	Investigation carried out in Ghent (Belgium) to compare the performance of two lab-scale plants (CAS and MBR) in treating hospital effluent. The MBR consisted of a 25 L tank equipped with 3 plate membrane modules ( pore size 0.4 µm; total surface area 0.3 m <sup>2</sup> ) HRT = 12 h in both reactors	Potential risk of HWWs- correlation between PhC and conventional parameters removal.	COD, total ammonium nitrogen, total coliforms, fecal coliforms, total aerobic bacteria, total anaerobic bacteria and Enterococci; Ethinylestradiol.
Pharmafilter Report, 2013	Report on the characteristics and the performance of a full-scale system (Pharmafilter) installed and tested in the Reinier de Graaf Gasthuis in Delft (Netherlands) in the period 2010-2012. The system is an integral concept for the optimization of care, processing waste and purifying wastewater in hospitals. It consists in: pretreatment (sieve), biological process (UF MBR), ozonation, GAC filtration. The sludge discharged from the MBR is fed back into the digester and any excess sludge water from the digestate formed in the digester can be transported to the MBR. The fate and removal of about 100	Potential health risk posed by HWWs	Potential health risk posed by HWWs PhCs

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
	PhCs was observed.		
PILLS Report, 2012	Report of the main results achieved within the European PILLS project developed in 2010-2012 involving four research units in different countries that investigated the removal of PhCs from HWW by means of MBR+PAC, MBR+O <sub>3</sub> +moving bed bioreactor, MBR+UV+moving bed bioreactor in Switzerland, MBR+RO, MBR+UV, MBR+ O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> in Luxembourg, MBR+O <sub>3</sub> +sand filtration, MBR+ PAC+sand filtration in Germany, MBR+O <sub>3</sub> +GAC, MBR+GAC+UV/H <sub>2</sub> O <sub>2</sub> +GAC in the Netherlands. Monitored parameters were PhCs and toxicity. See also Kovalova et al. (2012, 2013), Koeler et al. (2011); McArdell et al. (2011)	Effects of pharmaceuticals on environment water and potential measures to reduce their occurrence.	PhCs
Prado et al., 2011	Investigation carried out in Brazil involving detection of some enteric viruses and hepatitis A in hospital effluent and in the effluent from two different full scale treatment plants. The removal efficiencies observed in the two sequences: upflow anaerobic sludge blanket (UASB) +three serial anaerobic filters and CAS system followed by a chlorination tank were investigated and compared.	Quantification of enteric viruses and hepatitis A in the effluent of different hospital WWTPs.	Enteric viruses and hepatitis A
Prayitno et al., 2014	Investigation on a pilot scale plant consisting in an Aerated Fixed Film Biofilter (AF2B reactor) coupled with an ozonation reactor fed by the effluent from Malang City hospital in Indonesia.	Pollution and health problems for humans being caused by the discharge of HWWs.	Conventional pollutants: BOD <sub>5</sub> , phenols, fecal coliform and Pb.
Rezaee et al. 2005	Investigation carried out in Iran on a pilot-scale system consisting in an integrated anaerobic-aerobic fixed film reactor fed with hospital effluent before co-treatment with urban wastewater.	Potential reduction of the organic load in hospital effluent by biological pretreatment before its cotreatment.	Conventional parameters: COD, BOD <sub>5</sub> , NH <sub>4</sub> , Turbidity, Bacteria and <i>Escherchia coli</i> .
Shrestha et al., 2001	Analysis of the removal performance in a full scale two stage constructed wetland (CWs) designed and constructed in Nepal to treat hospital effluent (20 m <sup>3</sup> /d). The system consists in a three chambered septic tank, a horizontal flow bed (140 m <sup>2</sup> ), with 0.65 to 0.75 m depth and a vertical flow bed (120 m <sup>2</sup> ) with 1 m depth. The beds were planted with local reeds ( <i>Phragmites karka</i> ).	Transfer CW technology to developing countries to reduce pollution in aquatic environments.	Conventional parameters: TSS, BOD <sub>5</sub> , COD, NH <sub>4</sub> , PO <sub>4</sub> <sup>2-</sup> , total coliforms, <i>E. coli</i> , Streptococci.
Sim et al., 2013	Investigation carried out at two hospital WWTPs located in Korea to assess the occurrence and removal of selected pharmaceutical and personal care products. The wastewater treatment plants consist of (i) flocculation (FL)+ activated carbon filtration (AC); (ii) flocculation + CAS.	Potential risks of anthelmintics on non-target organisms in the environment and their resistance to biodegradation.	33 PhCs and personal care products

Reference	Main characteristics of experimental investigations and treatment plants	Rationale	Investigated parameters
Suarez et al., 2009	Investigation carried out in Spain into the pretreatment of hospital effluent. The efficacy of coagulation-flocculation (Coag-FL) and flotation (FLO) processes in removing PhCs was investigated in case of two kinds of hospital effluent: one from radiotherapy and outpatient consultation wards and one from hospitalized patients, surgery, laboratories, radiology and general services. Coagulation-flocculation assays were performed in a jar-test device and in a continuous pilot-scale plant. Ferric chloride ( $\text{FeCl}_3$ ) and aluminium sulphate ( $\text{Al}_2(\text{SO}_4)_3$ ) were added.	Potential risk of hospital wastewater to the environment.	13 PhCs and personal care products; TSS, COD, fat
Vasconcelos et al., 2009	Investigation carried out in Brazil into the potential pretreatment of hospital effluent to degrade persistent compounds. In particular the study investigated the performance of a lab-scale photo-induced oxidation, heterogeneous photocatalysis, ozonation and perozone in degrading the antimicrobial ciprofloxacin.	Environmental impact of Ciprofloxacin and analysis of its degradation by ozone and photoprocesses.	Ciprofloxacin, COD.
Venditti et al., 2011	Investigation carried out in Luxembourg on the removal of conventional pollutants and selected PhCs by means of a pilot MBR fed with hospital effluent ( $2 \text{ m}^3/\text{d}$ on average). The bioreactor consists of an anoxic/oxic compartments ( $0.175 \text{ m}^3$ , $0.515 \text{ m}^3$ respectively) and is equipped with two submerged microfiltration membrane modules (pore size $0.4 \mu\text{m}$ , total surface area $9.6 \text{ m}^2$ ). Average HRT 8 h, temperature $16\text{-}18 \text{ }^\circ\text{C}$ , biomass concentration $10\text{-}13.2 \text{ g/L}$ , SRT $> 30 \text{ d}$ .	Adequateness of MBR as a pretreatment for hospital effluent	10 common PhCs, DOC, COD, $\text{BOD}_5$ , $\text{NH}_4$ , $\text{NO}_3$ , total N total P.
Verlicchi et al., 2010	Investigation carried out at an Italian hospital by means of a pilot-scale MBR equipped with UF membranes.	Hospitals are the main source of PhCs. Guidelines for a full scale plant for hospital effluent	Monitored parameters were COD, $\text{BOD}_5$ , SS, $\text{NH}_4$ , Total P and <i>E. coli</i> .
Wen et al., 2004	Investigation carried out at Haidian community hospital (China), where a full-scale submerged hollow fiber MBR was installed.	Efficiency and operation stability of MBR equipped with microfiltration membranes in treating HWWs.	Monitored pollutants were COD, $\text{BOD}_5$ , $\text{NH}_4$ , turbidity and <i>Escherchia coli</i> .
Wilde et al., 2014	Investigation carried out in Brazil into the degradation of a mixture of beta-blockers in hospital effluent by ozonation and Fenton reaction	Optimization of the operational condition in the degradation of a mixture of PhCs in hospital effluent	Atenolol, propranolol and metoprolol



**Table 3** Dedicated treatment trains for hospital effluent included in the review

<b>Investigated Treatment/treatment train*</b>	<b>Reference</b>
(pre)Disinfection with ozone <sup>1</sup>	Chiang et al., 2003
(pre)Disinfection with chlorine <sup>1</sup>	Emmanuel et al., 2004; Nardi et al., 1995; Liu et al., 2010
(pre)Photo-Fenton <sup>1</sup>	Katjitvichyanukul and Suntronvipart 2006
Coagulation-flocculation; Coagulation-flocculation+flotation	Suarez et al., 2009
Coagulation+filtration + disinfection	Gautam et al., 2007
Screening + O <sub>3</sub> /UV or O <sub>3</sub> /UV/H <sub>2</sub> O <sub>2</sub> (+ biological step) <sup>2</sup>	Arslan et al., 2014
Septic tank+ anaerobic filter	de Almeida et al., 2013; Martins et al., 2008
Septic tank+HSF+VSF	Shrestha et al., 2001
Septic tank + Fenton	Berto et al., 2009
Flocculation + CA	Sim et al., 2013
Flocculation+ CAS	Sim et al., 2013
Anaerobic-aerobic fixed film reactor	Rezaee et al., 2005
Facultative and polishing ponds (II + III) <sup>2</sup>	Beyene and Redaie 2011
Aerated Fixed Film Biofilter+O <sub>3</sub>	Prayitno et al., 2014
CAS	Abd El Gawad and Aly, 2011; Azar et al., 2010
CAS + support media + UF	Mousaab et al., 2015
CAS + chlorination	Kosma et al., 2010; Mahvi et al., 2009; Prado et al., 2011
Fungal bioreactor	Cruz-Morato et al., 2014
UASB+ anaerobic filter	Prado et al., 2011
MBBR + ozonation	Andersen et al., 2014
MBR	Al Hashmia et al., 2013; Beier et al., 2012; Kovalova et al., 2012; Lenz et al., 2007a; Liu et al., 2010; Mahnik et al., 2007; Nielsen et al., 2013; Venditti et al., 2011; Weng et al., 2004
MBR + chlorination	Liu et al., 2010, Nielsen et al., 2013
MBR + GAC	Lenz et al., 2007b
MBR + GAC + O <sub>3</sub> and or H <sub>2</sub> O <sub>2</sub> + UV	Grundfos Biobooster 2012,
MBR + GAC + UV	Lenz et al., 2007b
MBR + H <sub>2</sub> O <sub>2</sub> +UV	Koheler et al., 2011,;Kovalova et al., 2013
MBR + O <sub>3</sub> + GAC	Pharmafilter, 2013
MBR + O <sub>3</sub> + GAC+ UV	Grundfos Biobooster 2012,
MBR + public sewage+ cotreatment	Beier et al., 2011
MBR + UV	Lenz et al., 2007b
MBR+ H <sub>2</sub> O <sub>2</sub>	Koheler et al., 2011
(MBR+) PAC <sup>3</sup>	Kovalova et al., 2013; Nielsen et al., 2013
(MBR+) O <sub>3</sub> <sup>3</sup>	Kovalova et al., 2013; Nielsen et al., 2013

(MBR+) O <sub>3</sub> /H <sub>2</sub> O <sub>2</sub> <sup>3</sup>	Nielsen et al., 2013
(MBR+) UV with/without TiO <sub>2</sub> <sup>3</sup>	Kovalova et al., 2013
UV/O <sub>3</sub> / TiO <sub>2</sub>	Kist et al., 2008
(Septic tank+ anaerobic filter+) O <sub>3</sub> , H <sub>2</sub> O <sub>2</sub> /O <sub>3</sub> <sup>3</sup>	Vasconcelos et al., 2009
(Septic tank+ anaerobic filter+) O <sub>3</sub> , Fe <sup>+2</sup> /O <sub>3</sub> <sup>3</sup>	Wilde et al., 2014
(Septic tank+ anaerobic filter+) UV <sup>3</sup>	Vasconcelos et al., 2009
(Septic tank+ anaerobic filter+)TiO <sub>2</sub> /UV <sup>3</sup>	Vasconcelos et al., 2009
NF/RO (polishing) <sup>4</sup>	Beier et al., 2010

<sup>1</sup> (pre): means preliminary treatment

<sup>2</sup> (biological treatment) means that the investigated treatment is upstream of a biological step

<sup>3</sup> Upstream treatments reported in brackets have to better define the step of the treatment considered and reported data on the removal efficiencies of PhCs do not include their contribution in the cited investigations.

<sup>4</sup> (II+III) means a series of secondary and tertiary ponds

**Table 4.** Main operational parameter in the UV reactors included in this study

↓Parameter	Unit→	Austria	Switzerland	Luxembourg
Plant type		Pilot	pilot	Pilot
Lamp		LP	LP	LP and MP
Actual Fluence, J/m <sup>2</sup>		110000	800, 2400, 7200	7400-29700 (LP) 10125-506250 (MP), λ=200-280 nm 5400-270000 (MP), λ =280-315 nm 4725-236250 (MP), λ =200-280 nm and 315-400 nm
Residence time, s		120	18, 54,162	18-71 (LP), 1.3-64 (MP)

**Table 5** Disinfection performance by means of AOPs

Method	Secondary effluent thermotolerant Coliforms Machado et al., 2007	Laundry effluent thermotolerant Coliforms Kist et al., 2008
Secondary effluent	1.1 10 <sup>6</sup>	9 10 <sup>6</sup>
UV/O <sub>3</sub>	17 000	110
UV	9000	
TiO <sub>2</sub>	170	
O <sub>3</sub>	170	
O <sub>3</sub> /TiO <sub>2</sub>	120	1700
UV/TiO <sub>2</sub>	40	20
UV/TiO <sub>2</sub> /O <sub>3</sub>	< 2	< 20

**Table 6.** Removal efficiencies expected for the different groups of compounds

<b>Group</b>	<b>PAC</b>	<b>AOP</b>	<b>UV</b>	<b>Cl<sub>2</sub>/ClO<sub>2</sub></b>	<b>Coag/Floc</b>
Antibiotics	40-90	20-90	40-90	20-90	<20
Antidepressants	70-90	20-90	40-90	20-70	<20-40
Analgesics/Anti-inflammatory	>90	20-90	70-90	20-70	<20
Lipid regulator	>90		>90	20-70	<20
X-ray contrast media	70-90	70-90	20-90	20-70	<20-40
Disinfectants/detergents	>90	>90	40-90	>20	<20-40

**Table 7. Investment and O&M costs for hospital effluent treatment by different technologies**

Author	Kajitvichyanukul and Suntronvipart 2006	Liu et al. 2010	Verlicchi et al. 2010	Beier et al. 2012	Pills project 2012				Kovalova et al. 2013	Nielsen et al. 2013								
Place	Thailand	China	Italy	Germany	Netherlands			Switzerland		Denmark								
Type of treatment	Photo-Fenton	MBR	MBR+O <sub>3</sub> +UV	MBR	MBR	MBR + GAC	MBR + O <sub>3</sub> + GAC	MBR +UV/H <sub>2</sub> O <sub>2</sub> + GAC	MBR + PAC	MBR + O <sub>3</sub>	O <sub>3</sub>	O <sub>3</sub>	O <sub>3</sub> +H <sub>2</sub> O <sub>2</sub>	O <sub>3</sub> +H <sub>2</sub> O <sub>2</sub>	PAC	PAC	ClO <sub>2</sub>	MBR+O <sub>3</sub>
Investment cost (€/m <sup>3</sup> )			3.6		3.25	3.35	3.5	3.65										
O&M cost (€/m <sup>3</sup> )	0.38 <sup>1</sup>	0.45-0.163 <sup>1</sup>			1.45	1.65	1.75	1.85			0.22	0.4	0.34	1.08	0.31	1.06	0.3	1
Total cost €/m <sup>3</sup>				4.1	4.7	5	5.3	5.5	2.7	2.4								

<sup>1</sup>Exchange rate refers to December 20<sup>th</sup> 2014

## FIGURE CAPTIONS

**Fig. 1 Observed removal efficiencies from HWW for selected PhCs in different primary treatments**

Data from: Suarez et al., 2009; Martins et al., 2008.

**Fig. 2 Observed removal efficiencies for a group of selected compounds in MBRs and CAS operating at different SRTs.**

Data from: Kosma et al., 2010; Kovalova et al., 2012; PILLS, 2012, Nielsen et al., 2013; Beier et al., 2011; Kohler et al., 2012.

**Fig. 3 Observed removal efficiencies for a group of selected compounds in MBRs and CAS operating at different SRTs.**

Data from: Kosma et al., 2010; Pauwels et al., 2006; Lenz et al., 2007<sup>a</sup>, 2007b; Kovalova et al., 2012; PILLS, 2012, Nielsen et al., 2013; Beier et al., 2011, Kohler et al., 2012

**Fig. 4. Observed removal efficiencies for a group of selected PhCs in HWW by PAC and GAS systems**

Data from: Kovalova et al., 2013; PILLS Report, 2012; Nielsen et al., 2013; Lenz et al., 2007b

**Fig. 5. Observed removal efficiencies for a group of selected PhCs in HWW by PAC and GAC systems**

Data from: Kovalova et al., 2013; PILLS Report, 2012; Nielsen et al., 2013.

**Fig. 6. Observed removal efficiencies for a group of selected PhCs in HWW by ozonation**

Data from: PILLS report, 2012; Kovalova et al., 2013; Nielsen et al., 2013; Lenz et al., 2007b

**Fig. 7. Observed removal efficiencies for a group of selected PhCs in HWW by ozonation**

Data from: PILLS report, 2012; Kovalova et al., 2013; Nielsen et al., 2013; Lenz et al., 2007b

**Fig. 8 Observed removal efficiency for a group of selected PhCs in HWW by UV treatment**

Data from: Kovalova et al., 2013, PILLS report, 2012; Kohler et al., 2012

**Fig. 9 Observed removal efficiency for a group of selected PhCs in HWW by UV treatment**

Data from: Lenz et al., 2007b, Kovalova et al., 2013, PILLS report, 2012; Kohler et al., 2012

**Fig. 10. Observed removal efficiencies for a group of selected PhCs in HWW by AOPs**

Data from: Lenz et al., 2007b; Vasconcelos et al., 2009; PILLS report, 2012; Nielsen et al., 2013

**Fig. 11. Removal of PhCs by final chlorination**

Data from: Nielsen et al., 2013

**Fig. 12. Comparison among secondary and tertiary treatments of HWW with a view of the number of investigated compounds and of compounds exhibiting a removal efficiency greater than 80%**



### FIGURES




Figure 1




Fig. 2




Fig. 3




Fig. 4.






Figure 5






Figure 6



**Figure 7**



**Fig. 8**




Fig. 9




Figure 10




Fig. 11




Figure 12

**Supplementary material for on-line publication only**

[Click here to download Supplementary material for on-line publication only: 1 Supp Data revisionato.docx](#)